Here I am with my first dog, a willful and sometimes fierce poodle.

 

He'd run like hell anytime he escaped from the house. That prompted one of our neighbors in tony Los Altos Hills to remind us in writing the community had a "lease [sic] aw."

 

He had it in for men. When meeting men for the first time, he'd go for their ankles, producing a distinctive tear near their trouser cuffs. My mother got to know many "invisible" tailors, so named because their repair work was undetectable.

 

I still have his favorite chair.

 

Great Bend, Kansas, June, 1967. Scan from a Kodachrome print.My scan of an original non-digital image in my collection to which I own all rights.

DOD CAPTION

APRA HARBOR, GUAM (Jan. 15, 2022)

 

The U.S. Navy ballistic-missile submarine USS NEVADA_SSBN 733 arrived at Naval Base Guam, Jan. 15. The port visit strengthens cooperation between the United States and allies in the region, demonstrating U.S. capability, flexibility, readiness, and continuing commitment to Indo-Pacific regional security and stability. USS Nevada, homeported in Naval Base Kitsap, Wash., is an Ohio-class ballistic-missile submarine, an undetectable launch platform for submarine-launched ballistic missiles, providing the United States with its most important survivable leg of the nuclear triad.

 

U.S. Navy photo by Mass Communication Specialist Darek Leary

©USN Official Photo

 

I had battery issues on various pieces of equipment last night, which I finally solved, and high, faint almost undetectable misty cloud, not to mention poor skies and bad light pollution, but at least I managed to get this. In hindsight I wish I had tried NGC 7000.

 

It was 15 subs at 300 seconds each, using a Canon 650D modified camera, stacked in DSS and processed with Pixinsight.

Hill Aerospace Museum

 

History of the F-117 "Nighthawk"

The F-117 "Nighthawk" is a single-seat, twin-engine strike-fighter built by Lockheed's Skunk Works. Designed as a stealth aircraft undetectable by enemy radar, the F-117 made its first flight in 1981. The Nighthawk was the first operational aircraft designed to exploit low-observable stealth technology to evade detection by radar or sensors, allowing it to carry out its mission and return home undetected.

 

The U.S. Air Force used the F-117 in the U.S. Invasion of Panama, the Gulf War, and Kosovo. It also flew missions over Afghanistan and in Operation Iraqi Freedom. The U.S. Air Force retired these aircraft from active service in 2008 as the more advanced F-22 "Raptor" assumed the role once held by the F-117. Lockheed built 64 Nighthawks total.

 

The F-117 "Nighthawk" at Hill Air Force Base

On 15 December 1998, Hill Air Force Base's Ogden Air Logistics Center was assigned the responsibility of F-117 battle/crash damage repair and depot field team support by way of Expeditionary Depot Maintenance expertise through the 649th Combat Logistics Support Squadron (CLSS). This new mission required the deployment of military teams worldwide to perform heavy maintenance and aircraft modifications on Nighthawks wherever necessary. The 649th performed this mission until 2008 when the F-117 retired from service.

 

The F-117 on display at the Hill Aerospace Museum made its first flight on 22 September 1983. It flew 5,234 flight hours and 54 combined combat sorties in Desert Storm, Allied Force, and Operation Iraqi Freedom with the 4450th Tactical Group (TG). In fact, #799 flew the most combat sorties out of all F-117s in Operation Iraqi Freedom. When in service, Airmen of the 4450 TG nicknamed this airframe "Midnight Rider." It was acquired by the museum for display in 2020.

 

Specifications

S/N 82-799

Manufacturer: Lockheed Aeronautical Systems Co.

Crew: One

Engine: Two General Electric F404 non-afterburning engines

Wingspant 43 ft 4 in

Length: 63 ft 9 in

Height: 12 ft 9.5 in

Weight: 52,500 pounds

Speed High subsonic

Range: Unlimited with air refueling

Service Ceiling: 45,000 ft

Armaments Internal weapons carriage; various ordinance

Cost: $45 million

The trademark ship of bounty hunter Kilvane Frost. Outfitted with ion blasters, plasma cannons, seeker missiles, fission missiles, and rear-deploying seismic charges and V.II Sabotage droids. Two hyper-computing droids run the ship's technological systems, including two high-powered scrambling devices that render the ship undetectable on radar and immune to targeting systems. Four thruster-type engines give the Manta unrivaled speed and maneuverability for a ship of its size.

-+-+-+-+-+-+-+-+-

I shortened and altered the tail section and gave the wings the ability to "lock into attack position".

Built for the new RPG Struggle for Klegon over at galactic-bricks.boards.net/board/7/struggle-klegon

Comments and criticism welcome! :D

Ronin

Be hold! It’s a toupee revolution!! Truly undetectable by any means! People will never notice it ever again! 100% money/hair back grantee! It blends in so well, and it looks so natural as if there is nothing. It is totally breathable as if there is nothing. It is ridiculously light as if there is nothing. This piece of hi-tech disguising gadget has been developed based on the latest advanced placebo techniques. Kaoruoka Products

This is an edited version of a talk I presented a talk of at Trampoline 2 [0] in Melbourne [1], Saturday 24th of October, 2009 called "Hacking People, Hacking Bullies". [2],[3],[4],[5],[6].

 

The talk was divided into three parts: a) "Know your Enemy, Hacking humans"; b) "In the field: real life examples"; and c) "Hacking Bullies". In this, the first part of the talk I identifying bullies and their modes of attack. The second will possibly never be written up for public consumption but it illustrated how bullies operate using using personal anecdotes. The last part of the talk I have already written up. It explains how you might go about Hacking Bullies [7] using network science concepts.

 

Preamble

My name is Peter. I'm a programmer. One of those gen-X slackers you hear about. My second computer was an Apple 2e clone shipped from Singapore in parts and hand assembled.

 

I'll be as lo-tech as you can get and read from sheets of paper. My talk is on bullies and what happens when they discover computers. I'm not a psychologist, I'm a technologist with crap social skills. I'm interested in how bullies are adapting to computers and network, how to identify and neutralise them.

 

The idea I want to explore, "Is there a better way to identify and disrupt Cyberbullies?". To do this we first must understand bullies and the mechanics of bullying.

 

Introduction

The effects of bullying is enough of a problem for the United States Secret Service to carry out a threat assessment [8] to understand why so many school kids carried out "targeted violence" [9] in American schools? One of the findings: Bullying was identified as a major contributor in shootings in the United States secondary schools. [10] The number of reported bully attacks in lower level schools in Norway 1983 was 1 in 7. In the same country the number of reported attacks in lower schools in 2001, increased by 50%. And more worrying statistic, the number of students in the most serious forms, up 67%. [11]

 

Bullying has serious implications and it can be quantified. So what and who are these bullies?

 

Know your enemy

First some terminology. I want to use the word ATTACKER and TARGET to describe a "bully" and their "victim". I choose these words carefully to redefine the problem. People who are attacked, shouldn't be thought of as being helpless as the term "victim" implies. Neither, should bullies be described in favourable terms.

 

When I say ATTACKER, I want you to think "bully" and "looser". When I say TARGET I want you to think, "could this be me?".

 

What is bullying?

Bullying is any negative action that is intentional, systematic and repeated. The majority of bullying is by two to three ATTACKERs. [12] The TARGET is chosen for a number of reasons, but mostly because of some in-balance of social power. [13]

 

Recognition

The key to recognition, is realising an ATTACKER is someone who has a strong need for power and negative dominance. Recognition relies on understanding the psychology of the ATTACKER, not just their appearance. This makes recognition difficult.

 

Fighting style

When it comes to attacking men, women, girls and boys each have their own particular style. The simplest explanation I can think of is "Men attack like paratroopers. Women, special agents". Males are aggressive and physical. Why bother talking, when you push, shove, kick and punch your TARGET. As a rule, males tend to be regressive and overt. Males attack their TARGET directly just like Paratroopers. Violent, fast, no retreat, no prisoners.

 

"Men attack like paratroopers. Women, special agents"

 

Females are less physically able than males but can be just as aggressive and have a uniquely adapted fighting style. They excel at indirect attack. Indirect attacks are concealed and subtle, something males can't quite comprehend. This is why females are special agents. They can get in under your guard and deliver attacks just devastating as the male, undetected. Do not underestimate the arsenal female ATTACKER have at their disposal.

 

Males might take things from you, be physical, be overtly verbal, make threats and force you to do things. Female use of social exclusion, spreading rumours, lies and sophisticated use of language is relatively undetectable in comparison to crude methods used by Males. [14]

 

Hacking Humans

Why do ATTACKERS try to hack humans? How do they find their TARGET? Why do they engage an audience?

 

Weakness

How does an ATTACKER select a TARGET? It's not difficult. An ATTACKER will select a TARGET by identifying and exploiting weakness in certain individuals. An ATTACKER will try to ascertain if a person is more vulnerable than others using a wide variety of criteria. Is the person socially excluded? Are they introverted? Are they different? Some common ways to access weakness include: Gait, [15] blind spots [16] and asymmetry. [17]

 

An anatomy of an attack

When an attack occurs the ATTACKER and TARGET engage in a sort of choreographed dance. ATTACKER, TARGET, HENCHMEN and OUTSIDERs playing a defined but changeable role.

  

- SCAN The ATTACKER views the battlefield scanning for TARGETs. [18] Them things happen fast.

 

- SIGNAL The ATTACKER has signaled the TARGET. At this point if the battleground is public, onlookers are now involved.

 

- ATTACK The bully can now joined by HENCHMEN, followers of the bully who actively join in on the attack. The TARGET probably has no idea this is going to happen because of blind spots and will be stunned. Unable to respond. It's at this stage OUTSIDERs, people who happen to be in the battleground become involved.

 

- CHOOSING SIDES The ATTACKER needs OUTSIDERS to join in to re-inforce their social status. An OUTSIDER has multiple choices. They can support the ATTACKER and actively join in or remain passive. An OUTSIDER may choose not to get involved and watch. An OUTSIDER might choose to actively DEFEND or potentially DEFEND.

 

- OUTCOME The ATTACKER has bullied the TARGET. Depending on the circumstances HENCHMEN may have also joined in.

 

Intervention as a solution?

What about the OUTSIDERS? Why didn't they DEFEND? Why did some join the ATTACKERS side? The sad truth is most OUTSIDERs are of no help to the TARGET. [18]

 

Why don't OUTSIDERs choose to help a TARGET? The most common explanation is OUTSIDERs are fearful of loosing status or worry about getting hurt or can't decide and choose to remain passive. The ATTACKER asymmetrically takes control of a larger group even though OUTSIDERs potentially have numerical advantage. This is called the "Bystander Paradox". [19]

 

For the TARGET there is no easy way out of this situation. It is up to the OUTSIDERs to intervene. By taking a stand, OUTSIDERs have a chance to reduce or circumvent the cycle of bullying. How do you do this? Counter attack the ATTACKER. The single point of weakness an ATTACKER is lack of numerical force. If you can turn enough bystanders back onto the ATTACKER and HENCHMEN you may be able to blunt and reduce the ATTACK at the SIGNAL phase. [20]

 

What about the bullying on the Internet? Bullies have now discovered the Internet. Can you start Hacking Bullies. [21]

 

Reference

[0] Peter Renshaw, Trampoline 2, flickr, "My Trampoline 2 flickr set: Trampoline was an informal day of sharing ideas in Melbourne, Australia, Saturday 24th of October, 2009." [Accessed Friday, 16th October 2009]

http://www.flickr.com/photos/bootload/sets/72157622667018586/

 

[1] Peter Renshaw, Melbourne, Australia, flickr, "My Melbourne Flickr set showing images from around Melbourne CBD.", [Accessed Friday, 16th October 2009]

http://www.flickr.com/photos/bootload/sets/72157600195992630/

 

[2] Peter Renshaw, seldomlogical, "Hacking Bullies: 'is there a better way to identify and disrupt Cyber Bullies?'"., [Accessed Saturday, 13th March 2010]

http://seldomlogical.com/2010/03/13/hacking-bullies/

 

[3] At the time, I didn't mention the focus of the talk. I was thinking about what might happen when you try to replicate "social networks" on-line exclusively for women. This was unintentional and might have turned a few listeners off.

Wikipedia defines "social networks" as "... a physical description of how people organise themselves. The self organising nature of social networks appear to follow the rules of network science which allows the study of networks to be done using various mathematical techniques.", [Accessed Saturday, 13th March 2010]

http://en.wikipedia.org/wiki/Social_network

www.flickr.com/photos/bootload/4501255443/

[4] Looking at bullying from a specific gender viewpoint is interesting, because I suspect the more verbal culture women exhibit captured online can now more easily be analysed for signs of bullying. I tend to write about these ideas to look for new insights into problems. Bullying is a problem. I've experienced it first hand but not on-line. I see bullying on-line as an bigger problem. We are now in a period of time where "social software" is growing quickly and worth exploring further. See point [2].

 

[5] Paul Graham, paulgraham.com, "What you can't say: 'It seems to be a constant throughout history: In every period, people believed things that were just ridiculous, and believed them so strongly that you would have gotten in terrible trouble for saying otherwise.'", [Accessed Friday, 16th October 2009]

http://paulgraham.com/say.html

 

[6] Peter Renshaw, flickr, "2009AUG251053: SBS INSIGHT: girls, relationships & cattiness: Computers are powerful amplifiers, so small spats between individuals can become front page news. Tactics used by Women that might work face to face, have the potential to back-fire big time on the Internet. Anywhere computers come into the conversation, the resultant data can be stored, searched, retrieved and with the advent of social software this can now be done real time.", [Accessed Friday, 16th October 2009]

http://www.flickr.com/photos/bootload/3854522410/

 

[7] Peter Renshaw, seldomlogical, "Hacking Bullies: The idea, a simple hypothesis, 'Is there a better way to identify and disrupt Cyber Bullies?'", 13 March 2010, [Accessed Saturday, 13th March 2010]

seldomlogical.com/2010/03/13/hacking-bullies/

 

[8] Fein, R.A. Ph.D., Vossekuil, B., Pollack, W.S. Ph.D., Borum, R. Psy.D., Modzeleski W., Reddy M., Ph.D., "Threat Assessment in Schools: A guide to managing threatening situations and to create safe school climates", United States Secret Service & United States Department of Education, Washington, D.C., 2002. (pdf, 754Kb), [Accessed Friday, 16th October 2009]

http://www.secretservice.gov/ntac/ssi_guide.pdf

 

[9] Fein, R.A. Ph.D., Vossekuil, B., Pollack, W.S. Ph.D., Borum, R. Psy.D., Modzeleski W., Reddy M., Ph.D., "Threat Assessment in Schools: A guide to managing threatening situations and to create safe school climates: 'Targeted violence' any incident of violence where a known or knowable attacker selects a 1 particular target prior to their violent attack.", P 3., Ibid, [Accessed Friday, 16th October 2009]

 

[10] Fein, R.A. Ph.D., Vossekuil, B., Pollack, W.S. Ph.D., Borum, R. Psy.D., Modzeleski W., Reddy M., Ph.D., "Chapter III - Key findings of the safe school initiative's study of targeted school violence: '... Many attackers felt bullied, persecuted, or injured by others prior to the attack ...'", P17., Ibid, [Accessed Friday, 16th October 2009]

 

[11] olweus.org, FAQ, "Question: How Common Is Bullying?",

[Accessed Friday, 16th October 2009]

http://www.olweus.org/public/faqs.page#Answer_numberCbQ7

 

[12] Center for the Study and Prevention of Violence, colorado.edu "Olweus Bullying Prevention Program (BPP): 'In the context of school bullying, the victim is usually a single student, who is generally harassed by a group of two or three students, often with a "negative leader." A considerable proportion of the victims, 20-40 percent, report, however, that they are mainly bullied by a single student.'", [Accessed Saturday, 13th March 2010]

http://www.colorado.edu/cspv/blueprints/modelprograms/BPP.html

 

[13] Center for the Study and Prevention of Violence, colorado.edu "Olweus Bullying Prevention Program (BPP): Prevalence of Bullying" Ibid, [Accessed Saturday, 13th March 2010]

 

[14] This is a gross generalisation but for the purposes of the talk it worked. It is interesting to read what Olweus has found looking at this issue. This is some of what he had to say:

"... This shows that it is boys who are more likely to be the perpetrators of what Olweus calls "direct" bullying, that is, bullying which involves direct physical or verbal attacks. He has concluded that girls are more likely to use indirect, subtle, social means to harass other girls. He refers to behaviour such as social exclusion, manipulation of friendship relationships, spreading rumours, etc. ..." (Olweus, D. 1993, Bullying at School: What We Know and What We Can Do. Oxford UK: Blackwell Publishers.)

 

Sudermann, Jaffe, Schieck, Watson, Lehmann, Greer "A School-based Anti-Violence Program", 1996, [Accessed Friday April 2, 2010]

http://www.lfcc.on.ca/bully.htm

 

[15] The study of Psychopaths has revealed interesting insights into possible ways TARGETS can be exploited for weakness by ATTACKERS. Weakness comes in many forms. One in particular is gait or the way people move. This helps explain how Bullies can scan for TARGETS so easily.

"Psychopaths target anything weak. They assess voice,

gait, circumstances, height, weight, etc. Yes fam with

gait studies"

 

Joe Navarro/@navarrotells, [Accessed Wednesday, 7th April 2010]

http://twitter.com/navarrotells/status/11069087171

 

Interested in spotting Psychopathic behaviour? Here are some further references:

 

a) Joe Navarro, "How to Spot a Psychopath", (Kindle Edition only), ASIN: B002TX70G8

[Accessed Wednesday, 7th April 2010]

www.amazon.com/How-Spot-Psychopath-ebook/dp/B002TX70G8/re...

b) Ian Walker, Fibro Majestic Film, "I, Psychopath: A 1hr documentary available on DVD who documents scientific testing 'Sam Vaknin' to see if he is in fact a Psychopath.", ASIN: B002W6ZI1Q, 2009. [Accessed Wednesday, 7th April 2010]

http://www.magicreal.com.au/filmandtv.php?film=4

www.amazon.com/I-Psychopath-Ian-Walker/dp/B002W6ZI1Q/ref=...

  

[16] The ATTACKER simply exploits a vulnerability in how individuals view themselves. We may be able to understand how others view some of our personality traits, but not all of them.

 

[17] ATTACKERS will exploit a TARGETs disparity in size, strength or social status. ATTACKERS use superior force and peer pressure.

 

[18] Read through reference [15] to understand how ATTACKERS achieve this.

 

[19] Bystander paradox How can the TARGET decide what the roles OUTSIDERs choose? Are OUTSIDERs supporting the ATTACKER?, helping the TARGET?, or remaining neutral? The TARGET cannot tell. If you fight back and take on an ATTACKER and OUTSIDER can you justify both? This is the bystander paradox - the ability to justify the response when attacked. The ATTACKER has no such problem.

 

[20] Larry Abramson, NPR (National Public Radio), "Hit Back At Bullies? Not At This School", "That's why the Olweus Bullying Prevention Program tries to turn anti-bullying efforts into part of the school culture, rather than just the topic of an occasional assembly. The concepts are simple: Don't bully, help those who are being bullied and tell an adult what's going on. Pearre tries to reinforce the idea that the bully doesn't act alone. The community can take away the bully's power by refusing to cheer him on, by telling an adult, or perhaps the ultimate step: stepping in to help the victim."

 

http://www.npr.org/templates/story/story.php?storyId=125137071

 

[21] Peter Renshaw, seldomlogical, "Hacking Bullies: 'is there a better way to identify and disrupt Cyber Bullies?'"., Ibid. [Accessed Saturday, 13th March 2010]

 

next >>>

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic.

 

Symptoms of COVID-19 are variable, but often include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. Of those people who develop noticeable symptoms, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction). Older people are more likely to have severe symptoms. At least a third of the people who are infected with the virus remain asymptomatic and do not develop noticeable symptoms at any point in time, but they still can spread the disease.[ Around 20% of those people will remain asymptomatic throughout infection, and the rest will develop symptoms later on, becoming pre-symptomatic rather than asymptomatic and therefore having a higher risk of transmitting the virus to others. Some people continue to experience a range of effects—known as long COVID—for months after recovery, and damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.

 

The virus that causes COVID-19 spreads mainly when an infected person is in close contact[a] with another person. Small droplets and aerosols containing the virus can spread from an infected person's nose and mouth as they breathe, cough, sneeze, sing, or speak. Other people are infected if the virus gets into their mouth, nose or eyes. The virus may also spread via contaminated surfaces, although this is not thought to be the main route of transmission. The exact route of transmission is rarely proven conclusively, but infection mainly happens when people are near each other for long enough. People who are infected can transmit the virus to another person up to two days before they themselves show symptoms, as can people who do not experience symptoms. People remain infectious for up to ten days after the onset of symptoms in moderate cases and up to 20 days in severe cases. Several testing methods have been developed to diagnose the disease. The standard diagnostic method is by detection of the virus' nucleic acid by real-time reverse transcription polymerase chain reaction (rRT-PCR), transcription-mediated amplification (TMA), or by reverse transcription loop-mediated isothermal amplification (RT-LAMP) from a nasopharyngeal swab.

 

Preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. The use of face masks or coverings has been recommended in public settings to minimise the risk of transmissions. Several vaccines have been developed and several countries have initiated mass vaccination campaigns.

 

Although work is underway to develop drugs that inhibit the virus, the primary treatment is currently symptomatic. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures.

 

SIGNS AND SYSTOMS

Symptoms of COVID-19 are variable, ranging from mild symptoms to severe illness. Common symptoms include headache, loss of smell and taste, nasal congestion and rhinorrhea, cough, muscle pain, sore throat, fever, diarrhea, and breathing difficulties. People with the same infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea. In people without prior ear, nose, and throat disorders, loss of taste combined with loss of smell is associated with COVID-19.

 

Most people (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) and 5% of patients suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction). At least a third of the people who are infected with the virus do not develop noticeable symptoms at any point in time. These asymptomatic carriers tend not to get tested and can spread the disease. Other infected people will develop symptoms later, called "pre-symptomatic", or have very mild symptoms and can also spread the virus.

 

As is common with infections, there is a delay between the moment a person first becomes infected and the appearance of the first symptoms. The median delay for COVID-19 is four to five days. Most symptomatic people experience symptoms within two to seven days after exposure, and almost all will experience at least one symptom within 12 days.

Most people recover from the acute phase of the disease. However, some people continue to experience a range of effects for months after recovery—named long COVID—and damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.

 

CAUSE

TRANSMISSION

Coronavirus disease 2019 (COVID-19) spreads from person to person mainly through the respiratory route after an infected person coughs, sneezes, sings, talks or breathes. A new infection occurs when virus-containing particles exhaled by an infected person, either respiratory droplets or aerosols, get into the mouth, nose, or eyes of other people who are in close contact with the infected person. During human-to-human transmission, an average 1000 infectious SARS-CoV-2 virions are thought to initiate a new infection.

 

The closer people interact, and the longer they interact, the more likely they are to transmit COVID-19. Closer distances can involve larger droplets (which fall to the ground) and aerosols, whereas longer distances only involve aerosols. Larger droplets can also turn into aerosols (known as droplet nuclei) through evaporation. The relative importance of the larger droplets and the aerosols is not clear as of November 2020; however, the virus is not known to spread between rooms over long distances such as through air ducts. Airborne transmission is able to particularly occur indoors, in high risk locations such as restaurants, choirs, gyms, nightclubs, offices, and religious venues, often when they are crowded or less ventilated. It also occurs in healthcare settings, often when aerosol-generating medical procedures are performed on COVID-19 patients.

 

Although it is considered possible there is no direct evidence of the virus being transmitted by skin to skin contact. A person could get COVID-19 indirectly by touching a contaminated surface or object before touching their own mouth, nose, or eyes, though this is not thought to be the main way the virus spreads. The virus is not known to spread through feces, urine, breast milk, food, wastewater, drinking water, or via animal disease vectors (although some animals can contract the virus from humans). It very rarely transmits from mother to baby during pregnancy.

 

Social distancing and the wearing of cloth face masks, surgical masks, respirators, or other face coverings are controls for droplet transmission. Transmission may be decreased indoors with well maintained heating and ventilation systems to maintain good air circulation and increase the use of outdoor air.

 

The number of people generally infected by one infected person varies. Coronavirus disease 2019 is more infectious than influenza, but less so than measles. It often spreads in clusters, where infections can be traced back to an index case or geographical location. There is a major role of "super-spreading events", where many people are infected by one person.

 

A person who is infected can transmit the virus to others up to two days before they themselves show symptoms, and even if symptoms never appear. People remain infectious in moderate cases for 7–12 days, and up to two weeks in severe cases. In October 2020, medical scientists reported evidence of reinfection in one person.

 

VIROLOGY

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan. All structural features of the novel SARS-CoV-2 virus particle occur in related coronaviruses in nature.

 

Outside the human body, the virus is destroyed by household soap, which bursts its protective bubble.

 

SARS-CoV-2 is closely related to the original SARS-CoV. It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13). The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S). The M protein of SARS-CoV-2 is about 98% similar to the M protein of bat SARS-CoV, maintains around 98% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only around 38% with the M protein of MERS-CoV. The structure of the M protein resembles the sugar transporter SemiSWEET.

 

The many thousands of SARS-CoV-2 variants are grouped into clades. Several different clade nomenclatures have been proposed. Nextstrain divides the variants into five clades (19A, 19B, 20A, 20B, and 20C), while GISAID divides them into seven (L, O, V, S, G, GH, and GR).

 

Several notable variants of SARS-CoV-2 emerged in late 2020. Cluster 5 emerged among minks and mink farmers in Denmark. After strict quarantines and a mink euthanasia campaign, it is believed to have been eradicated. The Variant of Concern 202012/01 (VOC 202012/01) is believed to have emerged in the United Kingdom in September. The 501Y.V2 Variant, which has the same N501Y mutation, arose independently in South Africa.

 

SARS-CoV-2 VARIANTS

Three known variants of SARS-CoV-2 are currently spreading among global populations as of January 2021 including the UK Variant (referred to as B.1.1.7) first found in London and Kent, a variant discovered in South Africa (referred to as 1.351), and a variant discovered in Brazil (referred to as P.1).

 

Using Whole Genome Sequencing, epidemiology and modelling suggest the new UK variant ‘VUI – 202012/01’ (the first Variant Under Investigation in December 2020) transmits more easily than other strains.

 

PATHOPHYSIOLOGY

COVID-19 can affect the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs). The lungs are the organs most affected by COVID-19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell. The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and decreasing ACE2 activity might be protective, though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective. As the alveolar disease progresses, respiratory failure might develop and death may follow.

 

Whether SARS-CoV-2 is able to invade the nervous system remains unknown. The virus is not detected in the CNS of the majority of COVID-19 people with neurological issues. However, SARS-CoV-2 has been detected at low levels in the brains of those who have died from COVID-19, but these results need to be confirmed. SARS-CoV-2 could cause respiratory failure through affecting the brain stem as other coronaviruses have been found to invade the CNS. While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain. The virus may also enter the bloodstream from the lungs and cross the blood-brain barrier to gain access to the CNS, possibly within an infected white blood cell.

 

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium as well as endothelial cells and enterocytes of the small intestine.

 

The virus can cause acute myocardial injury and chronic damage to the cardiovascular system. An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China, and is more frequent in severe disease. Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart. ACE2 receptors are highly expressed in the heart and are involved in heart function. A high incidence of thrombosis and venous thromboembolism have been found people transferred to Intensive care unit (ICU) with COVID-19 infections, and may be related to poor prognosis. Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels caused by blood clots) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in people infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia. Furthermore, microvascular blood vessel damage has been reported in a small number of tissue samples of the brains – without detected SARS-CoV-2 – and the olfactory bulbs from those who have died from COVID-19.

 

Another common cause of death is complications related to the kidneys. Early reports show that up to 30% of hospitalized patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.

 

Autopsies of people who died of COVID-19 have found diffuse alveolar damage, and lymphocyte-containing inflammatory infiltrates within the lung.

 

IMMUNOPATHOLOGY

Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, people with severe COVID-19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.

 

Additionally, people with COVID-19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.

 

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in people with COVID-19 . Lymphocytic infiltrates have also been reported at autopsy.

 

VIRAL AND HOST FACTORS

VIRUS PROTEINS

Multiple viral and host factors affect the pathogenesis of the virus. The S-protein, otherwise known as the spike protein, is the viral component that attaches to the host receptor via the ACE2 receptors. It includes two subunits: S1 and S2. S1 determines the virus host range and cellular tropism via the receptor binding domain. S2 mediates the membrane fusion of the virus to its potential cell host via the H1 and HR2, which are heptad repeat regions. Studies have shown that S1 domain induced IgG and IgA antibody levels at a much higher capacity. It is the focus spike proteins expression that are involved in many effective COVID-19 vaccines.

 

The M protein is the viral protein responsible for the transmembrane transport of nutrients. It is the cause of the bud release and the formation of the viral envelope. The N and E protein are accessory proteins that interfere with the host's immune response.

 

HOST FACTORS

Human angiotensin converting enzyme 2 (hACE2) is the host factor that SARS-COV2 virus targets causing COVID-19. Theoretically the usage of angiotensin receptor blockers (ARB) and ACE inhibitors upregulating ACE2 expression might increase morbidity with COVID-19, though animal data suggest some potential protective effect of ARB. However no clinical studies have proven susceptibility or outcomes. Until further data is available, guidelines and recommendations for hypertensive patients remain.

 

The virus' effect on ACE2 cell surfaces leads to leukocytic infiltration, increased blood vessel permeability, alveolar wall permeability, as well as decreased secretion of lung surfactants. These effects cause the majority of the respiratory symptoms. However, the aggravation of local inflammation causes a cytokine storm eventually leading to a systemic inflammatory response syndrome.

 

HOST CYTOKINE RESPONSE

The severity of the inflammation can be attributed to the severity of what is known as the cytokine storm. Levels of interleukin 1B, interferon-gamma, interferon-inducible protein 10, and monocyte chemoattractant protein 1 were all associated with COVID-19 disease severity. Treatment has been proposed to combat the cytokine storm as it remains to be one of the leading causes of morbidity and mortality in COVID-19 disease.

 

A cytokine storm is due to an acute hyperinflammatory response that is responsible for clinical illness in an array of diseases but in COVID-19, it is related to worse prognosis and increased fatality. The storm causes the acute respiratory distress syndrome, blood clotting events such as strokes, myocardial infarction, encephalitis, acute kidney injury, and vasculitis. The production of IL-1, IL-2, IL-6, TNF-alpha, and interferon-gamma, all crucial components of normal immune responses, inadvertently become the causes of a cytokine storm. The cells of the central nervous system, the microglia, neurons, and astrocytes, are also be involved in the release of pro-inflammatory cytokines affecting the nervous system, and effects of cytokine storms toward the CNS are not uncommon.

 

DIAGNOSIS

COVID-19 can provisionally be diagnosed on the basis of symptoms and confirmed using reverse transcription polymerase chain reaction (RT-PCR) or other nucleic acid testing of infected secretions. Along with laboratory testing, chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection. Detection of a past infection is possible with serological tests, which detect antibodies produced by the body in response to the infection.

 

VIRAL TESTING

The standard methods of testing for presence of SARS-CoV-2 are nucleic acid tests, which detects the presence of viral RNA fragments. As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited." The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used. Results are generally available within hours. The WHO has published several testing protocols for the disease.

 

A number of laboratories and companies have developed serological tests, which detect antibodies produced by the body in response to infection. Several have been evaluated by Public Health England and approved for use in the UK.

 

The University of Oxford's CEBM has pointed to mounting evidence that "a good proportion of 'new' mild cases and people re-testing positives after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with" and have called for "an international effort to standardize and periodically calibrate testing" On 7 September, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results."

 

IMAGING

Chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening. Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection. Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses. Characteristic imaging features on chest radiographs and computed tomography (CT) of people who are symptomatic include asymmetric peripheral ground-glass opacities without pleural effusions.

 

Many groups have created COVID-19 datasets that include imagery such as the Italian Radiological Society which has compiled an international online database of imaging findings for confirmed cases. Due to overlap with other infections such as adenovirus, imaging without confirmation by rRT-PCR is of limited specificity in identifying COVID-19. A large study in China compared chest CT results to PCR and demonstrated that though imaging is less specific for the infection, it is faster and more sensitive.

Coding

In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.

 

PATHOLOGY

The main pathological findings at autopsy are:

 

Macroscopy: pericarditis, lung consolidation and pulmonary oedema

Lung findings:

minor serous exudation, minor fibrin exudation

pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation

diffuse alveolar damage (DAD) with diffuse alveolar exudates. DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.

organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis

plasmocytosis in BAL

Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction

Liver: microvesicular steatosis

 

PREVENTION

Preventive measures to reduce the chances of infection include staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.

 

Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.

 

The first COVID-19 vaccine was granted regulatory approval on 2 December by the UK medicines regulator MHRA. It was evaluated for emergency use authorization (EUA) status by the US FDA, and in several other countries. Initially, the US National Institutes of Health guidelines do not recommend any medication for prevention of COVID-19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial. Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID-19 is trying to decrease and delay the epidemic peak, known as "flattening the curve". This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.

 

VACCINE

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus causing coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, there was an established body of knowledge about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which enabled accelerated development of various vaccine technologies during early 2020. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19.

 

In Phase III trials, several COVID‑19 vaccines have demonstrated efficacy as high as 95% in preventing symptomatic COVID‑19 infections. As of March 2021, 12 vaccines were authorized by at least one national regulatory authority for public use: two RNA vaccines (the Pfizer–BioNTech vaccine and the Moderna vaccine), four conventional inactivated vaccines (BBIBP-CorV, CoronaVac, Covaxin, and CoviVac), four viral vector vaccines (Sputnik V, the Oxford–AstraZeneca vaccine, Convidicea, and the Johnson & Johnson vaccine), and two protein subunit vaccines (EpiVacCorona and RBD-Dimer). In total, as of March 2021, 308 vaccine candidates were in various stages of development, with 73 in clinical research, including 24 in Phase I trials, 33 in Phase I–II trials, and 16 in Phase III development.

Many countries have implemented phased distribution plans that prioritize those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers. As of 17 March 2021, 400.22 million doses of COVID‑19 vaccine have been administered worldwide based on official reports from national health agencies. AstraZeneca-Oxford anticipates producing 3 billion doses in 2021, Pfizer-BioNTech 1.3 billion doses, and Sputnik V, Sinopharm, Sinovac, and Johnson & Johnson 1 billion doses each. Moderna targets producing 600 million doses and Convidicea 500 million doses in 2021. By December 2020, more than 10 billion vaccine doses had been preordered by countries, with about half of the doses purchased by high-income countries comprising 14% of the world's population.

 

SOCIAL DISTANCING

Social distancing (also known as physical distancing) includes infection control actions intended to slow the spread of the disease by minimising close contact between individuals. Methods include quarantines; travel restrictions; and the closing of schools, workplaces, stadiums, theatres, or shopping centres. Individuals may apply social distancing methods by staying at home, limiting travel, avoiding crowded areas, using no-contact greetings, and physically distancing themselves from others. Many governments are now mandating or recommending social distancing in regions affected by the outbreak.

 

Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing. In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID-19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.

 

SELF-ISOLATION

Self-isolation at home has been recommended for those diagnosed with COVID-19 and those who suspect they have been infected. Health agencies have issued detailed instructions for proper self-isolation. Many governments have mandated or recommended self-quarantine for entire populations. The strongest self-quarantine instructions have been issued to those in high-risk groups. Those who may have been exposed to someone with COVID-19 and those who have recently travelled to a country or region with the widespread transmission have been advised to self-quarantine for 14 days from the time of last possible exposure.

Face masks and respiratory hygiene

 

The WHO and the US CDC recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain. This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing. Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing. A face covering without vents or holes will also filter out particles containing the virus from inhaled and exhaled air, reducing the chances of infection. But, if the mask include an exhalation valve, a wearer that is infected (maybe without having noticed that, and asymptomatic) would transmit the virus outwards through it, despite any certification they can have. So the masks with exhalation valve are not for the infected wearers, and are not reliable to stop the pandemic in a large scale. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus.

 

Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease. When not wearing a mask, the CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. Proper hand hygiene after any cough or sneeze is encouraged. Healthcare professionals interacting directly with people who have COVID-19 are advised to use respirators at least as protective as NIOSH-certified N95 or equivalent, in addition to other personal protective equipment.

 

HAND-WASHING AND HYGIENE

Thorough hand hygiene after any cough or sneeze is required. The WHO also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose. The CDC recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available. For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant.

 

SURFACE CLEANING

After being expelled from the body, coronaviruses can survive on surfaces for hours to days. If a person touches the dirty surface, they may deposit the virus at the eyes, nose, or mouth where it can enter the body cause infection. Current evidence indicates that contact with infected surfaces is not the main driver of Covid-19, leading to recommendations for optimised disinfection procedures to avoid issues such as the increase of antimicrobial resistance through the use of inappropriate cleaning products and processes. Deep cleaning and other surface sanitation has been criticized as hygiene theater, giving a false sense of security against something primarily spread through the air.

 

The amount of time that the virus can survive depends significantly on the type of surface, the temperature, and the humidity. Coronaviruses die very quickly when exposed to the UV light in sunlight. Like other enveloped viruses, SARS-CoV-2 survives longest when the temperature is at room temperature or lower, and when the relative humidity is low (<50%).

 

On many surfaces, including as glass, some types of plastic, stainless steel, and skin, the virus can remain infective for several days indoors at room temperature, or even about a week under ideal conditions. On some surfaces, including cotton fabric and copper, the virus usually dies after a few hours. As a general rule of thumb, the virus dies faster on porous surfaces than on non-porous surfaces.

However, this rule is not absolute, and of the many surfaces tested, two with the longest survival times are N95 respirator masks and surgical masks, both of which are considered porous surfaces.

 

Surfaces may be decontaminated with 62–71 percent ethanol, 50–100 percent isopropanol, 0.1 percent sodium hypochlorite, 0.5 percent hydrogen peroxide, and 0.2–7.5 percent povidone-iodine. Other solutions, such as benzalkonium chloride and chlorhexidine gluconate, are less effective. Ultraviolet germicidal irradiation may also be used. The CDC recommends that if a COVID-19 case is suspected or confirmed at a facility such as an office or day care, all areas such as offices, bathrooms, common areas, shared electronic equipment like tablets, touch screens, keyboards, remote controls, and ATM machines used by the ill persons should be disinfected. A datasheet comprising the authorised substances to disinfection in the food industry (including suspension or surface tested, kind of surface, use dilution, disinfectant and inocuylum volumes) can be seen in the supplementary material of.

 

VENTILATION AND AIR FILTRATION

The WHO recommends ventilation and air filtration in public spaces to help clear out infectious aerosols.

 

HEALTHY DIET AND LIFESTYLE

The Harvard T.H. Chan School of Public Health recommends a healthy diet, being physically active, managing psychological stress, and getting enough sleep.

 

While there is no evidence that vitamin D is an effective treatment for COVID-19, there is limited evidence that vitamin D deficiency increases the risk of severe COVID-19 symptoms. This has led to recommendations for individuals with vitamin D deficiency to take vitamin D supplements as a way of mitigating the risk of COVID-19 and other health issues associated with a possible increase in deficiency due to social distancing.

 

TREATMENT

There is no specific, effective treatment or cure for coronavirus disease 2019 (COVID-19), the disease caused by the SARS-CoV-2 virus. Thus, the cornerstone of management of COVID-19 is supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support and prone positioning as needed, and medications or devices to support other affected vital organs.

 

Most cases of COVID-19 are mild. In these, supportive care includes medication such as paracetamol or NSAIDs to relieve symptoms (fever, body aches, cough), proper intake of fluids, rest, and nasal breathing. Good personal hygiene and a healthy diet are also recommended. The U.S. Centers for Disease Control and Prevention (CDC) recommend that those who suspect they are carrying the virus isolate themselves at home and wear a face mask.

 

People with more severe cases may need treatment in hospital. In those with low oxygen levels, use of the glucocorticoid dexamethasone is strongly recommended, as it can reduce the risk of death. Noninvasive ventilation and, ultimately, admission to an intensive care unit for mechanical ventilation may be required to support breathing. Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.

Several experimental treatments are being actively studied in clinical trials. Others were thought to be promising early in the pandemic, such as hydroxychloroquine and lopinavir/ritonavir, but later research found them to be ineffective or even harmful. Despite ongoing research, there is still not enough high-quality evidence to recommend so-called early treatment. Nevertheless, in the United States, two monoclonal antibody-based therapies are available for early use in cases thought to be at high risk of progression to severe disease. The antiviral remdesivir is available in the U.S., Canada, Australia, and several other countries, with varying restrictions; however, it is not recommended for people needing mechanical ventilation, and is discouraged altogether by the World Health Organization (WHO), due to limited evidence of its efficacy.

 

PROGNOSIS

The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. In 3–4% of cases (7.4% for those over age 65) symptoms are severe enough to cause hospitalization. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. The Italian Istituto Superiore di Sanità reported that the median time between the onset of symptoms and death was twelve days, with seven being hospitalised. However, people transferred to an ICU had a median time of ten days between hospitalisation and death. Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to ICU.

 

Some early studies suggest 10% to 20% of people with COVID-19 will experience symptoms lasting longer than a month.[191][192] A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath. On 30 October 2020 WHO chief Tedros Adhanom warned that "to a significant number of people, the COVID virus poses a range of serious long-term effects". He has described the vast spectrum of COVID-19 symptoms that fluctuate over time as "really concerning." They range from fatigue, a cough and shortness of breath, to inflammation and injury of major organs – including the lungs and heart, and also neurological and psychologic effects. Symptoms often overlap and can affect any system in the body. Infected people have reported cyclical bouts of fatigue, headaches, months of complete exhaustion, mood swings, and other symptoms. Tedros has concluded that therefore herd immunity is "morally unconscionable and unfeasible".

 

In terms of hospital readmissions about 9% of 106,000 individuals had to return for hospital treatment within 2 months of discharge. The average to readmit was 8 days since first hospital visit. There are several risk factors that have been identified as being a cause of multiple admissions to a hospital facility. Among these are advanced age (above 65 years of age) and presence of a chronic condition such as diabetes, COPD, heart failure or chronic kidney disease.

 

According to scientific reviews smokers are more likely to require intensive care or die compared to non-smokers, air pollution is similarly associated with risk factors, and pre-existing heart and lung diseases and also obesity contributes to an increased health risk of COVID-19.

 

It is also assumed that those that are immunocompromised are at higher risk of getting severely sick from SARS-CoV-2. One research that looked into the COVID-19 infections in hospitalized kidney transplant recipients found a mortality rate of 11%.

See also: Impact of the COVID-19 pandemic on children

 

Children make up a small proportion of reported cases, with about 1% of cases being under 10 years and 4% aged 10–19 years. They are likely to have milder symptoms and a lower chance of severe disease than adults. A European multinational study of hospitalized children published in The Lancet on 25 June 2020 found that about 8% of children admitted to a hospital needed intensive care. Four of those 582 children (0.7%) died, but the actual mortality rate could be "substantially lower" since milder cases that did not seek medical help were not included in the study.

 

Genetics also plays an important role in the ability to fight off the disease. For instance, those that do not produce detectable type I interferons or produce auto-antibodies against these may get much sicker from COVID-19. Genetic screening is able to detect interferon effector genes.

 

Pregnant women may be at higher risk of severe COVID-19 infection based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.

 

COMPLICATIONS

Complications may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death. Cardiovascular complications may include heart failure, arrhythmias, heart inflammation, and blood clots. Approximately 20–30% of people who present with COVID-19 have elevated liver enzymes, reflecting liver injury.

 

Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions). Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal. In very rare cases, acute encephalopathy can occur, and it can be considered in those who have been diagnosed with COVID-19 and have an altered mental status.

 

LONGER-TERM EFFECTS

Some early studies suggest that that 10 to 20% of people with COVID-19 will experience symptoms lasting longer than a month. A majority of those who were admitted to hospital with severe disease report long-term problems, including fatigue and shortness of breath. About 5-10% of patients admitted to hospital progress to severe or critical disease, including pneumonia and acute respiratory failure.

 

By a variety of mechanisms, the lungs are the organs most affected in COVID-19.[228] The majority of CT scans performed show lung abnormalities in people tested after 28 days of illness.

 

People with advanced age, severe disease, prolonged ICU stays, or who smoke are more likely to have long lasting effects, including pulmonary fibrosis. Overall, approximately one third of those investigated after 4 weeks will have findings of pulmonary fibrosis or reduced lung function as measured by DLCO, even in people who are asymptomatic, but with the suggestion of continuing improvement with the passing of more time.

 

IMMUNITY

The immune response by humans to CoV-2 virus occurs as a combination of the cell-mediated immunity and antibody production, just as with most other infections. Since SARS-CoV-2 has been in the human population only since December 2019, it remains unknown if the immunity is long-lasting in people who recover from the disease. The presence of neutralizing antibodies in blood strongly correlates with protection from infection, but the level of neutralizing antibody declines with time. Those with asymptomatic or mild disease had undetectable levels of neutralizing antibody two months after infection. In another study, the level of neutralizing antibody fell 4-fold 1 to 4 months after the onset of symptoms. However, the lack of antibody in the blood does not mean antibody will not be rapidly produced upon reexposure to SARS-CoV-2. Memory B cells specific for the spike and nucleocapsid proteins of SARS-CoV-2 last for at least 6 months after appearance of symptoms. Nevertheless, 15 cases of reinfection with SARS-CoV-2 have been reported using stringent CDC criteria requiring identification of a different variant from the second infection. There are likely to be many more people who have been reinfected with the virus. Herd immunity will not eliminate the virus if reinfection is common. Some other coronaviruses circulating in people are capable of reinfection after roughly a year. Nonetheless, on 3 March 2021, scientists reported that a much more contagious Covid-19 variant, Lineage P.1, first detected in Japan, and subsequently found in Brazil, as well as in several places in the United States, may be associated with Covid-19 disease reinfection after recovery from an earlier Covid-19 infection.

 

MORTALITY

Several measures are commonly used to quantify mortality. These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health. The mortality rate reflects the number of deaths within a specific demographic group divided by the population of that demographic group. Consequently, the mortality rate reflects the prevalence as well as the severity of the disease within a given population. Mortality rates are highly correlated to age, with relatively low rates for young people and relatively high rates among the elderly.

 

The case fatality rate (CFR) reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 2.2% (2,685,770/121,585,388) as of 18 March 2021. The number varies by region. The CFR may not reflect the true severity of the disease, because some infected individuals remain asymptomatic or experience only mild symptoms, and hence such infections may not be included in official case reports. Moreover, the CFR may vary markedly over time and across locations due to the availability of live virus tests.

 

INFECTION FATALITY RATE

A key metric in gauging the severity of COVID-19 is the infection fatality rate (IFR), also referred to as the infection fatality ratio or infection fatality risk. This metric is calculated by dividing the total number of deaths from the disease by the total number of infected individuals; hence, in contrast to the CFR, the IFR incorporates asymptomatic and undiagnosed infections as well as reported cases.

 

CURRENT ESTIMATES

A December 2020 systematic review and meta-analysis estimated that population IFR during the first wave of the pandemic was about 0.5% to 1% in many locations (including France, Netherlands, New Zealand, and Portugal), 1% to 2% in other locations (Australia, England, Lithuania, and Spain), and exceeded 2% in Italy. That study also found that most of these differences in IFR reflected corresponding differences in the age composition of the population and age-specific infection rates; in particular, the metaregression estimate of IFR is very low for children and younger adults (e.g., 0.002% at age 10 and 0.01% at age 25) but increases progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85. These results were also highlighted in a December 2020 report issued by the WHO.

 

EARLIER ESTIMATES OF IFR

At an early stage of the pandemic, the World Health Organization reported estimates of IFR between 0.3% and 1%.[ On 2 July, The WHO's chief scientist reported that the average IFR estimate presented at a two-day WHO expert forum was about 0.6%. In August, the WHO found that studies incorporating data from broad serology testing in Europe showed IFR estimates converging at approximately 0.5–1%. Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. As of 10 July, in New York City, with a population of 8.4 million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID-19 (0.3% of the population).Antibody testing in New York City suggested an IFR of ~0.9%,[258] and ~1.4%. In Bergamo province, 0.6% of the population has died. In September 2020 the U.S. Center for Disease Control & Prevention reported preliminary estimates of age-specific IFRs for public health planning purposes.

 

SEX DIFFERENCES

Early reviews of epidemiologic data showed gendered impact of the pandemic and a higher mortality rate in men in China and Italy. The Chinese Center for Disease Control and Prevention reported the death rate was 2.8% for men and 1.7% for women. Later reviews in June 2020 indicated that there is no significant difference in susceptibility or in CFR between genders. One review acknowledges the different mortality rates in Chinese men, suggesting that it may be attributable to lifestyle choices such as smoking and drinking alcohol rather than genetic factors. Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men. In Europe, 57% of the infected people were men and 72% of those died with COVID-19 were men. As of April 2020, the US government is not tracking sex-related data of COVID-19 infections. Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.

 

ETHNIC DIFFERENCES

In the US, a greater proportion of deaths due to COVID-19 have occurred among African Americans and other minority groups. Structural factors that prevent them from practicing social distancing include their concentration in crowded substandard housing and in "essential" occupations such as retail grocery workers, public transit employees, health-care workers and custodial staff. Greater prevalence of lacking health insurance and care and of underlying conditions such as diabetes, hypertension and heart disease also increase their risk of death. Similar issues affect Native American and Latino communities. According to a US health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults. The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water. Leaders have called for efforts to research and address the disparities. In the U.K., a greater proportion of deaths due to COVID-19 have occurred in those of a Black, Asian, and other ethnic minority background. More severe impacts upon victims including the relative incidence of the necessity of hospitalization requirements, and vulnerability to the disease has been associated via DNA analysis to be expressed in genetic variants at chromosomal region 3, features that are associated with European Neanderthal heritage. That structure imposes greater risks that those affected will develop a more severe form of the disease. The findings are from Professor Svante Pääbo and researchers he leads at the Max Planck Institute for Evolutionary Anthropology and the Karolinska Institutet. This admixture of modern human and Neanderthal genes is estimated to have occurred roughly between 50,000 and 60,000 years ago in Southern Europe.

 

COMORBIDITIES

Most of those who die of COVID-19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease. According to March data from the United States, 89% of those hospitalised had preexisting conditions. The Italian Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 96.1% of people had at least one comorbidity with the average person having 3.4 diseases. According to this report the most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), Ischemic Heart Disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).

 

Most critical respiratory comorbidities according to the CDC, are: moderate or severe asthma, pre-existing COPD, pulmonary fibrosis, cystic fibrosis. Evidence stemming from meta-analysis of several smaller research papers also suggests that smoking can be associated with worse outcomes. When someone with existing respiratory problems is infected with COVID-19, they might be at greater risk for severe symptoms. COVID-19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage.

 

In August 2020 the CDC issued a caution that tuberculosis infections could increase the risk of severe illness or death. The WHO recommended that people with respiratory symptoms be screened for both diseases, as testing positive for COVID-19 couldn't rule out co-infections. Some projections have estimated that reduced TB detection due to the pandemic could result in 6.3 million additional TB cases and 1.4 million TB related deaths by 2025.

 

NAME

During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus", with the disease sometimes called "Wuhan pneumonia". In the past, many diseases have been named after geographical locations, such as the Spanish flu, Middle East Respiratory Syndrome, and Zika virus. In January 2020, the WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent social stigma. The official names COVID-19 and SARS-CoV-2 were issued by the WHO on 11 February 2020. Tedros Adhanom explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019). The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.

 

HISTORY

The virus is thought to be natural and of an animal origin, through spillover infection. There are several theories about where the first case (the so-called patient zero) originated. Phylogenetics estimates that SARS-CoV-2 arose in October or November 2019. Evidence suggests that it descends from a coronavirus that infects wild bats, and spread to humans through an intermediary wildlife host.

 

The first known human infections were in Wuhan, Hubei, China. A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, reported the earliest date of onset of symptoms as 1 December 2019.Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019. Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020. According to official Chinese sources, these were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals. In May 2020 George Gao, the director of the CDC, said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early superspreading event, but that it was not the site of the initial outbreak.[ Traces of the virus have been found in wastewater samples that were collected in Milan and Turin, Italy, on 18 December 2019.

 

By December 2019, the spread of infection was almost entirely driven by human-to-human transmission. The number of coronavirus cases in Hubei gradually increased, reaching 60 by 20 December, and at least 266 by 31 December. On 24 December, Wuhan Central Hospital sent a bronchoalveolar lavage fluid (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus. A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December. On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for SARS, causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. The Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause" that same evening. Eight of these doctors, including Li Wenliang (punished on 3 January), were later admonished by the police for spreading false rumours and another, Ai Fen, was reprimanded by her superiors for raising the alarm.

 

The Wuhan Municipal Health Commission made the first public announcement of a pneumonia outbreak of unknown cause on 31 December, confirming 27 cases—enough to trigger an investigation.

 

During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days. In early and mid-January 2020, the virus spread to other Chinese provinces, helped by the Chinese New Year migration and Wuhan being a transport hub and major rail interchange. On 20 January, China reported nearly 140 new cases in one day, including two people in Beijing and one in Shenzhen. Later official data shows 6,174 people had already developed symptoms by then, and more may have been infected. A report in The Lancet on 24 January indicated human transmission, strongly recommended personal protective equipment for health workers, and said testing for the virus was essential due to its "pandemic potential". On 30 January, the WHO declared the coronavirus a Public Health Emergency of International Concern. By this time, the outbreak spread by a factor of 100 to 200 times.

 

Italy had its first confirmed cases on 31 January 2020, two tourists from China. As of 13 March 2020 the WHO considered Europe the active centre of the pandemic. Italy overtook China as the country with the most deaths on 19 March 2020. By 26 March the United States had overtaken China and Italy with the highest number of confirmed cases in the world. Research on coronavirus genomes indicates the majority of COVID-19 cases in New York came from European travellers, rather than directly from China or any other Asian country. Retesting of prior samples found a person in France who had the virus on 27 December 2019, and a person in the United States who died from the disease on 6 February 2020.

 

After 55 days without a locally transmitted case, Beijing reported a new COVID-19 case on 11 June 2020 which was followed by two more cases on 12 June. By 15 June there were 79 cases officially confirmed, most of them were people that went to Xinfadi Wholesale Market.

 

RT-PCR testing of untreated wastewater samples from Brazil and Italy have suggested detection of SARS-CoV-2 as early as November and December 2019, respectively, but the methods of such sewage studies have not been optimised, many have not been peer reviewed, details are often missing, and there is a risk of false positives due to contamination or if only one gene target is detected. A September 2020 review journal article said, "The possibility that the COVID-19 infection had already spread to Europe at the end of last year is now indicated by abundant, even if partially circumstantial, evidence", including pneumonia case numbers and radiology in France and Italy in November and December.

 

MISINFORMATION

After the initial outbreak of COVID-19, misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease rapidly spread online.

 

In September 2020, the U.S. CDC published preliminary estimates of the risk of death by age groups in the United States, but those estimates were widely misreported and misunderstood.

 

OTHER ANIMALS

Humans appear to be capable of spreading the virus to some other animals, a type of disease transmission referred to as zooanthroponosis.

 

Some pets, especially cats and ferrets, can catch this virus from infected humans. Symptoms in cats include respiratory (such as a cough) and digestive symptoms. Cats can spread the virus to other cats, and may be able to spread the virus to humans, but cat-to-human transmission of SARS-CoV-2 has not been proven. Compared to cats, dogs are less susceptible to this infection. Behaviors which increase the risk of transmission include kissing, licking, and petting the animal.

 

The virus does not appear to be able to infect pigs, ducks, or chickens at all.[ Mice, rats, and rabbits, if they can be infected at all, are unlikely to be involved in spreading the virus.

 

Tigers and lions in zoos have become infected as a result of contact with infected humans. As expected, monkeys and great ape species such as orangutans can also be infected with the COVID-19 virus.

 

Minks, which are in the same family as ferrets, have been infected. Minks may be asymptomatic, and can also spread the virus to humans. Multiple countries have identified infected animals in mink farms. Denmark, a major producer of mink pelts, ordered the slaughter of all minks over fears of viral mutations. A vaccine for mink and other animals is being researched.

 

RESEARCH

International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers. The CDC has classified it to require a BSL3 grade laboratory. There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand.

 

As of December 2020, hundreds of clinical trials have been undertaken, with research happening on every continent except Antarctica. As of November 2020, more than 200 possible treatments had been studied in humans so far.

Transmission and prevention research

Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission, diagnosis and prognosis of infection, estimation of the impact of interventions, or allocation of resources. Modelling studies are mostly based on epidemiological models, estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID-19 including computational fluid dynamics models to study the flow physics of COVID-19, retrofits of crowd movement models to study occupant exposure, mobility-data based models to investigate transmission, or the use of macroeconomic models to assess the economic impact of the pandemic. Further, conceptual frameworks from crisis management research have been applied to better understand the effects of COVID-19 on organizations worldwide.

 

TREATMENT-RELATED RESEARCH

Repurposed antiviral drugs make up most of the research into COVID-19 treatments. Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.

 

In March 2020, the World Health Organization (WHO) initiated the Solidarity trial to assess the treatment effects of some promising drugs: an experimental drug called remdesivir; anti-malarial drugs chloroquine and hydroxychloroquine; two anti-HIV drugs, lopinavir/ritonavir; and interferon-beta. More than 300 active clinical trials were underway as of April 2020.

 

Research on the antimalarial drugs hydroxychloroquine and chloroquine showed that they were ineffective at best, and that they may reduce the antiviral activity of remdesivir. By May 2020, France, Italy, and Belgium had banned the use of hydroxychloroquine as a COVID-19 treatment.

 

In June, initial results from the randomised RECOVERY Trial in the United Kingdom showed that dexamethasone reduced mortality by one third for people who are critically ill on ventilators and one fifth for those receiving supplemental oxygen. Because this is a well-tested and widely available treatment, it was welcomed by the WHO, which is in the process of updating treatment guidelines to include dexamethasone and other steroids. Based on those preliminary results, dexamethasone treatment has been recommended by the NIH for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID-19 who do not require supplemental oxygen.

 

In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19. The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID-19 (strong recommendation, based on moderate certainty evidence). The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID-19 (conditional recommendation, based on low certainty evidence). The updated guidance was based on a meta-analysis of clinical trials of critically ill COVID-19 patients.

 

WIKIPEDIA

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to an ongoing pandemic.

 

Symptoms of COVID-19 are variable, but often include fever, cough, fatigue, breathing difficulties, and loss of smell and taste. Symptoms begin one to fourteen days after exposure to the virus. Of those people who develop noticeable symptoms, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction). Older people are more likely to have severe symptoms. At least a third of the people who are infected with the virus remain asymptomatic and do not develop noticeable symptoms at any point in time, but they still can spread the disease.[ Around 20% of those people will remain asymptomatic throughout infection, and the rest will develop symptoms later on, becoming pre-symptomatic rather than asymptomatic and therefore having a higher risk of transmitting the virus to others. Some people continue to experience a range of effects—known as long COVID—for months after recovery, and damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.

 

The virus that causes COVID-19 spreads mainly when an infected person is in close contact[a] with another person. Small droplets and aerosols containing the virus can spread from an infected person's nose and mouth as they breathe, cough, sneeze, sing, or speak. Other people are infected if the virus gets into their mouth, nose or eyes. The virus may also spread via contaminated surfaces, although this is not thought to be the main route of transmission. The exact route of transmission is rarely proven conclusively, but infection mainly happens when people are near each other for long enough. People who are infected can transmit the virus to another person up to two days before they themselves show symptoms, as can people who do not experience symptoms. People remain infectious for up to ten days after the onset of symptoms in moderate cases and up to 20 days in severe cases. Several testing methods have been developed to diagnose the disease. The standard diagnostic method is by detection of the virus' nucleic acid by real-time reverse transcription polymerase chain reaction (rRT-PCR), transcription-mediated amplification (TMA), or by reverse transcription loop-mediated isothermal amplification (RT-LAMP) from a nasopharyngeal swab.

 

Preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. The use of face masks or coverings has been recommended in public settings to minimise the risk of transmissions. Several vaccines have been developed and several countries have initiated mass vaccination campaigns.

 

Although work is underway to develop drugs that inhibit the virus, the primary treatment is currently symptomatic. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures.

 

SIGNS AND SYSTOMS

Symptoms of COVID-19 are variable, ranging from mild symptoms to severe illness. Common symptoms include headache, loss of smell and taste, nasal congestion and rhinorrhea, cough, muscle pain, sore throat, fever, diarrhea, and breathing difficulties. People with the same infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea. In people without prior ear, nose, and throat disorders, loss of taste combined with loss of smell is associated with COVID-19.

 

Most people (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) and 5% of patients suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction). At least a third of the people who are infected with the virus do not develop noticeable symptoms at any point in time. These asymptomatic carriers tend not to get tested and can spread the disease. Other infected people will develop symptoms later, called "pre-symptomatic", or have very mild symptoms and can also spread the virus.

 

As is common with infections, there is a delay between the moment a person first becomes infected and the appearance of the first symptoms. The median delay for COVID-19 is four to five days. Most symptomatic people experience symptoms within two to seven days after exposure, and almost all will experience at least one symptom within 12 days.

Most people recover from the acute phase of the disease. However, some people continue to experience a range of effects for months after recovery—named long COVID—and damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.

 

CAUSE

TRANSMISSION

Coronavirus disease 2019 (COVID-19) spreads from person to person mainly through the respiratory route after an infected person coughs, sneezes, sings, talks or breathes. A new infection occurs when virus-containing particles exhaled by an infected person, either respiratory droplets or aerosols, get into the mouth, nose, or eyes of other people who are in close contact with the infected person. During human-to-human transmission, an average 1000 infectious SARS-CoV-2 virions are thought to initiate a new infection.

 

The closer people interact, and the longer they interact, the more likely they are to transmit COVID-19. Closer distances can involve larger droplets (which fall to the ground) and aerosols, whereas longer distances only involve aerosols. Larger droplets can also turn into aerosols (known as droplet nuclei) through evaporation. The relative importance of the larger droplets and the aerosols is not clear as of November 2020; however, the virus is not known to spread between rooms over long distances such as through air ducts. Airborne transmission is able to particularly occur indoors, in high risk locations such as restaurants, choirs, gyms, nightclubs, offices, and religious venues, often when they are crowded or less ventilated. It also occurs in healthcare settings, often when aerosol-generating medical procedures are performed on COVID-19 patients.

 

Although it is considered possible there is no direct evidence of the virus being transmitted by skin to skin contact. A person could get COVID-19 indirectly by touching a contaminated surface or object before touching their own mouth, nose, or eyes, though this is not thought to be the main way the virus spreads. The virus is not known to spread through feces, urine, breast milk, food, wastewater, drinking water, or via animal disease vectors (although some animals can contract the virus from humans). It very rarely transmits from mother to baby during pregnancy.

 

Social distancing and the wearing of cloth face masks, surgical masks, respirators, or other face coverings are controls for droplet transmission. Transmission may be decreased indoors with well maintained heating and ventilation systems to maintain good air circulation and increase the use of outdoor air.

 

The number of people generally infected by one infected person varies. Coronavirus disease 2019 is more infectious than influenza, but less so than measles. It often spreads in clusters, where infections can be traced back to an index case or geographical location. There is a major role of "super-spreading events", where many people are infected by one person.

 

A person who is infected can transmit the virus to others up to two days before they themselves show symptoms, and even if symptoms never appear. People remain infectious in moderate cases for 7–12 days, and up to two weeks in severe cases. In October 2020, medical scientists reported evidence of reinfection in one person.

 

VIROLOGY

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan. All structural features of the novel SARS-CoV-2 virus particle occur in related coronaviruses in nature.

 

Outside the human body, the virus is destroyed by household soap, which bursts its protective bubble.

 

SARS-CoV-2 is closely related to the original SARS-CoV. It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13). The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S). The M protein of SARS-CoV-2 is about 98% similar to the M protein of bat SARS-CoV, maintains around 98% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only around 38% with the M protein of MERS-CoV. The structure of the M protein resembles the sugar transporter SemiSWEET.

 

The many thousands of SARS-CoV-2 variants are grouped into clades. Several different clade nomenclatures have been proposed. Nextstrain divides the variants into five clades (19A, 19B, 20A, 20B, and 20C), while GISAID divides them into seven (L, O, V, S, G, GH, and GR).

 

Several notable variants of SARS-CoV-2 emerged in late 2020. Cluster 5 emerged among minks and mink farmers in Denmark. After strict quarantines and a mink euthanasia campaign, it is believed to have been eradicated. The Variant of Concern 202012/01 (VOC 202012/01) is believed to have emerged in the United Kingdom in September. The 501Y.V2 Variant, which has the same N501Y mutation, arose independently in South Africa.

 

SARS-CoV-2 VARIANTS

Three known variants of SARS-CoV-2 are currently spreading among global populations as of January 2021 including the UK Variant (referred to as B.1.1.7) first found in London and Kent, a variant discovered in South Africa (referred to as 1.351), and a variant discovered in Brazil (referred to as P.1).

 

Using Whole Genome Sequencing, epidemiology and modelling suggest the new UK variant ‘VUI – 202012/01’ (the first Variant Under Investigation in December 2020) transmits more easily than other strains.

 

PATHOPHYSIOLOGY

COVID-19 can affect the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs). The lungs are the organs most affected by COVID-19 because the virus accesses host cells via the enzyme angiotensin-converting enzyme 2 (ACE2), which is most abundant in type II alveolar cells of the lungs. The virus uses a special surface glycoprotein called a "spike" (peplomer) to connect to ACE2 and enter the host cell. The density of ACE2 in each tissue correlates with the severity of the disease in that tissue and decreasing ACE2 activity might be protective, though another view is that increasing ACE2 using angiotensin II receptor blocker medications could be protective. As the alveolar disease progresses, respiratory failure might develop and death may follow.

 

Whether SARS-CoV-2 is able to invade the nervous system remains unknown. The virus is not detected in the CNS of the majority of COVID-19 people with neurological issues. However, SARS-CoV-2 has been detected at low levels in the brains of those who have died from COVID-19, but these results need to be confirmed. SARS-CoV-2 could cause respiratory failure through affecting the brain stem as other coronaviruses have been found to invade the CNS. While virus has been detected in cerebrospinal fluid of autopsies, the exact mechanism by which it invades the CNS remains unclear and may first involve invasion of peripheral nerves given the low levels of ACE2 in the brain. The virus may also enter the bloodstream from the lungs and cross the blood-brain barrier to gain access to the CNS, possibly within an infected white blood cell.

 

The virus also affects gastrointestinal organs as ACE2 is abundantly expressed in the glandular cells of gastric, duodenal and rectal epithelium as well as endothelial cells and enterocytes of the small intestine.

 

The virus can cause acute myocardial injury and chronic damage to the cardiovascular system. An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China, and is more frequent in severe disease. Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart. ACE2 receptors are highly expressed in the heart and are involved in heart function. A high incidence of thrombosis and venous thromboembolism have been found people transferred to Intensive care unit (ICU) with COVID-19 infections, and may be related to poor prognosis. Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels caused by blood clots) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in people infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia. Furthermore, microvascular blood vessel damage has been reported in a small number of tissue samples of the brains – without detected SARS-CoV-2 – and the olfactory bulbs from those who have died from COVID-19.

 

Another common cause of death is complications related to the kidneys. Early reports show that up to 30% of hospitalized patients both in China and in New York have experienced some injury to their kidneys, including some persons with no previous kidney problems.

 

Autopsies of people who died of COVID-19 have found diffuse alveolar damage, and lymphocyte-containing inflammatory infiltrates within the lung.

 

IMMUNOPATHOLOGY

Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, people with severe COVID-19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL-2, IL-7, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α), and tumour necrosis factor-α (TNF-α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.

 

Additionally, people with COVID-19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.

 

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T-cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in people with COVID-19 . Lymphocytic infiltrates have also been reported at autopsy.

 

VIRAL AND HOST FACTORS

VIRUS PROTEINS

Multiple viral and host factors affect the pathogenesis of the virus. The S-protein, otherwise known as the spike protein, is the viral component that attaches to the host receptor via the ACE2 receptors. It includes two subunits: S1 and S2. S1 determines the virus host range and cellular tropism via the receptor binding domain. S2 mediates the membrane fusion of the virus to its potential cell host via the H1 and HR2, which are heptad repeat regions. Studies have shown that S1 domain induced IgG and IgA antibody levels at a much higher capacity. It is the focus spike proteins expression that are involved in many effective COVID-19 vaccines.

 

The M protein is the viral protein responsible for the transmembrane transport of nutrients. It is the cause of the bud release and the formation of the viral envelope. The N and E protein are accessory proteins that interfere with the host's immune response.

 

HOST FACTORS

Human angiotensin converting enzyme 2 (hACE2) is the host factor that SARS-COV2 virus targets causing COVID-19. Theoretically the usage of angiotensin receptor blockers (ARB) and ACE inhibitors upregulating ACE2 expression might increase morbidity with COVID-19, though animal data suggest some potential protective effect of ARB. However no clinical studies have proven susceptibility or outcomes. Until further data is available, guidelines and recommendations for hypertensive patients remain.

 

The virus' effect on ACE2 cell surfaces leads to leukocytic infiltration, increased blood vessel permeability, alveolar wall permeability, as well as decreased secretion of lung surfactants. These effects cause the majority of the respiratory symptoms. However, the aggravation of local inflammation causes a cytokine storm eventually leading to a systemic inflammatory response syndrome.

 

HOST CYTOKINE RESPONSE

The severity of the inflammation can be attributed to the severity of what is known as the cytokine storm. Levels of interleukin 1B, interferon-gamma, interferon-inducible protein 10, and monocyte chemoattractant protein 1 were all associated with COVID-19 disease severity. Treatment has been proposed to combat the cytokine storm as it remains to be one of the leading causes of morbidity and mortality in COVID-19 disease.

 

A cytokine storm is due to an acute hyperinflammatory response that is responsible for clinical illness in an array of diseases but in COVID-19, it is related to worse prognosis and increased fatality. The storm causes the acute respiratory distress syndrome, blood clotting events such as strokes, myocardial infarction, encephalitis, acute kidney injury, and vasculitis. The production of IL-1, IL-2, IL-6, TNF-alpha, and interferon-gamma, all crucial components of normal immune responses, inadvertently become the causes of a cytokine storm. The cells of the central nervous system, the microglia, neurons, and astrocytes, are also be involved in the release of pro-inflammatory cytokines affecting the nervous system, and effects of cytokine storms toward the CNS are not uncommon.

 

DIAGNOSIS

COVID-19 can provisionally be diagnosed on the basis of symptoms and confirmed using reverse transcription polymerase chain reaction (RT-PCR) or other nucleic acid testing of infected secretions. Along with laboratory testing, chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection. Detection of a past infection is possible with serological tests, which detect antibodies produced by the body in response to the infection.

 

VIRAL TESTING

The standard methods of testing for presence of SARS-CoV-2 are nucleic acid tests, which detects the presence of viral RNA fragments. As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited." The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used. Results are generally available within hours. The WHO has published several testing protocols for the disease.

 

A number of laboratories and companies have developed serological tests, which detect antibodies produced by the body in response to infection. Several have been evaluated by Public Health England and approved for use in the UK.

 

The University of Oxford's CEBM has pointed to mounting evidence that "a good proportion of 'new' mild cases and people re-testing positives after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with" and have called for "an international effort to standardize and periodically calibrate testing" On 7 September, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results."

 

IMAGING

Chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening. Bilateral multilobar ground-glass opacities with a peripheral, asymmetric, and posterior distribution are common in early infection. Subpleural dominance, crazy paving (lobular septal thickening with variable alveolar filling), and consolidation may appear as the disease progresses. Characteristic imaging features on chest radiographs and computed tomography (CT) of people who are symptomatic include asymmetric peripheral ground-glass opacities without pleural effusions.

 

Many groups have created COVID-19 datasets that include imagery such as the Italian Radiological Society which has compiled an international online database of imaging findings for confirmed cases. Due to overlap with other infections such as adenovirus, imaging without confirmation by rRT-PCR is of limited specificity in identifying COVID-19. A large study in China compared chest CT results to PCR and demonstrated that though imaging is less specific for the infection, it is faster and more sensitive.

Coding

In late 2019, the WHO assigned emergency ICD-10 disease codes U07.1 for deaths from lab-confirmed SARS-CoV-2 infection and U07.2 for deaths from clinically or epidemiologically diagnosed COVID-19 without lab-confirmed SARS-CoV-2 infection.

 

PATHOLOGY

The main pathological findings at autopsy are:

 

Macroscopy: pericarditis, lung consolidation and pulmonary oedema

Lung findings:

minor serous exudation, minor fibrin exudation

pulmonary oedema, pneumocyte hyperplasia, large atypical pneumocytes, interstitial inflammation with lymphocytic infiltration and multinucleated giant cell formation

diffuse alveolar damage (DAD) with diffuse alveolar exudates. DAD is the cause of acute respiratory distress syndrome (ARDS) and severe hypoxemia.

organisation of exudates in alveolar cavities and pulmonary interstitial fibrosis

plasmocytosis in BAL

Blood: disseminated intravascular coagulation (DIC); leukoerythroblastic reaction

Liver: microvesicular steatosis

 

PREVENTION

Preventive measures to reduce the chances of infection include staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, washing hands with soap and water often and for at least 20 seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.

 

Those diagnosed with COVID-19 or who believe they may be infected are advised by the CDC to stay home except to get medical care, call ahead before visiting a healthcare provider, wear a face mask before entering the healthcare provider's office and when in any room or vehicle with another person, cover coughs and sneezes with a tissue, regularly wash hands with soap and water and avoid sharing personal household items.

 

The first COVID-19 vaccine was granted regulatory approval on 2 December by the UK medicines regulator MHRA. It was evaluated for emergency use authorization (EUA) status by the US FDA, and in several other countries. Initially, the US National Institutes of Health guidelines do not recommend any medication for prevention of COVID-19, before or after exposure to the SARS-CoV-2 virus, outside the setting of a clinical trial. Without a vaccine, other prophylactic measures, or effective treatments, a key part of managing COVID-19 is trying to decrease and delay the epidemic peak, known as "flattening the curve". This is done by slowing the infection rate to decrease the risk of health services being overwhelmed, allowing for better treatment of current cases, and delaying additional cases until effective treatments or a vaccine become available.

 

VACCINE

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus causing coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, there was an established body of knowledge about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which enabled accelerated development of various vaccine technologies during early 2020. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19.

 

In Phase III trials, several COVID‑19 vaccines have demonstrated efficacy as high as 95% in preventing symptomatic COVID‑19 infections. As of March 2021, 12 vaccines were authorized by at least one national regulatory authority for public use: two RNA vaccines (the Pfizer–BioNTech vaccine and the Moderna vaccine), four conventional inactivated vaccines (BBIBP-CorV, CoronaVac, Covaxin, and CoviVac), four viral vector vaccines (Sputnik V, the Oxford–AstraZeneca vaccine, Convidicea, and the Johnson & Johnson vaccine), and two protein subunit vaccines (EpiVacCorona and RBD-Dimer). In total, as of March 2021, 308 vaccine candidates were in various stages of development, with 73 in clinical research, including 24 in Phase I trials, 33 in Phase I–II trials, and 16 in Phase III development.

Many countries have implemented phased distribution plans that prioritize those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers. As of 17 March 2021, 400.22 million doses of COVID‑19 vaccine have been administered worldwide based on official reports from national health agencies. AstraZeneca-Oxford anticipates producing 3 billion doses in 2021, Pfizer-BioNTech 1.3 billion doses, and Sputnik V, Sinopharm, Sinovac, and Johnson & Johnson 1 billion doses each. Moderna targets producing 600 million doses and Convidicea 500 million doses in 2021. By December 2020, more than 10 billion vaccine doses had been preordered by countries, with about half of the doses purchased by high-income countries comprising 14% of the world's population.

 

SOCIAL DISTANCING

Social distancing (also known as physical distancing) includes infection control actions intended to slow the spread of the disease by minimising close contact between individuals. Methods include quarantines; travel restrictions; and the closing of schools, workplaces, stadiums, theatres, or shopping centres. Individuals may apply social distancing methods by staying at home, limiting travel, avoiding crowded areas, using no-contact greetings, and physically distancing themselves from others. Many governments are now mandating or recommending social distancing in regions affected by the outbreak.

 

Outbreaks have occurred in prisons due to crowding and an inability to enforce adequate social distancing. In the United States, the prisoner population is aging and many of them are at high risk for poor outcomes from COVID-19 due to high rates of coexisting heart and lung disease, and poor access to high-quality healthcare.

 

SELF-ISOLATION

Self-isolation at home has been recommended for those diagnosed with COVID-19 and those who suspect they have been infected. Health agencies have issued detailed instructions for proper self-isolation. Many governments have mandated or recommended self-quarantine for entire populations. The strongest self-quarantine instructions have been issued to those in high-risk groups. Those who may have been exposed to someone with COVID-19 and those who have recently travelled to a country or region with the widespread transmission have been advised to self-quarantine for 14 days from the time of last possible exposure.

Face masks and respiratory hygiene

 

The WHO and the US CDC recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain. This recommendation is meant to reduce the spread of the disease by asymptomatic and pre-symptomatic individuals and is complementary to established preventive measures such as social distancing. Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing. A face covering without vents or holes will also filter out particles containing the virus from inhaled and exhaled air, reducing the chances of infection. But, if the mask include an exhalation valve, a wearer that is infected (maybe without having noticed that, and asymptomatic) would transmit the virus outwards through it, despite any certification they can have. So the masks with exhalation valve are not for the infected wearers, and are not reliable to stop the pandemic in a large scale. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus.

 

Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease. When not wearing a mask, the CDC recommends covering the mouth and nose with a tissue when coughing or sneezing and recommends using the inside of the elbow if no tissue is available. Proper hand hygiene after any cough or sneeze is encouraged. Healthcare professionals interacting directly with people who have COVID-19 are advised to use respirators at least as protective as NIOSH-certified N95 or equivalent, in addition to other personal protective equipment.

 

HAND-WASHING AND HYGIENE

Thorough hand hygiene after any cough or sneeze is required. The WHO also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose. The CDC recommends using an alcohol-based hand sanitiser with at least 60% alcohol, but only when soap and water are not readily available. For areas where commercial hand sanitisers are not readily available, the WHO provides two formulations for local production. In these formulations, the antimicrobial activity arises from ethanol or isopropanol. Hydrogen peroxide is used to help eliminate bacterial spores in the alcohol; it is "not an active substance for hand antisepsis". Glycerol is added as a humectant.

 

SURFACE CLEANING

After being expelled from the body, coronaviruses can survive on surfaces for hours to days. If a person touches the dirty surface, they may deposit the virus at the eyes, nose, or mouth where it can enter the body cause infection. Current evidence indicates that contact with infected surfaces is not the main driver of Covid-19, leading to recommendations for optimised disinfection procedures to avoid issues such as the increase of antimicrobial resistance through the use of inappropriate cleaning products and processes. Deep cleaning and other surface sanitation has been criticized as hygiene theater, giving a false sense of security against something primarily spread through the air.

 

The amount of time that the virus can survive depends significantly on the type of surface, the temperature, and the humidity. Coronaviruses die very quickly when exposed to the UV light in sunlight. Like other enveloped viruses, SARS-CoV-2 survives longest when the temperature is at room temperature or lower, and when the relative humidity is low (<50%).

 

On many surfaces, including as glass, some types of plastic, stainless steel, and skin, the virus can remain infective for several days indoors at room temperature, or even about a week under ideal conditions. On some surfaces, including cotton fabric and copper, the virus usually dies after a few hours. As a general rule of thumb, the virus dies faster on porous surfaces than on non-porous surfaces.

However, this rule is not absolute, and of the many surfaces tested, two with the longest survival times are N95 respirator masks and surgical masks, both of which are considered porous surfaces.

 

Surfaces may be decontaminated with 62–71 percent ethanol, 50–100 percent isopropanol, 0.1 percent sodium hypochlorite, 0.5 percent hydrogen peroxide, and 0.2–7.5 percent povidone-iodine. Other solutions, such as benzalkonium chloride and chlorhexidine gluconate, are less effective. Ultraviolet germicidal irradiation may also be used. The CDC recommends that if a COVID-19 case is suspected or confirmed at a facility such as an office or day care, all areas such as offices, bathrooms, common areas, shared electronic equipment like tablets, touch screens, keyboards, remote controls, and ATM machines used by the ill persons should be disinfected. A datasheet comprising the authorised substances to disinfection in the food industry (including suspension or surface tested, kind of surface, use dilution, disinfectant and inocuylum volumes) can be seen in the supplementary material of.

 

VENTILATION AND AIR FILTRATION

The WHO recommends ventilation and air filtration in public spaces to help clear out infectious aerosols.

 

HEALTHY DIET AND LIFESTYLE

The Harvard T.H. Chan School of Public Health recommends a healthy diet, being physically active, managing psychological stress, and getting enough sleep.

 

While there is no evidence that vitamin D is an effective treatment for COVID-19, there is limited evidence that vitamin D deficiency increases the risk of severe COVID-19 symptoms. This has led to recommendations for individuals with vitamin D deficiency to take vitamin D supplements as a way of mitigating the risk of COVID-19 and other health issues associated with a possible increase in deficiency due to social distancing.

 

TREATMENT

There is no specific, effective treatment or cure for coronavirus disease 2019 (COVID-19), the disease caused by the SARS-CoV-2 virus. Thus, the cornerstone of management of COVID-19 is supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support and prone positioning as needed, and medications or devices to support other affected vital organs.

 

Most cases of COVID-19 are mild. In these, supportive care includes medication such as paracetamol or NSAIDs to relieve symptoms (fever, body aches, cough), proper intake of fluids, rest, and nasal breathing. Good personal hygiene and a healthy diet are also recommended. The U.S. Centers for Disease Control and Prevention (CDC) recommend that those who suspect they are carrying the virus isolate themselves at home and wear a face mask.

 

People with more severe cases may need treatment in hospital. In those with low oxygen levels, use of the glucocorticoid dexamethasone is strongly recommended, as it can reduce the risk of death. Noninvasive ventilation and, ultimately, admission to an intensive care unit for mechanical ventilation may be required to support breathing. Extracorporeal membrane oxygenation (ECMO) has been used to address the issue of respiratory failure, but its benefits are still under consideration.

Several experimental treatments are being actively studied in clinical trials. Others were thought to be promising early in the pandemic, such as hydroxychloroquine and lopinavir/ritonavir, but later research found them to be ineffective or even harmful. Despite ongoing research, there is still not enough high-quality evidence to recommend so-called early treatment. Nevertheless, in the United States, two monoclonal antibody-based therapies are available for early use in cases thought to be at high risk of progression to severe disease. The antiviral remdesivir is available in the U.S., Canada, Australia, and several other countries, with varying restrictions; however, it is not recommended for people needing mechanical ventilation, and is discouraged altogether by the World Health Organization (WHO), due to limited evidence of its efficacy.

 

PROGNOSIS

The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. In 3–4% of cases (7.4% for those over age 65) symptoms are severe enough to cause hospitalization. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. The Italian Istituto Superiore di Sanità reported that the median time between the onset of symptoms and death was twelve days, with seven being hospitalised. However, people transferred to an ICU had a median time of ten days between hospitalisation and death. Prolonged prothrombin time and elevated C-reactive protein levels on admission to the hospital are associated with severe course of COVID-19 and with a transfer to ICU.

 

Some early studies suggest 10% to 20% of people with COVID-19 will experience symptoms lasting longer than a month.[191][192] A majority of those who were admitted to hospital with severe disease report long-term problems including fatigue and shortness of breath. On 30 October 2020 WHO chief Tedros Adhanom warned that "to a significant number of people, the COVID virus poses a range of serious long-term effects". He has described the vast spectrum of COVID-19 symptoms that fluctuate over time as "really concerning." They range from fatigue, a cough and shortness of breath, to inflammation and injury of major organs – including the lungs and heart, and also neurological and psychologic effects. Symptoms often overlap and can affect any system in the body. Infected people have reported cyclical bouts of fatigue, headaches, months of complete exhaustion, mood swings, and other symptoms. Tedros has concluded that therefore herd immunity is "morally unconscionable and unfeasible".

 

In terms of hospital readmissions about 9% of 106,000 individuals had to return for hospital treatment within 2 months of discharge. The average to readmit was 8 days since first hospital visit. There are several risk factors that have been identified as being a cause of multiple admissions to a hospital facility. Among these are advanced age (above 65 years of age) and presence of a chronic condition such as diabetes, COPD, heart failure or chronic kidney disease.

 

According to scientific reviews smokers are more likely to require intensive care or die compared to non-smokers, air pollution is similarly associated with risk factors, and pre-existing heart and lung diseases and also obesity contributes to an increased health risk of COVID-19.

 

It is also assumed that those that are immunocompromised are at higher risk of getting severely sick from SARS-CoV-2. One research that looked into the COVID-19 infections in hospitalized kidney transplant recipients found a mortality rate of 11%.

See also: Impact of the COVID-19 pandemic on children

 

Children make up a small proportion of reported cases, with about 1% of cases being under 10 years and 4% aged 10–19 years. They are likely to have milder symptoms and a lower chance of severe disease than adults. A European multinational study of hospitalized children published in The Lancet on 25 June 2020 found that about 8% of children admitted to a hospital needed intensive care. Four of those 582 children (0.7%) died, but the actual mortality rate could be "substantially lower" since milder cases that did not seek medical help were not included in the study.

 

Genetics also plays an important role in the ability to fight off the disease. For instance, those that do not produce detectable type I interferons or produce auto-antibodies against these may get much sicker from COVID-19. Genetic screening is able to detect interferon effector genes.

 

Pregnant women may be at higher risk of severe COVID-19 infection based on data from other similar viruses, like SARS and MERS, but data for COVID-19 is lacking.

 

COMPLICATIONS

Complications may include pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, septic shock, and death. Cardiovascular complications may include heart failure, arrhythmias, heart inflammation, and blood clots. Approximately 20–30% of people who present with COVID-19 have elevated liver enzymes, reflecting liver injury.

 

Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions). Following the infection, children may develop paediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal. In very rare cases, acute encephalopathy can occur, and it can be considered in those who have been diagnosed with COVID-19 and have an altered mental status.

 

LONGER-TERM EFFECTS

Some early studies suggest that that 10 to 20% of people with COVID-19 will experience symptoms lasting longer than a month. A majority of those who were admitted to hospital with severe disease report long-term problems, including fatigue and shortness of breath. About 5-10% of patients admitted to hospital progress to severe or critical disease, including pneumonia and acute respiratory failure.

 

By a variety of mechanisms, the lungs are the organs most affected in COVID-19.[228] The majority of CT scans performed show lung abnormalities in people tested after 28 days of illness.

 

People with advanced age, severe disease, prolonged ICU stays, or who smoke are more likely to have long lasting effects, including pulmonary fibrosis. Overall, approximately one third of those investigated after 4 weeks will have findings of pulmonary fibrosis or reduced lung function as measured by DLCO, even in people who are asymptomatic, but with the suggestion of continuing improvement with the passing of more time.

 

IMMUNITY

The immune response by humans to CoV-2 virus occurs as a combination of the cell-mediated immunity and antibody production, just as with most other infections. Since SARS-CoV-2 has been in the human population only since December 2019, it remains unknown if the immunity is long-lasting in people who recover from the disease. The presence of neutralizing antibodies in blood strongly correlates with protection from infection, but the level of neutralizing antibody declines with time. Those with asymptomatic or mild disease had undetectable levels of neutralizing antibody two months after infection. In another study, the level of neutralizing antibody fell 4-fold 1 to 4 months after the onset of symptoms. However, the lack of antibody in the blood does not mean antibody will not be rapidly produced upon reexposure to SARS-CoV-2. Memory B cells specific for the spike and nucleocapsid proteins of SARS-CoV-2 last for at least 6 months after appearance of symptoms. Nevertheless, 15 cases of reinfection with SARS-CoV-2 have been reported using stringent CDC criteria requiring identification of a different variant from the second infection. There are likely to be many more people who have been reinfected with the virus. Herd immunity will not eliminate the virus if reinfection is common. Some other coronaviruses circulating in people are capable of reinfection after roughly a year. Nonetheless, on 3 March 2021, scientists reported that a much more contagious Covid-19 variant, Lineage P.1, first detected in Japan, and subsequently found in Brazil, as well as in several places in the United States, may be associated with Covid-19 disease reinfection after recovery from an earlier Covid-19 infection.

 

MORTALITY

Several measures are commonly used to quantify mortality. These numbers vary by region and over time and are influenced by the volume of testing, healthcare system quality, treatment options, time since the initial outbreak, and population characteristics such as age, sex, and overall health. The mortality rate reflects the number of deaths within a specific demographic group divided by the population of that demographic group. Consequently, the mortality rate reflects the prevalence as well as the severity of the disease within a given population. Mortality rates are highly correlated to age, with relatively low rates for young people and relatively high rates among the elderly.

 

The case fatality rate (CFR) reflects the number of deaths divided by the number of diagnosed cases within a given time interval. Based on Johns Hopkins University statistics, the global death-to-case ratio is 2.2% (2,685,770/121,585,388) as of 18 March 2021. The number varies by region. The CFR may not reflect the true severity of the disease, because some infected individuals remain asymptomatic or experience only mild symptoms, and hence such infections may not be included in official case reports. Moreover, the CFR may vary markedly over time and across locations due to the availability of live virus tests.

 

INFECTION FATALITY RATE

A key metric in gauging the severity of COVID-19 is the infection fatality rate (IFR), also referred to as the infection fatality ratio or infection fatality risk. This metric is calculated by dividing the total number of deaths from the disease by the total number of infected individuals; hence, in contrast to the CFR, the IFR incorporates asymptomatic and undiagnosed infections as well as reported cases.

 

CURRENT ESTIMATES

A December 2020 systematic review and meta-analysis estimated that population IFR during the first wave of the pandemic was about 0.5% to 1% in many locations (including France, Netherlands, New Zealand, and Portugal), 1% to 2% in other locations (Australia, England, Lithuania, and Spain), and exceeded 2% in Italy. That study also found that most of these differences in IFR reflected corresponding differences in the age composition of the population and age-specific infection rates; in particular, the metaregression estimate of IFR is very low for children and younger adults (e.g., 0.002% at age 10 and 0.01% at age 25) but increases progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85. These results were also highlighted in a December 2020 report issued by the WHO.

 

EARLIER ESTIMATES OF IFR

At an early stage of the pandemic, the World Health Organization reported estimates of IFR between 0.3% and 1%.[ On 2 July, The WHO's chief scientist reported that the average IFR estimate presented at a two-day WHO expert forum was about 0.6%. In August, the WHO found that studies incorporating data from broad serology testing in Europe showed IFR estimates converging at approximately 0.5–1%. Firm lower limits of IFRs have been established in a number of locations such as New York City and Bergamo in Italy since the IFR cannot be less than the population fatality rate. As of 10 July, in New York City, with a population of 8.4 million, 23,377 individuals (18,758 confirmed and 4,619 probable) have died with COVID-19 (0.3% of the population).Antibody testing in New York City suggested an IFR of ~0.9%,[258] and ~1.4%. In Bergamo province, 0.6% of the population has died. In September 2020 the U.S. Center for Disease Control & Prevention reported preliminary estimates of age-specific IFRs for public health planning purposes.

 

SEX DIFFERENCES

Early reviews of epidemiologic data showed gendered impact of the pandemic and a higher mortality rate in men in China and Italy. The Chinese Center for Disease Control and Prevention reported the death rate was 2.8% for men and 1.7% for women. Later reviews in June 2020 indicated that there is no significant difference in susceptibility or in CFR between genders. One review acknowledges the different mortality rates in Chinese men, suggesting that it may be attributable to lifestyle choices such as smoking and drinking alcohol rather than genetic factors. Sex-based immunological differences, lesser prevalence of smoking in women and men developing co-morbid conditions such as hypertension at a younger age than women could have contributed to the higher mortality in men. In Europe, 57% of the infected people were men and 72% of those died with COVID-19 were men. As of April 2020, the US government is not tracking sex-related data of COVID-19 infections. Research has shown that viral illnesses like Ebola, HIV, influenza and SARS affect men and women differently.

 

ETHNIC DIFFERENCES

In the US, a greater proportion of deaths due to COVID-19 have occurred among African Americans and other minority groups. Structural factors that prevent them from practicing social distancing include their concentration in crowded substandard housing and in "essential" occupations such as retail grocery workers, public transit employees, health-care workers and custodial staff. Greater prevalence of lacking health insurance and care and of underlying conditions such as diabetes, hypertension and heart disease also increase their risk of death. Similar issues affect Native American and Latino communities. According to a US health policy non-profit, 34% of American Indian and Alaska Native People (AIAN) non-elderly adults are at risk of serious illness compared to 21% of white non-elderly adults. The source attributes it to disproportionately high rates of many health conditions that may put them at higher risk as well as living conditions like lack of access to clean water. Leaders have called for efforts to research and address the disparities. In the U.K., a greater proportion of deaths due to COVID-19 have occurred in those of a Black, Asian, and other ethnic minority background. More severe impacts upon victims including the relative incidence of the necessity of hospitalization requirements, and vulnerability to the disease has been associated via DNA analysis to be expressed in genetic variants at chromosomal region 3, features that are associated with European Neanderthal heritage. That structure imposes greater risks that those affected will develop a more severe form of the disease. The findings are from Professor Svante Pääbo and researchers he leads at the Max Planck Institute for Evolutionary Anthropology and the Karolinska Institutet. This admixture of modern human and Neanderthal genes is estimated to have occurred roughly between 50,000 and 60,000 years ago in Southern Europe.

 

COMORBIDITIES

Most of those who die of COVID-19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease. According to March data from the United States, 89% of those hospitalised had preexisting conditions. The Italian Istituto Superiore di Sanità reported that out of 8.8% of deaths where medical charts were available, 96.1% of people had at least one comorbidity with the average person having 3.4 diseases. According to this report the most common comorbidities are hypertension (66% of deaths), type 2 diabetes (29.8% of deaths), Ischemic Heart Disease (27.6% of deaths), atrial fibrillation (23.1% of deaths) and chronic renal failure (20.2% of deaths).

 

Most critical respiratory comorbidities according to the CDC, are: moderate or severe asthma, pre-existing COPD, pulmonary fibrosis, cystic fibrosis. Evidence stemming from meta-analysis of several smaller research papers also suggests that smoking can be associated with worse outcomes. When someone with existing respiratory problems is infected with COVID-19, they might be at greater risk for severe symptoms. COVID-19 also poses a greater risk to people who misuse opioids and methamphetamines, insofar as their drug use may have caused lung damage.

 

In August 2020 the CDC issued a caution that tuberculosis infections could increase the risk of severe illness or death. The WHO recommended that people with respiratory symptoms be screened for both diseases, as testing positive for COVID-19 couldn't rule out co-infections. Some projections have estimated that reduced TB detection due to the pandemic could result in 6.3 million additional TB cases and 1.4 million TB related deaths by 2025.

 

NAME

During the initial outbreak in Wuhan, China, the virus and disease were commonly referred to as "coronavirus" and "Wuhan coronavirus", with the disease sometimes called "Wuhan pneumonia". In the past, many diseases have been named after geographical locations, such as the Spanish flu, Middle East Respiratory Syndrome, and Zika virus. In January 2020, the WHO recommended 2019-nCov and 2019-nCoV acute respiratory disease as interim names for the virus and disease per 2015 guidance and international guidelines against using geographical locations (e.g. Wuhan, China), animal species, or groups of people in disease and virus names in part to prevent social stigma. The official names COVID-19 and SARS-CoV-2 were issued by the WHO on 11 February 2020. Tedros Adhanom explained: CO for corona, VI for virus, D for disease and 19 for when the outbreak was first identified (31 December 2019). The WHO additionally uses "the COVID-19 virus" and "the virus responsible for COVID-19" in public communications.

 

HISTORY

The virus is thought to be natural and of an animal origin, through spillover infection. There are several theories about where the first case (the so-called patient zero) originated. Phylogenetics estimates that SARS-CoV-2 arose in October or November 2019. Evidence suggests that it descends from a coronavirus that infects wild bats, and spread to humans through an intermediary wildlife host.

 

The first known human infections were in Wuhan, Hubei, China. A study of the first 41 cases of confirmed COVID-19, published in January 2020 in The Lancet, reported the earliest date of onset of symptoms as 1 December 2019.Official publications from the WHO reported the earliest onset of symptoms as 8 December 2019. Human-to-human transmission was confirmed by the WHO and Chinese authorities by 20 January 2020. According to official Chinese sources, these were mostly linked to the Huanan Seafood Wholesale Market, which also sold live animals. In May 2020 George Gao, the director of the CDC, said animal samples collected from the seafood market had tested negative for the virus, indicating that the market was the site of an early superspreading event, but that it was not the site of the initial outbreak.[ Traces of the virus have been found in wastewater samples that were collected in Milan and Turin, Italy, on 18 December 2019.

 

By December 2019, the spread of infection was almost entirely driven by human-to-human transmission. The number of coronavirus cases in Hubei gradually increased, reaching 60 by 20 December, and at least 266 by 31 December. On 24 December, Wuhan Central Hospital sent a bronchoalveolar lavage fluid (BAL) sample from an unresolved clinical case to sequencing company Vision Medicals. On 27 and 28 December, Vision Medicals informed the Wuhan Central Hospital and the Chinese CDC of the results of the test, showing a new coronavirus. A pneumonia cluster of unknown cause was observed on 26 December and treated by the doctor Zhang Jixian in Hubei Provincial Hospital, who informed the Wuhan Jianghan CDC on 27 December. On 30 December, a test report addressed to Wuhan Central Hospital, from company CapitalBio Medlab, stated an erroneous positive result for SARS, causing a group of doctors at Wuhan Central Hospital to alert their colleagues and relevant hospital authorities of the result. The Wuhan Municipal Health Commission issued a notice to various medical institutions on "the treatment of pneumonia of unknown cause" that same evening. Eight of these doctors, including Li Wenliang (punished on 3 January), were later admonished by the police for spreading false rumours and another, Ai Fen, was reprimanded by her superiors for raising the alarm.

 

The Wuhan Municipal Health Commission made the first public announcement of a pneumonia outbreak of unknown cause on 31 December, confirming 27 cases—enough to trigger an investigation.

 

During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days. In early and mid-January 2020, the virus spread to other Chinese provinces, helped by the Chinese New Year migration and Wuhan being a transport hub and major rail interchange. On 20 January, China reported nearly 140 new cases in one day, including two people in Beijing and one in Shenzhen. Later official data shows 6,174 people had already developed symptoms by then, and more may have been infected. A report in The Lancet on 24 January indicated human transmission, strongly recommended personal protective equipment for health workers, and said testing for the virus was essential due to its "pandemic potential". On 30 January, the WHO declared the coronavirus a Public Health Emergency of International Concern. By this time, the outbreak spread by a factor of 100 to 200 times.

 

Italy had its first confirmed cases on 31 January 2020, two tourists from China. As of 13 March 2020 the WHO considered Europe the active centre of the pandemic. Italy overtook China as the country with the most deaths on 19 March 2020. By 26 March the United States had overtaken China and Italy with the highest number of confirmed cases in the world. Research on coronavirus genomes indicates the majority of COVID-19 cases in New York came from European travellers, rather than directly from China or any other Asian country. Retesting of prior samples found a person in France who had the virus on 27 December 2019, and a person in the United States who died from the disease on 6 February 2020.

 

After 55 days without a locally transmitted case, Beijing reported a new COVID-19 case on 11 June 2020 which was followed by two more cases on 12 June. By 15 June there were 79 cases officially confirmed, most of them were people that went to Xinfadi Wholesale Market.

 

RT-PCR testing of untreated wastewater samples from Brazil and Italy have suggested detection of SARS-CoV-2 as early as November and December 2019, respectively, but the methods of such sewage studies have not been optimised, many have not been peer reviewed, details are often missing, and there is a risk of false positives due to contamination or if only one gene target is detected. A September 2020 review journal article said, "The possibility that the COVID-19 infection had already spread to Europe at the end of last year is now indicated by abundant, even if partially circumstantial, evidence", including pneumonia case numbers and radiology in France and Italy in November and December.

 

MISINFORMATION

After the initial outbreak of COVID-19, misinformation and disinformation regarding the origin, scale, prevention, treatment, and other aspects of the disease rapidly spread online.

 

In September 2020, the U.S. CDC published preliminary estimates of the risk of death by age groups in the United States, but those estimates were widely misreported and misunderstood.

 

OTHER ANIMALS

Humans appear to be capable of spreading the virus to some other animals, a type of disease transmission referred to as zooanthroponosis.

 

Some pets, especially cats and ferrets, can catch this virus from infected humans. Symptoms in cats include respiratory (such as a cough) and digestive symptoms. Cats can spread the virus to other cats, and may be able to spread the virus to humans, but cat-to-human transmission of SARS-CoV-2 has not been proven. Compared to cats, dogs are less susceptible to this infection. Behaviors which increase the risk of transmission include kissing, licking, and petting the animal.

 

The virus does not appear to be able to infect pigs, ducks, or chickens at all.[ Mice, rats, and rabbits, if they can be infected at all, are unlikely to be involved in spreading the virus.

 

Tigers and lions in zoos have become infected as a result of contact with infected humans. As expected, monkeys and great ape species such as orangutans can also be infected with the COVID-19 virus.

 

Minks, which are in the same family as ferrets, have been infected. Minks may be asymptomatic, and can also spread the virus to humans. Multiple countries have identified infected animals in mink farms. Denmark, a major producer of mink pelts, ordered the slaughter of all minks over fears of viral mutations. A vaccine for mink and other animals is being researched.

 

RESEARCH

International research on vaccines and medicines in COVID-19 is underway by government organisations, academic groups, and industry researchers. The CDC has classified it to require a BSL3 grade laboratory. There has been a great deal of COVID-19 research, involving accelerated research processes and publishing shortcuts to meet the global demand.

 

As of December 2020, hundreds of clinical trials have been undertaken, with research happening on every continent except Antarctica. As of November 2020, more than 200 possible treatments had been studied in humans so far.

Transmission and prevention research

Modelling research has been conducted with several objectives, including predictions of the dynamics of transmission, diagnosis and prognosis of infection, estimation of the impact of interventions, or allocation of resources. Modelling studies are mostly based on epidemiological models, estimating the number of infected people over time under given conditions. Several other types of models have been developed and used during the COVID-19 including computational fluid dynamics models to study the flow physics of COVID-19, retrofits of crowd movement models to study occupant exposure, mobility-data based models to investigate transmission, or the use of macroeconomic models to assess the economic impact of the pandemic. Further, conceptual frameworks from crisis management research have been applied to better understand the effects of COVID-19 on organizations worldwide.

 

TREATMENT-RELATED RESEARCH

Repurposed antiviral drugs make up most of the research into COVID-19 treatments. Other candidates in trials include vasodilators, corticosteroids, immune therapies, lipoic acid, bevacizumab, and recombinant angiotensin-converting enzyme 2.

 

In March 2020, the World Health Organization (WHO) initiated the Solidarity trial to assess the treatment effects of some promising drugs: an experimental drug called remdesivir; anti-malarial drugs chloroquine and hydroxychloroquine; two anti-HIV drugs, lopinavir/ritonavir; and interferon-beta. More than 300 active clinical trials were underway as of April 2020.

 

Research on the antimalarial drugs hydroxychloroquine and chloroquine showed that they were ineffective at best, and that they may reduce the antiviral activity of remdesivir. By May 2020, France, Italy, and Belgium had banned the use of hydroxychloroquine as a COVID-19 treatment.

 

In June, initial results from the randomised RECOVERY Trial in the United Kingdom showed that dexamethasone reduced mortality by one third for people who are critically ill on ventilators and one fifth for those receiving supplemental oxygen. Because this is a well-tested and widely available treatment, it was welcomed by the WHO, which is in the process of updating treatment guidelines to include dexamethasone and other steroids. Based on those preliminary results, dexamethasone treatment has been recommended by the NIH for patients with COVID-19 who are mechanically ventilated or who require supplemental oxygen but not in patients with COVID-19 who do not require supplemental oxygen.

 

In September 2020, the WHO released updated guidance on using corticosteroids for COVID-19. The WHO recommends systemic corticosteroids rather than no systemic corticosteroids for the treatment of people with severe and critical COVID-19 (strong recommendation, based on moderate certainty evidence). The WHO suggests not to use corticosteroids in the treatment of people with non-severe COVID-19 (conditional recommendation, based on low certainty evidence). The updated guidance was based on a meta-analysis of clinical trials of critically ill COVID-19 patients.

 

WIKIPEDIA

Camera: Zero 2000 Pinhole

Film: Fuji Acros 100

Exposure Time: 11 seconds

Location: Bowman Bay - Deception Pass State Park, Washington State

    

Lately I have been drawn to creating images which either capture motion in the landscape, or inducing it myself (hand held images). Doing so has allowed me to record a world on film that would otherwise be undetectable by the human eye. Perhaps that is what I love so much about photography, it's ability to write with light, capturing a scene in an infinite number of ways. Each photograph uniquely different than the ones taken before it, and those which will be captured going forward.

    

Two photographers on Flickr in particular have inspired and motivated me immensely.. The first of which is Dog_Dreamzzz, who's ability to envision and interpret the world with a camera in her hand fascinates me, particularly her micro-click photographs. Examples of her work here and here. The second photographer is Falling Thru The Lens, who's unique style of landscape photography continually challenges me to rethink how I see the world around me. I am particularly impressed with her ability to tell a story via a few short words, no easy task. Examples of her work can be seen here and here. I highly recommend spending some time exploring their respective photostreams.

    

The above image was taken on a particularly stormy day, the winds where swirling and the surf was rougher than usual. It was your stereotypical blustery winter day in the Pacific Northwest. The dock was rocking quite violently back and forth, which caught my curiosity. Naturally I ventured out onto it to, to record the movement with my pinhole camera. I won't like I got a little motion sick during the exposure time and had to sit down on solid ground for a bit afterward.

Sphaerocoris annulus

 

Going under cover.

 

I was able to get some good shots of this adorable bug before it retreated into the heart of the hedge from the surface branch on which it had been basking. Its artsy colours and design made it almost undetectable in its habitat. I could have missed it.

  

Port Harcourt, Nigeria

Blueberry juice feels rather decadent when you consider how many of the tiny fruits are required to produce just a glass or two of juice. Luckily, blueberry pulp is very easy to use. It becomes almost invisible when combined with chocolate or cocoa powder in baked goods, where it lends moisture and can even replace some of the oil or butter in your recipe.

 

www.foodthinkers.com/2010/05/blueberry-papaya-cucumber-ju...

  

BLUEBERRY PAPAYA CUCUMBER JUICE

 

Juice Ingredients

 

1¼ cup blueberries

1 medium papaya, peeled, and trimmed, seeds removed

1 large cucumber, peeled and seededjuice of 1 to 2 sweet limes or 1 Valencia orange

 

Juice Instructions

 

1. Process blueberries and cucumber in your juicer and reserve the pulp in one bag.

2. Juice papaya and reserve its pulp separately.

3. Add the sweet lime or orange juice to the mixture, stir, and enjoy.

Serves 3.

 

BLUEBERRY CHOCOLATE CAKE WITH DARK CHOCOLATE GANACHE AND TOASTED COCONUT

 

The above juice left me with about 4 ounces (½ cup) of cucumber-blueberry pulp and ¾ cup of papaya pulp. Using slightly more or less pulp in your recipe probably will not affect your finished product all that much.

 

Here I adapted my standard vegan chocolate cake recipe, with the pulp serving as a substitute for a large portion of the oil. As I mentioned above, the pulp in the batter is virtually undetectable and the cake came out incredibly moist and tender.

 

Cake Ingredients

 

1½ cups whole wheat pastry flour

1½ cups all purpose flour

⅔ cup unsweetened cocoa powder, plus extra for dusting

(I add a tablespoon or two of black onyx cocoa powder to my regular cocoa when I make chocolate cake — it gives a slightly richer product. Onyx cocoa powder can be ordered from the Savory Spice Shop.)

1½ cups sugar

1 teaspoon baking soda

1 teaspoon salt

½ cup blueberry-cucumber pulp

½ cup vegetable oil

2 cups brewed black tea*, chilled

1 tablespoon vanilla

4 tablespoons apple cider vinegar

*Either coffee or tea works very well in this recipe — for best results be sure to use a strong brew.

 

Cake Instructions

 

1. Grease two 9-inch round cake pans and dust with cocoa powder. Line bottoms of the pans with parchment paper and grease the parchment as well.

2. Preheat oven to 375°F (190°C) with a rack in the middle.

3. Sift flours, sugar, cocoa, baking soda, and salt together in a large bowl.

4. In a separate bowl, combine the blueberry-cucumber pulp, vegetable oil, chilled tea, and vanilla.

5. Pour the wet ingredients into the dry and combine with a rubber spatula. Add the vinegar and mix in with as few strokes as possible (it’s okay if there are streaks in the batter).

6. Pour batter into the prepared pans and bake for 30 to 35 minutes, testing doneness with a wooden toothpick.

7. Let cakes cool in their pans for 5 to 10 minutes before running a knife around the edge of each pan and unmolding to cool completely.

  

While cakes are cooling, put the papaya pulp and a tablespoon or two or orange juice into a small saucepan and bring to a simmer. Add a tablespoon of sugar and stir as the mixture simmers gently for about 5 minutes. Cook until you have a thick, spreadable paste. Cool.

 

Filling Instructions

 

When the cake has cooled you may want to even out the surface of your first layer by slicing off the dome to create a flat, even round. Spread the papaya filling over the bottom cake layer and top with second cake.

 

Ganache Ingredients

 

8 ounces chopped dark chocolate, or chocolate chips (about 60% cocoa)

⅔ cup soy milk

4 tablespoons maple syrup

topping: ½ cup toasted* unsweetened shredded coconut

(*spread coconut onto a sheet pan and toast at 325°F (163°C) in a toaster oven for about 10 minutes)

 

Ganache Instructions

 

1. Heat the soy milk in a small saucepan until it begins to boil. Remove from heat and immediately add the chocolate.

2. Stir until all the chocolate has melted, then stir in maple syrup until the mixture is completely smooth.

3. Let cool slightly before pouring over the cake. Top your cake with the toasted coconut, and chill in fridge to set the ganache.

 

This cake keeps beautifully for 3 to 4 days at room temperature when wrapped in plastic or stored inside a cake dome.

+++ DISCLAIMER +++

Nothing you see here is real, even though the conversion or the presented background story might be based historical facts. BEWARE!

 

Some background:

NAe São Paulo is a Clemenceau-class aircraft carrier currently in service with the Brazilian Navy. São Paulo was first commissioned in 1963 by the French Navy as Foch and was transferred in 2000 to Brazil, where she became the new flagship of the Brazilian Navy. In December 2014 it was announced that São Paulo will be expected to continue active service until 2039, at which time the vessel will be nearly 80 years old.

 

From this carrier, the Marinha do Brasil operates its only fixed-wing aircraft, and these were initially A-4 Skyhawks. In 1997 Brazil negotiated a $70 million contract for purchase of 20 A-4KU and three TA-4KU Skyhawks from Kuwait. The Kuwaiti Skyhawks, modified A-4Ms and TA-4Js delivered in 1977, were among the last of those models built by Douglas. The Kuwaiti Skyhawks were selected by Brazil because of low flight time, excellent physical condition, and a favorable price tag. The Brazilian Navy Re-designated AF-1 and AF-1A Falcões (Hawks), the ex-Kuwaiti Skyhawks arrived in Arraial do Cabo on 5 September 1998.

 

Anyway, the Skyhawks' life span was limited and in 2005 the Brazilian Navy started looking for a potential replacement, while the AF-1s were to kept operational due to limited military budgets. On 14 April 2009, Brazlian aircraft manufacturer EMBRAER signed a contract to modernize 12 Skyhawks, nine AF-1s (single-seat) and three AF-1As (two-seat). This upgrade will restore the operating capacity of the Navy 1st Intercept and Attack Plane Squadron (VF-1). The program includes restoring the aircraft and their current systems, as well as implementing new avionics, radar, power production, and autonomous oxygen generating systems. The first of the 12 modified Skyhawks was delivered on 27 May 2015. EMBRAER stated that the modifications would allow the aircraft to remain operational until 2025, by which time a successor was to be fully operational.

 

Several replacement candidates were evaluated under Brazil's F-X2 fighter program together with the Air Force which was looking to replace its Northrop F‐5EM and Dassault Mirage 2000C aircraft. In October 2008, Brazil selected three finalists: the Dassault Rafale, the Boeing F/A-18 Super Hornet, and the SAAB JAS 39 Gripen. The Brazilian Air Force initially planned to procure at least 36 and possibly up to 120 aircraft later, while the Brazilian Navy was looking for 24 aircraft (20 single seater and 4 two-seaters with dual controls) until 2025.

 

In February 2009, SAAB submitted a tender, and on 5 January 2010, reports claimed that the final evaluation report placed the Gripen ahead of other contenders; the decisive factor was reportedly lower unit and operational costs, the most compact size and the Swedish manufacturer's willingness to accept EMBRAER as a technological partner for the aircraft's further development, especially for the navalized version.

 

Amid delays due to financial constraints, President Dilma Rousseff announced in December 2011 the Gripen NG's selection and the start of a joint Swedish-Brazilian joint venture called SABRA. Argentina and Ecuador were interested in procuring Gripens from or through Brazil, and Mexico and Argenitina were potential export targets for SABRA's navalized Gripen derivative that was tailored to the Marinha do Brasil's needs.

 

The respective SABRA aircraft was appropriately christened "Grifo" and the development of thei 4th generation fighter started immediately after closing the cooperation deal in 2011. While based on the SAAB 39, the Grifo became a very different aircraft, due to several factors. The major influence was the carrier operation capability, which called for major structural modifications and enforcements as well as special equipment like foldable wings, a strengthened landing gear, an arrester hook and a new engine that would better cope with the naval environment than the Swedish RM 12 engine, a derivative of the General Electric F404-400.

 

Additionally, the mission focus of air superiority with additional attack capabilities was reversed, and the need for excellent low speed handling for carrier approaches was requested.

 

This led to a complelety different aircraft layout, with the SAAB 39's instable canard design being changed into a conservative aircraft with conventional tailplanes. The nose section was shortened in order to provide the pilot with a better field of view, while the more powerful F414-EPE afterburning turbofan was moved slightly forward due to CG reasons, resulting in a slightly shortened rear fuselage.

 

A mock-up of the new aircraft for the Brazlian Navy was presented and approved in early 2012, and the government placed an official order for two prototypes. Even though the Grifo appeared like a completely different aircraft, it shared a lot of elements with the SAAB 39, so that development time and costs could be reduced to a minimum - and the first prototype, internally designated EMB 391-001, made its maiden flight in early 2013. The second aircraft followed 3 months later.

 

The Grifo's equipment includes an AN/APG-79 active electronically scanned array (AESA), capable of executing simultaneous air-to-air and air-to-ground attacks, and providing higher quality high-resolution ground mapping at long standoff ranges. The AESA radar can also detect smaller targets, such as inbound missiles, and can track air targets beyond the range of the aircraft's air-to-air missiles, which include the AIM-9 Sidewinder for close range and the AIM-120 AMRAAM for medium range.

 

The Grifo features, like the Gripen fighter, an advanced and integrated electronic warfare suite, capable of operating in an undetectable passive mode or to actively jam hostile radar; a missile approach warning system passively detects and tracks incoming missiles.

 

The Grifo can be tailored to specific missions through external sensor pods, e .g. for reconnaissance and target designation. These include Rafael's LITENING targeting pod, Saab's Modular Reconnaissance Pod System or Thales' Digital Joint Reconnaissance Pod. On the Brazilian Navy's request the Grifo is also designed that it can be equipped with an aerial refueling system (ARS) or "buddy store" for the refueling of other aircraft, filling the tactical airborne tanker role.

 

The two prototypes completed a thorough test program until summer 2015 and subsequently went on a sales tour in South America and Asia. In the meantime, serial production started at EMBRAER's Gavião Peixoto in November 2015. The first serial machines, now officially designated AF-2A, arrived at the Brazilian Navy's São Pedro da Aldeia air base where a new Intercept and Attack Plane Squadron, VF-2 'Arquieros' (Archers) was founded. The squadron became operational in April 2016 and Grifos embarked on NAe São Paulo for the first time in September 2016, serving alongside the venerable AF-1.

  

General characteristics:

Crew: 1

Payload: 5,300 kg (11,700 lb)

Length: 13,54 m (44 ft 4 in)

Wingspan (incl. wing tip launch rails): 8.32 m (27 ft 2 in)

Height: 4.25 m (13 ft 11 in)

Wing area: 30.0 m² (323 ft²)

Empty weight: 6,800 kg[330] (14,990 lb)

Loaded weight: 8,500 kg (18,700 lb)

Max. takeoff weight: 14,000 kg (31,000 lb)

Wheel track: 2.4 m (7 ft 10 in)

Powerplant:

1 × General Electric F414-EPE afterburning turbofan with

a dry thrust of 54 kN (12,100 lbf) and 85 kN (19,100 lbf) with afterburner

 

Performance:

Maximum speed: Mach 2 (2,204 km/h (1,190 kn; 1,370 mph) at high altitude

Combat radius: 800 km (497 mi, 432 nmi)

Ferry range: 3,200 km (1,983 mi) with drop tanks

Service ceiling: 15,240 m (50,000 ft)

Wing loading: 283 kg/m² (58 lb/ft²)

Thrust/weight: 0.97

Maximum g-load: +9 g

 

Armament:

1× 27 mm Mauser BK-27 Revolver cannon with 120 rounds

Eight hardpoints (three on each wing and two under fuselage)

for a wide range of guide and unguided ordnance of up to 14,330 lb (6.5 t)

  

The kit and its assembly:

The fictional Grifo is the result of a generic idea of converting a canard layout aircraft like the Saab Viggen into a conventional design. The Viggen was actually a serious candidate, but then I found an Italeri Gripen in the stash without a real purpose (it had been cheap, though), and with Brazil's real world procurement as background, the more conservative Grifo was born.

 

I wanted to use as many OOB Gripen parts as possible, and there are actually only a few external donations involved – with the outlook of converting further Gripens this way. You never know… ;)

 

Work started with the wings, which were cut off of the fuselage shell. Having the landing gear retract into the fuselage (much like the X-29) is a convenient detail of the Gripen, making the wing transplantation easier than on a Viggen where the wells have to be moved, too.

 

The original canard attachment points were faired over/hidden. The pointed Gripen nose with its pitot was cut off and replaced by a shorter, more stocky nose tip - from an F-4 Phantom II IIRC. Once the fuselage was completed, the wings were mounted, closer to the air intakes. This went smoothly, only some gaps on the undersides had to be filled.

 

Once the wings were in place I had to make a decision concerning the stabilizers. Despite the plan to use as many OOB parts as possible I found the OOB canards to be too sharply swept and considered several donation options.

I eventually settled for the most unique option: the stabilizers are actually main wings from a (rather malformed) Italeri/Dragon 1:200 F-117 that comes as a set with the B-2 bomber. A part of the F-117’s fuselage flank was cut off and taken over to the Grifo, too, so that these create ‘muscular’ bulges.

 

The stabilizers were mounted on scratched consoles/trailing wing root extensions that were somewhat inspired by the F-16’s tail design – putting the stabilizers directly onto the fuselage would have looked awkward, and with this solution I was able to extend the Gripen’s BWB-design all along the fuselage. As a side effect these consoles also offered a plausible place for rearward chaff dispensers.

 

The rear fuselage was shortened by 3mm, too – through the shorter nose and the wings further forward, the rest of the aircraft looked rather tail-heavy. While 3mm does not sound much, it helped with overall proportions.

 

The cannon fairing and the OOB pylons were taken over, as well as the cockpit interior. For carrier operations, several details were added, though: folding wing mechanism seams were engraved on the wings and an arrester hook with a fairing added under the tail section, flanked by new stabilizer fins.

 

The landing gear was basically taken OOB, too, but lengthened with styrene inserts for a higher stance: the main struts are now 2mm longer, while the front strut is 3mm taller. The latter was reversed, so that a catapult hook could be added to the front side, and slightly bigger wheels were mounted, too, so that the Grifo now has a rather stalky stance with a nose-up attitude. Simple, but effective!

 

The Sidewinders were taken OOB while the pair of AGM-84 Harpoon comes from Italeri’s 1:72 NATO weapons set.

 

Painting and markings:

I used the contemporary AF-1 paint scheme in three shades of grey as benchmark. These are FS 36187 (RAF Ocean Grey), FS 36307 (Flint Grey) and FS 36515 (Canadian Voodoo Grey) - sourced from a painting guide from Brazilian decal manufacturer FCM and backed by other knowledgeable sources from the region, too. And while the Ocean Grey appears a bit dark, I think that overall the colors are authentic. All paints are Modelmaster enamels.

 

After basic painting a light black ink wash was applied and panels highlighted through dry-brushing with lighter tones.

 

The cockpit interior was painted in Neutral Grey (FS 36173), while the landing gear became all-white.

The Brazilian Navy markings had to be improvised - there are 1:72 AF-1 decals available, but either not obtainable or prohibitively expensive - or both. Therefore I rather improvised, with basic Brazilian Navy markings from a vintage FCM Decal sheet for various Brazilian aircraft.

 

The respective roundels and codes actually belong to helicopters, and I had to wing it somehow. Unfortunately, the old FCM decals turned out to be ...old. Brittle and very delicate, application was already messy and they did not adhere well to the model. To make matters worse the acrylic varnish turned cloudy, so that a lot of paintwork repair had to be done - not helping much with a satisfactory kit finish. :(

  

Another interesting conversion – I am amazed how purposeful the Grifo looks. It reminds me with its high stance of a modern A-4 Skyhawk (what it somehow is), and there’s also some Super Étendard in it, esp. in the profile? At some point before painting it also had a somewhat Chinese look - maybe because the top view and the wing planform reminds of the classic MiG-21…? The wings might have been placed 3-4mm further backwards, since it is always difficult to judge proportions while work is still, but the Grifo looks convincingly like a real aircraft (model).

 

Aeronaves bonita! :D

The female face was hidden by its profanation: both as that which is set outside public religious view (not fully in the sight of God) and, differently, by its genocidal erasure. Moreover, the female face could barely reflect the glory of God into the world for God's face was itself profaned or covered over. Yet hiddenness implies (undetectable) presence.

-The Female Face of God in Auschwitz: A Jewish Feminist Theology of the Holocaust (Religion and Gender)

Melissa Raphael

  

The three bugs on the back of the Sunflower were undetectable when I took this image, but I consider it an added bonus.

DOD CAPTION

APRA HARBOR, GUAM (Jan. 15, 2022)

 

The U.S. Navy ballistic-missile submarine USS NEVADA_SSBN 733 arrived at Naval Base Guam, Jan. 15. The port visit strengthens cooperation between the United States and allies in the region, demonstrating U.S. capability, flexibility, readiness, and continuing commitment to Indo-Pacific regional security and stability. USS Nevada, homeported in Naval Base Kitsap, Wash., is an Ohio-class ballistic-missile submarine, an undetectable launch platform for submarine-launched ballistic missiles, providing the United States with its most important survivable leg of the nuclear triad.

 

U.S. Navy photo by Mass Communication Specialist Darek Leary

©USN Official Photo

 

About 100 miles West of Houston lies the near-undetectable immigrant community of Dubina, TX - known only for its "painted church", Saints Cyril and Methodius, on FM 1383. The building was repainted by members of the congregation in 1909 and was featured in a PBS Documentary about all the "painted churches" of rural Texas. Read more at www.klru.org/paintedchurches/

___________

Fujica GW690 @ f3.5 and 1/60 second handheld ;

Portra 400 shot and developed at 400 ;

Scanned with an Epson V500 Flatbed Photo Scanner ;

Resized/Sharpened in Photoshop CS6

@easilocksusa

no heat

no glue

no sewing

no damage to the natural hair

comfortable to wear & undetectable

you can wear you hair up in different styles

super comfortable

application lasts up to 3 months

the hair is reusable

#longhair #hairextensions #hairextension #easilocks #easilocksusa

This is a portrait of myself inside a philosophical art installation called Being Undetectable by Royal College of Art Design Interactions MA Graduate Peter Hudson

www.peterdavidhudson.com/

design-interactions.rca.ac.uk/students/peter-hudson

 

The black cube is rubber-clad, with half-metre thick, metal-lined, walls and door.

 

The photo was taken by the artist. - You, Google, facebook, Commerce and Industry, the World and his Wife will note from the EXIF data that that the poor chap cannot afford a proper phone like an iPhone 6S Plus, and instead has to muddle through life with an ageing Samsung Galaxy S5 - despite its declining popularity - www.flickr.com/cameras/samsung/galaxy-s5/

 

So.

 

No targeted ads for Beluga Caviar for you mate!

 

I told the artist that I had once been (intentionally / voluntarily) locked inside an Anechoic Chamber [en.wikipedia.org/wiki/Anechoic_chamber] which he assumed to be an eloctromagnetically isolated wi-fi / Google proof electromagnetic free (since loss of privacy these days is all about radio waves) - instead of an acoustic noise and echo free - room.

www.amps.net/media/files/library/techdocs/PostOffice_Anec...

 

The chamber I was previously in was steel lined too, so I don't suppose you get a lot of Notifications in there...

The stealthy Night Raider prowls the Brikverse to hunt down and disable lost convoys and vulnerable orbital stations. Its shrouded engines and angular design make it nearly undetectable to conventional sensor systems, allowing it to unleash a deadly surprise attack with its multiple cannons and armor-piercing missiles. The Rubrum Crucesignatis has a standing bounty on all Night Raiders, but its uncanny aptitude at hit-and-fade tactics have made it difficult to catch.

 

The Empire of Luchardsko is a cool-looking, if lore-light, faction created by Falk for Brikwars. One of my favorites.

The Gift of Health. Zero-I never really wanted to get a zero on a test--until now. Went for my first PSA test after having my prostate gland removed due to prostate cancer. The PSA is a test for Prostate specific Antigen, which is produced by cancerous prostate cells. The results said my PSA was undetectable! I'll have it monitored for every 3 months for the next year and if all goes well, we'll assume that all the cancer was contained within the prostate. A wonderful gift. The second favorite gift was a White Christmas, the first in the Atlanta area since 1882. Who would have thought that two weeks later, I could have re-enacted it for Project Flickr as we got 8" of snow last night

In the beginning of space travel, the ranges of FTL travel were limited to the drives themselves. As time went on, drives became more advanced and ships began to rely more on fuel. Captains had to pack their cargo holds with fuel or find somewhere to stop and refill.

 

Out on the Galactic Rim (where a hold full of cargo is an explosive possibility) independently minded people have been quick to take advantage. Like the hermit crabs of old Earth, purveyors of these refuelling depots find a suitable rock, burrow inside, set up basic life support and open as a going concern.

 

Captains usually set themselves up in very densely populated asteroid belts and have the ability to shut down all beacons and power and become undetectable at a moment's notice. The threat of fuel pirates are an ever present one and depot captains often contract mercenaries for protection during times of local upheaval.

 

This model has a long range communication system and is able to store and transmit messages over extra long distances. Entrepreneurial depot captains take a stipend from each message, further augmenting their incomes.

 

Crew: 2-10

Manufacturer: No standard design, asteroid dependent.

Weaponry: Nil.

Special: Augmented fuel capacity. Long range communication beacon.

Shibuya, Tokyo, Japan

"A highly accurate, undetectable, uninterceptable nuclear weapon."

 

Inspired by Moko.

This week seemed very long. It was filled with ethnic food, friends, and another Tegan and Sara show, but it also was the week I found out that an undetectable heartbeat inside my sister in-law's womb would change their lives forever. It's hard to fathom what they could be going through. Is it too soon to release the grief and confusion I feel for them to the will of the powers that be? Or should it have been instantaneous? Is intense emotion a sign or our humanity, or it is a sign our our unevolved species? Does it makes us weaker or stronger? Yes. Yes. Yes.

Accidentally shot TMAX100 at 100 & 400 on same roll. Developed in caffenol stand developer for 70 min.

Used Imagefrugals/reinhold recipe.

Grain is so fine it is almost undetectable.

Slightly edited mobile phone cam shot of Me&Mobie, reflected on the sunglasses of the head of my Security detail in Amsterdam. Taken with my C905 phone. No editing besides some added contrast&saturation, no magic tricks, no Photoshop :)

 

As you might remember, I've been attacked by a Madman and a freaked out Taxi driver while I was peacefully biking through the best city in the world some time ago and as a consequence, I will not leave the house anymore without my trustworthy Security people, not that I'm a coward but I don't want to ruin my shutter finger by punching the nose of some dimwitted MoFo into his tiny brain with a swift, almost undetectable movement (my specialty, haha ;)) that would surely get me in trouble with the law if it wasn't applied so skillfully that even to close bystanders only the faintest rush of air and a body falling to the ground unconsciously prove that anything has ever happened at all...so yeah, now I let my guys sort these things out, I need to protect my valuable assets so that I can continue to entertain you with these wicked figments of my imagination, hahaha ;-P

   

More AmsterS@m Self shots

 

More wicked reflections

 

www.amstersam.com

Tamil Nadu ([ˈt̪ɐmɨɻ ˈn̪aːɽɯ], "Tamil Country"), formerly Madras State, is one of the 29 states of India. Its capital and largest city is Chennai (formerly known as Madras). Tamil Nadu lies in the southernmost part of the Indian subcontinent and is bordered by the union territory of Puducherry and the South Indian states of Kerala, Karnataka, and Andhra Pradesh. It is bounded by the Eastern Ghats on the north, by the Nilgiri Mountains, the Meghamalai Hills, and Kerala on the west, by the Bay of Bengal in the east, by the Gulf of Mannar and the Palk Strait on the southeast, and by the Indian Ocean on the south. The state shares a maritime border with the nation of Sri Lanka.

 

The region was ruled by several empires, including the three great empires – Chola, Chera, and Pandyan empires, which shape the region's cuisine, culture, and architecture. The British Colonial rule during the modern period led to the emergence of Chennai, then known as Madras, as a world-class city. Modern-day Tamil Nadu was formed in 1956 after the reorganization of states on linguistic lines. The state is home to a number of historic buildings, multi-religious pilgrimage sites, hill stations and three World Heritage sites.

 

Tamil Nadu is the eleventh largest Indian state by area and the sixth largest by population. The economy of Tamil Nadu is the second-largest state economy in India with ₹16.05 lakh crore (US$230 billion) in gross domestic product after Maharashtra and a per capita GDP of ₹186,000 (US$2,700). Tamil Nadu has the sixth highest ranking among Indian states in human development index.[6] It was ranked as one of the top seven developed states in India based on a "Multidimensional Development Index" in a 2013 report published by the Reserve Bank of India. Its official language is Tamil, which is one of the longest-surviving classical languages in the world.

 

HISTORY

PREHISTORY

Archaeological evidence points to this area being one of the longest continuous habitations in the Indian peninsula. In Attirampakkam, archaeologists from the Sharma Centre for Heritage Education excavated ancient stone tools which suggests that a humanlike population existed in the Tamil Nadu region somewhere around 300,000 years before homo sapiens arrived from Africa. In Adichanallur, 24 km from Tirunelveli, archaeologists from the Archaeological Survey of India (ASI) unearthed 169 clay urns containing human skulls, skeletons, bones, husks, grains of rice, charred rice and celts of the Neolithic period, 3,800 years ago. The ASI archaeologists have proposed that the script used at that site is "very rudimentary" Tamil Brahmi. Adichanallur has been announced as an archaeological site for further excavation and studies. About 60 per cent of the total epigraphical inscriptions found by the ASI in India are from Tamil Nadu, and most of these are in the Tamil language.

 

INDUS VALLEY SCIPT BETWEEN 2000 and 1500 BCE

A Neolithic stone celt (a hand-held axe) with the Indus script on it was discovered at Sembian-Kandiyur near Mayiladuthurai in Tamil Nadu. According to epigraphist Iravatham Mahadevan, this was the first datable artefact bearing the Indus script to be found in Tamil Nadu. According to Mahadevan, the find was evidence of the use of the Harappan language, and therefore that the "Neolithic people of the Tamil country spoke a Harappan language". The date of the celt was estimated at between 1500 BCE and 2000 BCE. Though this finding remains contested, like the claim of historian Michel Danino who rubbishes the theory of the latter’s southward migration in a paper he presented at the International Symposium on Indus Civilisation and Tamil Language in 2007. He wrote: ‘There is no archaeological evidence of a southward migration through the Deccan after the end of the urban phase of the Indus- Sarasvati civilization… The only actual evidence of movements at that period is of Late Harappans migrating towards the Ganges plains and towards Gujarat... Migration apart, there is a complete absence of Harappan artefacts and features south of the Vindhyas: no Harappan designs on pottery, no Harappan seals, crafts and ornaments, no trace of Harappan urbanism… Cultural continuity from Harappan to historical times has been increasingly documented in North India, but not in the South… This means, in effect, that the south-bound Late Harappans would have reverted from an advanced urban bronze-age culture to a Neolithic one! Their migration to South would thus constitute a double “archaeological miracle”: apart from being undetectable on the ground, it implies that the migrants experienced a total break with all their traditions. Such a phenomenon is unheard of.

 

SANGAM PERIOD (500 BCE – 300 CE)

The early history of the people and rulers of Tamil Nadu is a topic in Tamil literary sources known as Sangam literature. Numismatic, archaeological and literary sources corroborate that the Sangam period lasted for about eight centuries, from 500 BC to AD 300. The recent excavations in Alagankulam archaeological site suggests that Alagankulam is one of the important trade centre or port city in Sangam Era.

 

BHAKTI MOVEMENT

The Bhakti movement originated in the Tamil speaking region of South India and rapidly spread bhakti poetry and devotion north through India, beginning with the Saiva Nayanars (4th–10th centuries) and the Vaisnava Alvars.

 

MIDDLE KINGDOMS (600–1300 CE)

During the 4th to 8th centuries, Tamil Nadu saw the rise of the Pallava dynasty under Mahendravarman I and his son Mamalla Narasimhavarman I. The Pallavas ruled parts of South India with Kanchipuram as their capital. Tamil architecture reached its peak during Pallava rule. Narasimhavarman II built the Shore Temple which is a UNESCO World Heritage Site.

 

Much later, the Pallavas were replaced by the Chola dynasty as the dominant kingdom in the 9th century and they in turn were replaced by the Pandyan Dynasty in the 13th century. The Pandyan capital Madurai was in the deep south away from the coast. They had extensive trade links with the south east Asian maritime empires of Srivijaya and their successors, as well as contacts, even formal diplomatic contacts, reaching as far as the Roman Empire. During the 13th century, Marco Polo mentioned the Pandyas as the richest empire in existence. Temples such as the Meenakshi Amman Temple at Madurai and Nellaiappar Temple at Tirunelveli are the best examples of Pandyan temple architecture.[40] The Pandyas excelled in both trade and literature. They controlled the pearl fisheries along the south coast of India, between Sri Lanka and India, which produced some of the finest pearls in the known ancient world.

 

CHOLA EMPIRE

During the 9th century, the Chola dynasty was once again revived by Vijayalaya Chola, who established Thanjavur as Chola's new capital by conquering central Tamil Nadu from Mutharaiyar and the Pandya king Varagunavarman II. Aditya I and his son Parantaka I expanded the kingdom to the northern parts of Tamil Nadu by defeating the last Pallava king, Aparajitavarman. Parantaka Chola II expanded the Chola empire into what is now interior Andhra Pradesh and coastal Karnataka, while under the great Rajaraja Chola and his son Rajendra Chola, the Cholas rose to a notable power in south east Asia. Now the Chola Empire stretched as far as Bengal and Sri Lanka. At its peak, the empire spanned almost 3,600,000 km2. Rajaraja Chola conquered all of peninsular south India and parts of Sri Lanka. Rajendra Chola's navy went even further, occupying coasts from Burma (now ) to Vietnam, the Andaman and Nicobar Islands, Lakshadweep, Sumatra, Java, Malaya, Philippines[41] in South East Asia and Pegu islands. He defeated Mahipala, the king of Bengal, and to commemorate his victory he built a new capital and named it Gangaikonda Cholapuram. The Cholas were prolific temple builders right from the times of the first medieval king Vijayalaya Chola. These are the earliest specimen of Dravidian temples under the Cholas. His son Aditya I built several temples around the Kanchi and Kumbakonam regions. The Cholas went on to becoming a great power and built some of the most imposing religious structures in their lifetime and they also renovated temples and buildings of the Pallavas, acknowledging their common socio-religious and cultural heritage. The celebrated Nataraja temple at Chidambaram and the Sri Ranganathaswami Temple at Srirangam held special significance for the Cholas which have been mentioned in their inscriptions as their tutelary deities. Rajaraja Chola I and his son Rajendra Chola built temples such as the Brihadeshvara Temple of Thanjavur and Brihadeshvara Temple of Gangaikonda Cholapuram, the Airavatesvara Temple of Darasuram and the Sarabeswara (Shiva) Temple, also called the Kampahareswarar Temple at Thirubhuvanam, the last two temples being located near Kumbakonam. The first three of the above four temples are titled Great Living Chola Temples among the UNESCO World Heritage Sites.

 

VIJAYANAGAR AND NAYAK PERIOD (1336–1646)

The Muslim invasions of southern India triggered the establishment of the Hindu Vijayanagara Empire with Vijayanagara in modern Karnataka as its capital. The Vijayanagara empire eventually conquered the entire Tamil country by c. 1370 and ruled for almost two centuries until its defeat in the Battle of Talikota in 1565 by a confederacy of Deccan sultanates. Subsequently, as the Vijayanagara Empire went into decline after the mid-16th century, many local rulers, called Nayaks, succeeded in gaining the trappings of independence. This eventually resulted in the further weakening of the empire; many Nayaks declared themselves independent, among whom the Nayaks of Madurai and Tanjore were the first to declare their independence, despite initially maintaining loose links with the Vijayanagara kingdom. The Nayaks of Madurai and Nayaks of Thanjavur were the most prominent of Nayaks in the 17th century. They reconstructed some of the well-known temples in Tamil Nadu such as the Meenakshi Temple.

 

POWER STRUGGLES OF THE 18TH CENTURY (1688–1802)

By the early 18th century, the political scene in Tamil Nadu saw a major change-over and was under the control of many minor rulers aspiring to be independent. The fall of the Vijayanagara empire and the Chandragiri Nayakas gave the sultanate of Golconda a chance to expand into the Tamil heartland. When the sultanate was incorporated into the Mughal Empire in 1688, the northern part of current-day Tamil Nadu was administrated by the nawab of the Carnatic, who had his seat in Arcot from 1715 onward. Meanwhile, to the south, the fall of the Thanjavur Nayaks led to a short-lived Thanjavur Maratha kingdom. The fall of the Madurai Nayaks brought up many small Nayakars of southern Tamil Nadu, who ruled small parcels of land called palayams. The chieftains of these Palayams were known as Palaiyakkarar (or 'polygar' as called by British) and were ruling under the nawabs of the Carnatic.

 

Europeans started to establish trade centres during the 17th century in the eastern coastal regions. Around 1609, the Dutch established a settlement in Pulicat, while the Danes had their establishment in Tharangambadi also known as Tranquebar. In 1639, the British, under the East India Company, established a settlement further south of Pulicat, in present-day Chennai. British constructed Fort St. George and established a trading post at Madras. The office of mayoralty of Madras was established in 1688. The French established trading posts at Pondichéry by 1693. The British and French were competing to expand the trade in the northern parts of Tamil Nadu which also witnessed many battles like Battle of Wandiwash as part of the Seven Years' War. British reduced the French dominions in India to Puducherry. Nawabs of the Carnatic bestowed tax revenue collection rights on the East India Company for defeating the Kingdom of Mysore. Muhammad Ali Khan Wallajah surrendered much of his territory to the East India Company which firmly established the British in the northern parts. In 1762, a tripartite treaty was signed between Thanjavur Maratha, Carnatic and the British by which Thanjavur became a vassal of the Nawab of the Carnatic which eventually ceded to British.

 

In the south, Nawabs granted taxation rights to the British which led to conflicts between British and the Palaiyakkarar, which resulted in series of wars called Polygar war to establish independent states by the aspiring Palaiyakkarar. Puli Thevar was one of the earliest opponents of the British rule in South India. Thevar's prominent exploits were his confrontations with Marudhanayagam, who later rebelled against the British in the late 1750s and early 1760s. Rani Velu Nachiyar, was the first woman freedom fighter of India and Queen of Sivagangai. She was drawn to war after her husband Muthu Vaduganatha Thevar (1750–1772), King of Sivaganga was murdered at Kalayar Kovil temple by British. Before her death, Queen Velu Nachi granted powers to the Maruthu brothers to rule Sivaganga. Kattabomman (1760–1799), Palaiyakkara chief of Panchalakurichi who fought the British in the First Polygar War. He was captured by the British at the end of the war and hanged near Kayattar in 1799. Veeran Sundaralingam (1700–1800) was the General of Kattabomman Nayakan's palayam, who died in the process of blowing up a British ammunition dump in 1799 which killed more than 150 British soldiers to save Kattapomman Palace. Oomaithurai, younger brother of Kattabomman, took asylum under the Maruthu brothers, Periya Marudhu and Chinna Marudhu and raised an army. They formed a coalition with Dheeran Chinnamalai and Kerala Varma Pazhassi Raja which fought the British in Second Polygar Wars. Dheeran Chinnamalai (1756–1805), Polygar chieftain of Kongu and ally of Tipu Sultan who fought the British in the Second Polygar War. After winning the Polygar wars in 1801, the East India Company consolidated most of southern India into the Madras Presidency.

 

PRINCELY STATE OF PUHUKOTTAI (1680–1948 CE)

The Pudhukkottai Thondaimans rose to power over the Pudhukkottai area by the end of the 17th Century. The Pudukkottai kingdom has the distinction of being the only princely state in Tamil Nadu, and only became part of the Indian union in 1948 after independence.

 

BRITISH COLONIAL PERIOD (1801–1947 CE)

At the beginning of the 19th century, the British firmly established governance over entirety of Tamil Nadu. The Vellore mutiny on 10 July 1806 was the first instance of a large-scale mutiny by Indian sepoys against the British East India Company, predating the Indian Rebellion of 1857 by half a century. The revolt, which took place in Vellore, was brief, lasting one full day, but brutal as mutineers broke into the Vellore fort and killed or wounded 200 British troops, before they were subdued by reinforcements from nearby Arcot. The British crown took over the control governance from the Company and the remainder of the 19th century did not witness any native resistance until the beginning of 20th century Indian Independence movements. During the administration of Governor George Harris (1854–1859) measures were taken to improve education and increase representation of Indians in the administration. Legislative powers given to the Governor's council under the Indian Councils Act 1861 and 1909 Minto-Morley Reforms eventually led to the establishment of the Madras Legislative Council. Failure of the summer monsoons and administrative shortcomings of the Ryotwari system resulted in two severe famines in the Madras Presidency, the Great Famine of 1876–78 and the Indian famine of 1896–97. The famine led to migration of people as bonded labours for British to various countries which eventually formed the present Tamil diaspora.

 

POST-INDEPENDENCE (1947-PRESENT)

When India became independent in 1947, Madras presidency became Madras state, comprising present-day Tamil Nadu, coastal Andhra Pradesh up to Ganjam district in Odisha, South Canara district Karnataka, and parts of Kerala. The state was subsequently split up along linguistic lines. In 1969, Madras State was renamed Tamil Nadu, meaning "Tamil country".

 

GEOGRAPHY

Tamil Nadu covers an area of 130,058 km2, and is the eleventh largest state in India. The bordering states are Kerala to the west, Karnataka to the north west and Andhra Pradesh to the north. To the east is the Bay of Bengal and the state encircles the union territory of Puducherry. The southernmost tip of the Indian Peninsula is Kanyakumari which is the meeting point of the Arabian Sea, the Bay of Bengal, and the Indian Ocean.

 

The western, southern and the north western parts are hilly and rich in vegetation. The Western Ghats and the Eastern Ghats meet at the Nilgiri hills. The Western Ghats traverse the entire western border with Kerala, effectively blocking much of the rain bearing clouds of the south west monsoon from entering the state. The eastern parts are fertile coastal plains and the northern parts are a mix of hills and plains. The central and the south central regions are arid plains and receive less rainfall than the other regions.

 

Tamil Nadu has the country's third longest coastline at about 906.9 km. Tamil Nadu's coastline bore the brunt of the 2004 Indian Ocean tsunami when it hit India, which caused 7,793 direct deaths in the state. Tamil Nadu falls mostly in a region of low seismic hazard with the exception of the western border areas that lie in a low to moderate hazard zone; as per the 2002 Bureau of Indian Standards (BIS) map, Tamil Nadu falls in zones II and III. Historically, parts of this region have experienced seismic activity in the M5.0 range.

 

CLIMATE

Tamil Nadu is mostly dependent on monsoon rains, and thereby is prone to droughts when the monsoons fail. The climate of the state ranges from dry sub-humid to semi-arid. The state has two distinct periods of rainfall:

 

south west monsoon from June to September, with strong southwest winds;

North east monsoon from October to December, with dominant north east winds;

 

The annual rainfall of the state is about 945 mm of which 48 per cent is through the north east monsoon, and 32 per cent through the south west monsoon. Since the state is entirely dependent on rains for recharging its water resources, monsoon failures lead to acute water scarcity and severe drought. Tamil Nadu is divided into seven agro-climatic zones: north east, north west, west, southern, high rainfall, high altitude hilly, and Kaveri Delta (the most fertile agricultural zone).

 

FLORA AND FAUNA

There are about 2,000 species of wildlife that are native to Tamil Nadu. Protected areas provide safe habitat for large mammals including elephants, tigers, leopards, wild dogs, sloth bears, gaurs, lion-tailed macaques, Nilgiri langurs, Nilgiri tahrs, grizzled giant squirrels and sambar deer, resident and migratory birds such as cormorants, darters, herons, egrets, open-billed storks, spoonbills and white ibises, little grebes, Indian moorhen, black-winged stilts, a few migratory ducks and occasionally grey pelicans, marine species such as the dugongs, turtles, dolphins, Balanoglossus and a wide variety of fish and insects.

 

Indian Angiosperm diversity comprises 17,672 species with Tamil Nadu leading all states in the country, with 5640 species accounting for 1/3 of the total flora of India. This includes 1,559 species of medicinal plants, 533 endemic species, 260 species of wild relatives of cultivated plants and 230 red-listed species. The Gymnosperm diversity of the country is 64 species of which Tamil Nadu has four indigenous species and about 60 introduced species. The Pteridophytes diversity of India includes 1,022 species of which Tamil Nadu has about 184 species. Vast numbers of bryophytes, lichen, fungi, algae and bacteria are among the wild plant diversity of Tamil Nadu.

 

Common plant species include the state tree: palmyra palm, eucalyptus, rubber, cinchona, clumping bamboos (Bambusa arundinacea), common teak, Anogeissus latifolia, Indian laurel, grewia, and blooming trees like Indian labumusum, ardisia, and solanaceae. Rare and unique plant life includes Combretum ovalifolium, ebony (Diospyros nilagrica), Habenaria rariflora (orchid), Alsophila, Impatiens elegans, Ranunculus reniformis, and royal fern.

 

NATIONAL AND STATE PARKS

Tamil Nadu has a wide range of Biomes extending east from the South Western Ghats montane rain forests in the Western Ghats through the South Deccan Plateau dry deciduous forests and Deccan thorn scrub forests to tropical dry broadleaf forests and then to the beaches, estuaries, salt marshes, mangroves, Seagrasses and coral reefs of the Bay of Bengal. The state has a range of flora and fauna with many species and habitats. To protect this diversity of wildlife there are Protected areas of Tamil Nadu as well as biospheres which protect larger areas of natural habitat often include one or more National Parks. The Gulf of Mannar Biosphere Reserve established in 1986 is a marine ecosystem with seaweed seagrassrass communities, coral reefs, salt marshes and mangrove forests. The Nilgiri Biosphere Reserve located in the Western Ghats and Nilgiri Hills comprises part of adjoining states of Kerala and Karnataka. The Agasthyamala Biosphere Reserve is in the south west of the state bordering Kerala in the Western Ghats. Tamil Nadu is home to five declared national parks located in Anamalai, Mudumalai, Mukurithi, Gulf of Mannar, Guindy located in the centre of Chennai city and Vandalur located in South Chennai. Sathyamangalam Tiger Reserve, Mukurthi National Park and Kalakkad Mundanthurai Tiger Reserve are the tiger reserves in the state.

 

GOVERNANCE AND ADMINISTRATION

The Governor is the constitutional head of the state while the Chief Minister is the head of the government and the head of the council of ministers. The Chief Justice of the Madras High Court is the head of the judiciary. The present Governor, Chief Minister and the Chief Justice are Banwarilal Purohit (governor), Edappadi K. Palaniswami and Vijaya Kamlesh Tahilramani respectively. Administratively the state is divided into 33 districts. Chennai (formerly known as Madras) is the state capital. It is the fourth largest urban agglomeration in India and is also one of the major Metropolitan cities of India. The state comprises 39 Lok Sabha constituencies and 234 Legislative Assembly constituencies.

 

Tamil Nadu had a bicameral legislature until 1986, when it was replaced with a unicameral legislature, like most other states in India. The term length of the government is five years. The present government is headed by Edappadi K. Palaniswami, after the demise of former Chief Minister of Tamil Nadu, J. Jayalalithaa of the All India Anna Dravida Munnetra Kazhagam. The Tamil Nadu legislative assembly is housed at the Fort St. George in Chennai. The state had come under the President's rule on four occasions – first from 1976 to 1977, next for a short period in 1980, then from 1988 to 1989 and the latest in 1991.

 

Tamil Nadu has been a pioneering state of E-Governance initiatives in India. A large part of the government records like land ownership records are digitised and all major offices of the state government like Urban Local Bodies – all the corporations and municipal office activities – revenue collection, land registration offices, and transport offices have been computerised. Tamil Nadu is one of the states where law and order has been maintained largely successfully. The Tamil Nadu Police Force is over 140 years old. It is the fifth largest state police force in India (as of 2015, total police force of TN is 1,11,448) and has the highest proportion of women police personnel in the country (total women police personnel of TN is 13,842 which is about 12.42%) to specifically handled violence against women in Tamil Nadu. In 2003, the state had a total police population ratio of 1:668, higher than the national average of 1:717.

 

POLITICS

PRE-INDEPENDENCE

Prior to Indian independence Tamil Nadu was under British colonial rule as part of the Madras Presidency. The main party in Tamil Nadu at that time was the Indian National Congress (INC). Regional parties have dominated state politics since 1916. One of the earliest regional parties, the South Indian Welfare Association, a forerunner to Dravidian parties in Tamil Nadu, was started in 1916. The party was called after its English organ, Justice Party, by its opponents. Later, South Indian Liberal Federation was adopted as its official name. The reason for victory of the Justice Party in elections was the non-participation of the INC, demanding complete independence of India.

 

The Justice Party which was under E.V.Ramaswamy was renamed Dravidar Kazhagam in 1944. It was a non-political party which demanded the establishment of an independent state called Dravida Nadu. However, due to the differences between its two leaders EVR and C.N. Annadurai, the party was split. Annadurai left the party to form the Dravida Munnetra Kazhagam (DMK). The DMK decided to enter politics in 1956.

 

POST-INDEPENDENCE

DEMOGRAPHICS

Tamil Nadu is the seventh most populous state in India. 48.4 per cent of the state's population live in urban areas, the third highest percentage among large states in India. The state has registered the lowest fertility rate in India in year 2005–06 with 1.7 children born for each woman, lower than required for population sustainability.

 

At the 2011 India census, Tamil Nadu had a population of 72,147,030. The sex ratio of the state is 995 with 36,137,975 males and 36,009,055 females. There are a total of 23,166,721 households. The total children under the age of 6 is 7,423,832. A total of 14,438,445 people constituting 20.01 per cent of the total population belonged to Scheduled Castes (SC) and 794,697 people constituting 1.10 per cent of the population belonged to Scheduled tribes (ST).

 

The state has 51,837,507 literates, making the literacy rate 80.33 per cent. There are a total of 27,878,282 workers, comprising 4,738,819 cultivators, 6,062,786 agricultural labourers, 1,261,059 in house hold industries, 11,695,119 other workers, 4,120,499 marginal workers, 377,220 marginal cultivators, 2,574,844 marginal agricultural labourers, 238,702 marginal workers in household industries and 929,733 other marginal workers.

 

Among the cities in 2011, the state capital Chennai, was the most populous city in the state, followed by Coimbatore, Madurai, Trichy and Salem respectively. India has a human development index calculated as 0.619, while the corresponding figure for Tamil Nadu is 0.736, placing it among the top states in the country. The life expectancy at birth for males is 65.2 years and for females it is 67.6 years. However, it has a high level of poverty especially in the rural areas. In 2004–2005, the poverty line was set at ₹ 351.86/month for rural areas and ₹ 547.42/month for urban areas. Poverty in the state dropped from 51.7 per cent in 1983 to 21.1 per cent in 2001 For the period 2004–2005, the Trend in Incidence of Poverty in the state was 22.5 per cent compared with the national figure of 27.5 per cent. The World Bank is currently assisting the state in reducing poverty, High drop-out and low completion of secondary schools continue to hinder the quality of training in the population. Other problems include class, gender, inter-district and urban-rural disparities. Based on URP – Consumption for the period 2004–2005, percentage of the state's population Below Poverty Line was 27.5 per cent. The Oxford Poverty and Human Development Initiative ranks Tamil Nadu to have a Multidimensional Poverty Index of 0.141, which is in the level of Ghana among the developing countries. Corruption is a major problem in the state with Transparency International ranking it the second most corrupt among the states of India.

 

RELIGION

As per the religious census of 2011, Tamil Nadu had 87.6% Hindus, 6.1% Christians, 5.9% Muslims, 0.1% Jains and 0.3% following other religions or no religion.

 

LANGUAGE

Tamil is the sole official language of Tamil Nadu while English is declared an additional official language for communication purposes. When India adopted national standards Tamil was the first language to be recognised as a classical language of India. As of 2001 census Tamil is spoken as the first language by nearly 90 percent of the state's population followed by Telugu (5.65%), Kannada (1.67%), Urdu (1.51%), Malayalam (0.89%), Marathi (0.1%) and Saurashtra (0.1%).

 

EDUCATION

Tamil Nadu is one of the most literate states in India.[94] Tamil Nadu has performed reasonably well in terms of literacy growth during the decade 2001–2011. A survey conducted by the industry body Assocham ranks Tamil Nadu top among Indian states with about 100 per cent Gross Enrollment Ratio (GER) in primary and upper primary education. One of the basic limitations for improvement in education in the state is the rate of absence of teachers in public schools, which at 21.4 per cent is significant. The analysis of primary school education in the state by Pratham shows a low drop-off rate but poor quality of state education compared to other states. Tamil Nadu has 37 universities, 552 engineering colleges 449 Polytechnic Colleges and 566 arts and science colleges, 34,335 elementary schools, 5,167 high schools, 5,054 higher secondary schools and 5,000 hospitals. Some of the notable educational institutes present in Tamil Nadu are Indian Institute of Technology Madras, Madras Institute of Technology, College of Engineering, Guindy, Indian Institute of Management Tiruchirappalli, St. Joseph’s Institute of Management Tiruchirappalli, Indian Maritime University, National Institute of Technology, Tiruchirappalli, Tamil Nadu Dr. Ambedkar Law University, Madras Medical College, Madras Veterinary College, Stanley Medical College, Chennai, Loyola College, Chennai, Ethiraj College for Women, Stella Maris College, Chennai, Anna University, PSG College of Technology, Government College of Technology, Coimbatore, Bharathiar University, Coimbatore and Tamil Nadu Agricultural University, Coimbatore, Sri Ramachandra Medical College and Research Institute.

 

Tamil Nadu now has 69 per cent reservation in educational institutions for socially backward section of the society, the highest among all Indian states. The Midday Meal Scheme programme in Tamil Nadu was first initiated by Kamaraj, then it was expanded by M G Ramachandran in 1983.

 

CULTURE

Tamil Nadu has a long tradition of venerable culture. Tamil Nadu is known for its rich tradition of literature, art, music and dance which continue to flourish today. Tamil Nadu is a land most known for its monumental ancient Hindu temples and classical form of dance Bharata Natyam. Unique cultural features like Bharatanatyam (dance), Tanjore painting, and Tamil architecture were developed and continue to be practised in Tamil Nadu.

 

CUISINE

Salem is renowned for its unique mangoes, Madurai is the place of origin of the milk dessert Jigarthanda while Palani is known for its Panchamirtham. Coffee and tea are the staple drinks.

 

ECONOMY

For the year 2014–15 Tamil Nadu's GSDP was ₹9.767 trillion (US$140 billion), and growth was 14.86. It ranks third in foreign direct investment (FDI) approvals (cumulative 1991–2002) of ₹ 225.826 billion ($5,000 million), next only to Maharashtra and Delhi constituting 9.12 per cent of the total FDI in the country. The per capita income in 2007–2008 for the state was ₹ 72,993 ranking third among states with a population over 10 million and has steadily been above the national average.

 

According to the 2011 Census, Tamil Nadu is the most urbanised state in India (49 per cent), accounting for 9.6 per cent of the urban population while only comprising 6 per cent of India's total population. Services contributes to 45 per cent of the economic activity in the state, followed by manufacturing at 34 per cent and agriculture at 21 per cent. Government is the major investor in the state with 51 per cent of total investments, followed by private Indian investors at 29.9 per cent and foreign private investors at 14.9 per cent. Tamil Nadu has a network of about 113 industrial parks and estates offering developed plots with supporting infrastructure. According to the publications of the Tamil Nadu government the Gross State Domestic Product at Constant Prices (Base year 2004–2005) for the year 2011–2012 is ₹4.281 trillion (US$62 billion), an increase of 9.39 per cent over the previous year. The per capita income at current price is ₹ 72,993.

 

Tamil Nadu has six Nationalised Home Banks which originated in this state; Two government-sector banks Indian Bank and Indian Overseas Bank in Chennai, and Four private-sector banks City Union Bank in Kumbakonam, Karur Vysya Bank, Lakshmi Vilas Bank in Karur, and Tamilnad Mercantile Bank Limited in Tuticorin.

 

AGRICULTURE

Tamil Nadu has historically been an agricultural state and is a leading producer of agricultural products in India. In 2008, Tamil Nadu was India's fifth biggest producer of rice. The total cultivated area in the state was 5.60 million hectares in 2009–10. The Cauvery delta region is known as the Rice Bowl of Tamil Nadu. In terms of production, Tamil Nadu accounts for 10 percent in fruits and 6 percent in vegetables, in India. Annual food grains production in the year 2007–08 was 10035,000 mt.

 

The state is the largest producer of bananas, turmeric, flowers, tapioca, the second largest producer of mango, natural rubber, coconut, groundnut and the third largest producer of coffee, sapota, Tea and Sugarcane. Tamil Nadu's sugarcane yield per hectare is the highest in India. The state has 17,000 hectares of land under oil palm cultivation, the second highest in India.

 

Dr M.S. Swaminathan, known as the "father of the Indian Green Revolution" was from Tamil Nadu. Tamil Nadu Agricultural University with its seven colleges and thirty two research stations spread over the entire state contributes to evolving new crop varieties and technologies and disseminating through various extension agencies. Among states in India, Tamil Nadu is one of the leaders in livestock, poultry and fisheries production. Tamil Nadu had the second largest number of poultry amongst all the states and accounted for 17.7 per cent of the total poultry population in India. In 2003–2004, Tamil Nadu had produced 3783.6 million of eggs, which was the second highest in India representing 9.37 per cent of the total egg production in the country. With the second longest coastline in India, Tamil Nadu represented 27.54 per cent of the total value of fish and fishery products exported by India in 2006. Namakkal is also one of the major centres of egg production in India. Oddanchatram is one of the major centre for vegetable supply in Tamilnadu and is also known as the vegetable city of Tamilnadu.Coimbatore is one of the major centres for poultry production.

 

TEXTILES AND LEATHER

Tamil Nadu is one of the leading states in the textile sector and it houses the country's largest spinning industry accounting for almost 80 per cent of the total installed capacity in India. When it comes to yarn production, the State contributes 40 per cent of the total production in the country. There are 2,614 Hand Processing Units (25 per cent of total units in the country) and 985 Power Processing Units (40 per cent of total units in the country) in Tamil Nadu. According to official data, the textile industry in Tamil Nadu accounts for 17 percent of the total invested capital in all the industries.[160] Coimbatore is often referred to as the "Manchester of South India" due to its cotton production and textile industries. Tirupur is the country's largest exporter of knitwear. for its cotton production.

 

AUTOMOBILES

Tamil Nadu has seen major investments in the automobile industry over many decades manufacturing cars, railway coaches, battle-tanks, tractors, motorcycles, automobile spare parts and accessories, tyres and heavy vehicles. Chennai is known as the Detroit of India. Major global automobile companies including BMW, Ford, Robert Bosch, Renault-Nissan, Caterpillar, Hyundai, Mitsubishi Motors, and Michelin as well as Indian automobile majors like Mahindra & Mahindra, Ashok Leyland, Eicher Motors, Isuzu Motors, TI cycles, Hindustan Motors, TVS Motors, Irizar-TVS, Royal Enfield, MRF, Apollo Tyres, TAFE Tractors, Daimler AG Company invested (₹) 4 billion for establishing a new plant in Tamil Nadu.

 

HEAVY INDUSTRY AND ENGINEERING

Tamil Nadu is one of the highly industrialised states in India. Over 11% of the S&P CNX 500 conglomerates have corporate offices in Tamil Nadu.

 

The state government owns the Tamil Nadu Newsprint and Papers, in Karur.

 

Coimbatore is also referred to as "the Pump City" as it supplies two-thirds of India's requirements of motors and pumps. The city is one of the largest exporters of wet grinders and auto components and the term "Coimbatore Wet Grinder" has been given a Geographical indication.

 

ELECTRONICS AND SOFTWARE

Electronics manufacturing is a growing industry in Tamil Nadu, with many international companies like Nokia, Flex, Motorola, Sony-Ericsson, Foxconn, Samsung, Cisco, Moser Baer, Lenovo, Dell, Sanmina-SCI, Bosch, Texas Instruments having chosen Chennai as their south Asian manufacturing hub. Products manufactured include circuit boards and cellular phone handsets.

 

Tamil Nadu is the second largest software exporter by value in India. Software exports from Tamil Nadu grew from ₹ 76 billion ($1.6 billion) in 2003–04 to ₹ 207 billion {$5 billion} by 2006–07 according to NASSCOM and to ₹ 366 billion in 2008–09 which shows 29 per cent growth in software exports according to STPI. Major national and global IT Companies such as Atos Syntel, Infosys, Wipro, HCL Technologies, Tata Consultancy Services, Verizon, Hewlett-Packard Enterprise, Amazon.com, Capgemini, CGI, PayPal, IBM, NTT DATA, Accenture, Ramco Systems, Robert Bosch GmbH, DXC Technology, Cognizant, Tech Mahindra, Virtusa, LTI, Mphasis, Mindtree, Hexaware Technologies and many others have offices in Tamil Nadu. The top engineering colleges in Tamil Nadu have been a major recruiting hub for the IT firms. According to estimates, about 50 percent of the HR required for the IT and ITES industry was being sourced from the state. Coimbatore is the second largest software producer in the state, next to Chennai.

 

WIKIPEDIA

About 100 miles West of Houston lies the near-undetectable immigrant community of Dubina, TX - known only for its "painted church", Saints Cyril and Methodius, on FM 1383. The building was repainted by members of the congregation in 1909 (a picture of the interior will be uploaded soon).

_____

Fujica GW690 @ f8 handheld ;

Portra 400 shot and developed at 400 ;

Scanned with an Epson V500 Flatbed Photo Scanner ;

Edited for shadows/highlights in CS6

The stealthy Night Raider prowls the Brikverse to hunt down and disable lost convoys and vulnerable orbital stations. Its shrouded engines and angular design make it nearly undetectable to conventional sensor systems, allowing it to unleash a deadly surprise attack with its multiple cannons and armor-piercing missiles. The Rubrum Crucesignatis has a standing bounty on all Night Raiders, but its uncanny aptitude at hit-and-fade tactics have made it difficult to catch.

 

The Empire of Luchardsko is a cool-looking, if lore-light, faction created by Falk for Brikwars. One of my favorites.

Papplewick Pumping Station. Model Submarines & Spring Fair. April 2024.

--

German submarine U-31 (S181).

U-31 (S181) is a Type 212A submarine of the German Navy, and the lead ship of her class. U-31 was built by TKMS, with construction taking place at the shipyards of Thyssen Nordseewerke of Emden and Howaldtswerke at Kiel. Launched on 20 March 2002, U-31 was commissioned alongside her sister ship U-32 by German Minister of Defence Peter Struck in Eckernförde on 19 October 2005. U-31 is propelled by one diesel engine and an electric motor driven by nine fuel cells, making the submarine virtually undetectable. Korvettenkapitän Bert Petzold is the submarine's commanding officer.

--

The pumping station returned to steam after the long winter months with model submarines in the pond and on display, plus a craft fair, live music and children's play area. A good time had by all :)

--

No Group Awards/Banners, thanks

The railway line with it's high embankments was used to create a World War Two Anti-Tank Ditch, this small stream runs on from the railway, not sure if it's originally connected or not. Anti-Tank Obstacles were often constructed by improving natural obstacles, such as rivers, railway lines, and adding man made defences to them.

 

Bridges, Railway Bridges and other key points were prepared for ''demolition'' at short notice by preparing chambers filled with explosives, a Depth Charge Crater was a sited in a road (usually at a junction) prepared with buried explosives that could be detonated to instantly form a deep crater as an Anti-Tank Obstacle. The Canadian Pipe Mine (later known as the McNaughton Tube after General Andrew McNaughton) was a horizontally bored pipe packed with explosives, once in place this could be used to instantly ruin a road or runway. Prepared demolitions had the advantage of being undetectable from the air, the enemy could not take any precautions against them, or plot a route of attack around them.

 

Crossing points in the Defence Network, bridges, tunnels and other weak spots were called 'Nodes or Points of Resistance'. These were fortified with removable Road Blocks, Barbed Wire Entanglements and Land Mines. These passive defences were overlooked by Trench Works, Gun and Mortar Emplacements, and Pillboxes. In places, entire villages were fortified using Barriers of Admiralty Scaffolding, Sandbagged Positions and Loopholes in existing buildings.

 

Nodes were designated 'A', 'B' or 'C' depending upon how long they were expected to hold out, Home Guard Troops were largely responsible for the defence of Nodal Points and other centres of resistance, such as towns and defended villages. Category 'A' Nodal Points and Anti-Tank Islands were usually garrisoned by regular Troops. The rate of construction was frenetic, by the end of September 1940, 18,000 Pillboxes and numerous other preparations had been completed. Some existing defences such as Mediaeval Castles and Napoleonic Forts were augmented with modern additions such as Dragon's Teeth and Pillboxes, some Iron Age Forts housed Anti-Aircraft and Observer Positions. About 28,000 Pillboxes and other Hardened Field Fortifications were constructed in the United Kingdom of which about 6,500 still survive. Some defences were disguised and examples are known of Pillboxes constructed to resemble haystacks, logpiles and innocuous buildings such as churches and railway stations.

  

Sourced from Wikipedia:

en.m.wikipedia.org/wiki/British_anti-invasion_preparation...

Has since been upgraded.

 

During the opening years of the twenty-first century, the US military's prime light tactical

vehicle, the original M998 High Mobility Multipurpose Wheeled Vehicle (or "Humvee") was shown to be ineffective in heavy combat situations, because of it's light crew protection and underpowered engine. The series was scheduled for replacement, and almost was, before the true value of the Humvee chassis became widely known.

 

When the Second Eastern European War broke out in 2011, many of the Coalition's units where equipped with purchased American equipment, including the Humvee. When combined with up-armor kits, and armed with heavier weapons, such as TOW missiles, the combination of the M998's unmatched agility and almost undetectability provided vital in many major engagements. The chassis itself was also more durable than it's intended successor. The Marine Corps initially requested that the production of the M998 High Mobility Multipurpose Wheeled Vehicle be reopened, but in a model based of of the highly successful modifications that where made to the vehicles by the smaller eastern European nations. Soon, the Army chose to back the new project, instead of investing the money to perfect a new replacement design. By the end of the year, the entire US military was firmly behind the project, and the M9982 was born.

Blueberry juice feels rather decadent when you consider how many of the tiny fruits are required to produce just a glass or two of juice. Luckily, blueberry pulp is very easy to use. It becomes almost invisible when combined with chocolate or cocoa powder in baked goods, where it lends moisture and can even replace some of the oil or butter in your recipe.

 

www.foodthinkers.com/2010/05/blueberry-papaya-cucumber-ju...

  

BLUEBERRY PAPAYA CUCUMBER JUICE

 

Juice Ingredients

 

1¼ cup blueberries

1 medium papaya, peeled, and trimmed, seeds removed

1 large cucumber, peeled and seededjuice of 1 to 2 sweet limes or 1 Valencia orange

 

Juice Instructions

 

1. Process blueberries and cucumber in your juicer and reserve the pulp in one bag.

2. Juice papaya and reserve its pulp separately.

3. Add the sweet lime or orange juice to the mixture, stir, and enjoy.

Serves 3.

 

BLUEBERRY CHOCOLATE CAKE WITH DARK CHOCOLATE GANACHE AND TOASTED COCONUT

 

The above juice left me with about 4 ounces (½ cup) of cucumber-blueberry pulp and ¾ cup of papaya pulp. Using slightly more or less pulp in your recipe probably will not affect your finished product all that much.

 

Here I adapted my standard vegan chocolate cake recipe, with the pulp serving as a substitute for a large portion of the oil. As I mentioned above, the pulp in the batter is virtually undetectable and the cake came out incredibly moist and tender.

 

Cake Ingredients

 

1½ cups whole wheat pastry flour

1½ cups all purpose flour

⅔ cup unsweetened cocoa powder, plus extra for dusting

(I add a tablespoon or two of black onyx cocoa powder to my regular cocoa when I make chocolate cake — it gives a slightly richer product. Onyx cocoa powder can be ordered from the Savory Spice Shop.)

1½ cups sugar

1 teaspoon baking soda

1 teaspoon salt

½ cup blueberry-cucumber pulp

½ cup vegetable oil

2 cups brewed black tea*, chilled

1 tablespoon vanilla

4 tablespoons apple cider vinegar

*Either coffee or tea works very well in this recipe — for best results be sure to use a strong brew.

 

Cake Instructions

 

1. Grease two 9-inch round cake pans and dust with cocoa powder. Line bottoms of the pans with parchment paper and grease the parchment as well.

2. Preheat oven to 375°F (190°C) with a rack in the middle.

3. Sift flours, sugar, cocoa, baking soda, and salt together in a large bowl.

4. In a separate bowl, combine the blueberry-cucumber pulp, vegetable oil, chilled tea, and vanilla.

5. Pour the wet ingredients into the dry and combine with a rubber spatula. Add the vinegar and mix in with as few strokes as possible (it’s okay if there are streaks in the batter).

6. Pour batter into the prepared pans and bake for 30 to 35 minutes, testing doneness with a wooden toothpick.

7. Let cakes cool in their pans for 5 to 10 minutes before running a knife around the edge of each pan and unmolding to cool completely.

  

While cakes are cooling, put the papaya pulp and a tablespoon or two or orange juice into a small saucepan and bring to a simmer. Add a tablespoon of sugar and stir as the mixture simmers gently for about 5 minutes. Cook until you have a thick, spreadable paste. Cool.

 

Filling Instructions

 

When the cake has cooled you may want to even out the surface of your first layer by slicing off the dome to create a flat, even round. Spread the papaya filling over the bottom cake layer and top with second cake.

 

Ganache Ingredients

 

8 ounces chopped dark chocolate, or chocolate chips (about 60% cocoa)

⅔ cup soy milk

4 tablespoons maple syrup

topping: ½ cup toasted* unsweetened shredded coconut

(*spread coconut onto a sheet pan and toast at 325°F (163°C) in a toaster oven for about 10 minutes)

 

Ganache Instructions

 

1. Heat the soy milk in a small saucepan until it begins to boil. Remove from heat and immediately add the chocolate.

2. Stir until all the chocolate has melted, then stir in maple syrup until the mixture is completely smooth.

3. Let cool slightly before pouring over the cake. Top your cake with the toasted coconut, and chill in fridge to set the ganache.

 

This cake keeps beautifully for 3 to 4 days at room temperature when wrapped in plastic or stored inside a cake dome.

The Devaraja market in Mysore was built during the reign of Chamaraja Wodeyar IX (1868 – 1894). It is said that there was at this place a small weekly market which may have been as old as the origin of the city itself.

_______________________

 

The chili pepper (also chile pepper, chilli pepper, or simply chilli) from Nahuatl chīlli Nahuatl pronunciation: [ˈt͡ʃiːli] (About this sound listen)) is the fruit of plants from the genus Capsicum, members of the nightshade family, Solanaceae. They are widely used in many cuisines to add spiciness to dishes. The substances that give chili peppers their intensity when ingested or applied topically are capsaicin and related compounds known as capsaicinoids.

 

Chili peppers originated in Mexico. After the Columbian Exchange, many cultivars of chili pepper spread across the world, used for both food and traditional medicine.

 

Worldwide in 2014, 32.3 million tonnes of green chili peppers and 3.8 million tonnes of dried chili peppers were produced. China is the world's largest producer of green chillies, providing half of the global total.

 

HISTORY

Chili peppers have been a part of the human diet in the Americas since at least 7500 BCE. The most recent research shows that chili peppers were domesticated more than 6000 years ago in Mexico, in the region that extends across southern Puebla and northern Oaxaca to southeastern Veracruz, and were one of the first self-pollinating crops cultivated in Mexico, Central and parts of South America.

 

Peru is considered the country with the highest cultivated Capsicum diversity because it is a center of diversification where varieties of all five domesticates were introduced, grown, and consumed in pre-Columbian times. Bolivia is considered to be the country where the largest diversity of wild Capsicum peppers are consumed. Bolivian consumers distinguish two basic forms: ulupicas, species with small round fruits including C. eximium, C. cardenasii, C. eshbaughii, and C. caballeroi landraces; and arivivis with small elongated fruits including C. baccatum var. baccatum and C. chacoense varieties.

 

Christopher Columbus was one of the first Europeans to encounter them (in the Caribbean), and called them "peppers" because they, like black pepper of the Piper genus known in Europe, have a spicy, hot taste unlike other foodstuffs. Upon their introduction into Europe, chilies were grown as botanical curiosities in the gardens of Spanish and Portuguese monasteries. Christian monks experimented with the culinary potential of chili and discovered that their pungency offered a substitute for black peppercorns, which at the time were so costly that they were used as legal currency in some countries.

 

Chilies were cultivated around the globe after Indigenous people shared them with travelers. Diego Álvarez Chanca, a physician on Columbus' second voyage to the West Indies in 1493, brought the first chili peppers to Spain and first wrote about their medicinal effects in 1494.

 

The spread of chili peppers to Asia was most likely a natural consequence of its introduction to Portuguese traders (Lisbon was a common port of call for Spanish ships sailing to and from the Americas) who, aware of its trade value, would have likely promoted its commerce in the Asian spice trade routes then dominated by Portuguese and Arab traders. It was introduced in India by the Portuguese towards the end of 15th century. Today chilies are an integral part of South Asian and Southeast Asian cuisines.

 

The chili pepper features heavily in the cuisine of the Goan region of India, which was the site of a Portuguese colony (e.g., vindaloo, an Indian interpretation of a Portuguese dish). Chili peppers journeyed from India, through Central Asia and Turkey, to Hungary, where they became the national spice in the form of paprika.

 

An alternate, although not so plausible account (no obvious correlation between its dissemination in Asia and Spanish presence or trade routes), defended mostly by Spanish historians, was that from Mexico, at the time a Spanish colony, chili peppers spread into their other colony the Philippines and from there to India, China, Indonesia. To Japan, it was brought by the Portuguese missionaries in 1542, and then later, it was brought to Korea.

 

In 1995 archaeobotanist Hakon Hjelmqvist published an article in Svensk Botanisk Tidskrift claiming there was evidence for the presence of chili peppers in Europe in pre-Columbian times. According to Hjelmqvist, archaeologists at a dig in St Botulf in Lund found a Capsicum frutescens in a layer from the 13th century. Hjelmqvist thought it came from Asia. Hjelmqvist also said that Capsicum was described by the Greek Theophrastus (370–286 BCE) in his Historia Plantarum, and in other sources. Around the first century CE, the Roman poet Martialis (Martial) mentioned "Piperve crudum" (raw pepper) in Liber XI, XVIII, allegedly describing them as long and containing seeds (a description which seems to fit chili peppers - but could also fit the long pepper, which was well known to ancient Romans).

 

PRODUCTION

In 2014, world production of fresh green chillies and peppers was 33.2 million tonnes, led by China with 48% of the global total. Global production of dried chillies and peppers was about nine times less than for fresh production, led by India with 32% of the world total.

 

SPECIES AND CULTIVARS

The five domesticated species of chili peppers are as follows:

 

Capsicum annuum, which includes many common varieties such as bell peppers, wax, cayenne, jalapeños, chiltepin, and all forms of New Mexico chile.

Capsicum frutescens, which includes malagueta, tabasco and Thai peppers, piri piri, and Malawian Kambuzi

Capsicum chinense, which includes the hottest peppers such as the naga, habanero, Datil and Scotch bonnet

Capsicum pubescens, which includes the South American rocoto peppers

Capsicum baccatum, which includes the South American aji peppers

 

Though there are only a few commonly used species, there are many cultivars and methods of preparing chili peppers that have different names for culinary use. Green and red bell peppers, for example, are the same cultivar of C. annuum, immature peppers being green. In the same species are the jalapeño, the poblano (which when dried is referred to as ancho), New Mexico, serrano, and other cultivars.

 

Peppers are commonly broken down into three groupings: bell peppers, sweet peppers, and hot peppers. Most popular pepper varieties are seen as falling into one of these categories or as a cross between them.

 

INTENSITY

The substances that give chili peppers their pungency (spicy heat) when ingested or applied topically are capsaicin (8-methyl-N-vanillyl-6-nonenamide) and several related chemicals, collectively called capsaicinoids. The quantity of capsaicin varies by variety, and on growing conditions. Water stressed peppers usually produce stronger pods. When a habanero plant is stressed, for example low water, the concentration of capsaicin increases in some parts of the fruit.

 

When peppers are consumed, capsaicin binds with pain receptors in the mouth and throat, potentially evoking pain via spinal relays to the brainstem and thalamus where heat and discomfort are perceived. The intensity of the "heat" of chili peppers is commonly reported in Scoville heat units (SHU). Historically, it was a measure of the dilution of an amount of chili extract added to sugar syrup before its heat becomes undetectable to a panel of tasters; the more it has to be diluted to be undetectable, the more powerful the variety, and therefore the higher the rating. The modern method is a quantitative analysis of SHU using high-performance liquid chromatography (HPLC) to directly measure the capsaicinoid content of a chili pepper variety. Pure capsaicin is a hydrophobic, colorless, odorless, and crystalline-to-waxy solid at room temperature, and measures 16,000,000 SHU.

 

USE

CULINARY USES

Chili pepper pods, which are berries, are used fresh or dried. Chilies are dried to preserve them for long periods of time, which may also be done by pickling.

 

Dried chilies are often ground into powders, although many Mexican dishes including variations on chiles rellenos use the entire chili. Dried whole chilies may be reconstituted before grinding to a paste. The chipotle is the smoked, dried, ripe jalapeño.

 

Many fresh chilies such as poblano have a tough outer skin that does not break down on cooking. Chilies are sometimes used whole or in large slices, by roasting, or other means of blistering or charring the skin, so as not to entirely cook the flesh beneath. When cooled, the skins will usually slip off easily.

 

The leaves of every species of Capsicum are edible. Though almost all other Solanaceous crops have toxins in their leaves, chili peppers do not. The leaves, which are mildly bitter and nowhere near as hot as the fruit, are cooked as greens in Filipino cuisine, where they are called dahon ng sili (literally "chili leaves"). They are used in the chicken soup tinola. In Korean cuisine, the leaves may be used in kimchi. In Japanese cuisine, the leaves are cooked as greens, and also cooked in tsukudani style for preservation.

 

Chili is by far the most important fruit in Bhutan. Local markets are never without chilies in different colors and sizes, in fresh and dried form. Bhutanese call this crop ema (in Dzongkha) or solo (in Sharchop). Chili is a staple fruit in Bhutan; the ema datsi recipe is entirely made of chili mixed with local cheese. Chili is also an important ingredient in almost all curries and food recipes in the country.

 

In India, most households always keep a stack of fresh hot green chilies at hand, and use them to flavor most curries and dry dishes. It is typically lightly fried with oil in the initial stages of preparation of the dish. Some states in India, such as Rajasthan, make entire dishes only by using spices and chilies.

 

Chilies are present in many cuisines. Some notable dishes other than the ones mentioned elsewhere in this article include:

 

Arrabbiata sauce from Italy is a tomato-based sauce for pasta always including dried hot chilies.

Puttanesca sauce is tomato-based with olives, capers, anchovy and, sometimes, chilies.

Paprikash from Hungary uses significant amounts of mild, ground, dried chilies, known as paprika, in a braised chicken dish.

Chiles en nogada from the Puebla region of Mexico uses fresh mild chilies stuffed with meat and covered with a creamy nut-thickened sauce.

Curry dishes usually contain fresh or dried chillies.

Kung pao chicken (Mandarin Chinese: 宫保鸡丁 gōng bǎo jī dīng) from the Sichuan region of China uses small hot dried chilies briefly fried in oil to add spice to the oil then used for frying.

Mole poblano from the city of Puebla in Mexico uses several varieties of dried chilies, nuts, spices, and fruits to produce a thick, dark sauce for poultry or other meats.

Nam phrik are traditional Thai chili pastes and sauces, prepared with chopped fresh or dry chilies, and additional ingredients such as fish sauce, lime juice, and herbs, but also fruit, meat or seafood.

'Nduja, a more typical example of Italian spicy specialty, from the region of Calabria, is a soft pork sausage made "hot" by the addition of the locally grown variety of jalapeño chili.

Paprykarz szczeciński is a Polish fish paste with rice, onion, tomato concentrate, vegetable oil, chili pepper powder and other spices.

Sambal terasi or sambal belacan is a traditional Indonesian and Malay hot condiment made by frying a mixture of mainly pounded dried chillies, with garlic, shallots, and fermented shrimp paste. It is customarily served with rice dishes and is especially popular when mixed with crunchy pan-roasted ikan teri or ikan bilis (sun-dried anchovies), when it is known as sambal teri or sambal ikan bilis. Various sambal variants existed in Indonesian archipelago, among others are sambal badjak, sambal oelek, sambal pete (prepared with green stinky beans) and sambal pencit (prepared with unripe green mango).

Som tam, a green papaya salad from Thai and Lao cuisine, traditionally has, as a key ingredient, a fistful of chopped fresh hot Thai chili, pounded in a mortar.

Fresh or dried chilies are often used to make hot sauce, a liquid condiment - usually bottled when commercially available - that adds spice to other dishes. Hot sauces are found in many cuisines including harissa from North Africa, chili oil from China (known as rāyu in Japan), and sriracha from Thailand.

Capsaicin is also the primary component in pepper spray, a less-than-lethal weapon.

 

PSYCHOLOGY

Psychologist Paul Rozin suggests that eating chilies is an example of a "constrained risk" like riding a roller coaster, in which extreme sensations like pain and fear can be enjoyed because individuals know that these sensations are not actually harmful. This method lets people experience extreme feelings without any risk of bodily harm.

 

MEDICINAL

Capsaicin, the chemical in chili peppers that makes them hot, is used as an analgesic in topical ointments, nasal sprays, and dermal patches to relieve pain.

 

PEPPER SPRAY

Capsaicin extracted from chilies is used in pepper spray as an irritant, a form of less-lethal weapon.

 

CROP DEFENSE

Conflicts between farmers and elephants have long been widespread in African and Asian countries, where elephants nightly destroy crops, raid grain houses, and sometimes kill people. Farmers have found the use of chilies effective in crop defense against elephants. Elephants do not like capsaicin, the chemical in chilies that makes them hot. Because the elephants have a large and sensitive olfactory and nasal system, the smell of the chili causes them discomfort and deters them from feeding on the crops. By planting a few rows of the pungent fruit around valuable crops, farmers create a buffer zone through which the elephants are reluctant to pass. Chilly-Dung Bombs are also used for this purpose. They are bricks made of mixing dung and chili, and are burned, creating a noxious smoke that keeps hungry elephants out of farmers' fields. This can lessen dangerous physical confrontation between people and elephants.

 

FOOD DEFENSE

Birds do not have the same sensitivity to capsaicin, because it targets a specific pain receptor in mammals. Chili peppers are eaten by birds living in the chili peppers' natural range, possibly contributing to seed dispersal and evolution of the protective capsaicin in chili peppers.

 

NUTRITIONAL VALUE

While red chilies contain large amounts of vitamin C (table), other species contain significant amounts of provitamin A beta-carotene. In addition, peppers are a rich source of vitamin B6

 

SPELLING AND USAGE

The three primary spellings are chili, chile and chilli, all of which are recognized by dictionaries.

 

Chili is widely used in historically Anglophone regions of the United States and Canada. However, it is also commonly used as a short name for chili con carne (literally "chili with meat"). Most versions are seasoned with chili powder, which can refer to pure dried, ground chili peppers, or to a mixture containing other spices.

Chile is the most common Spanish spelling in Mexico and several other Latin American countries, as well as some parts of the United States and Canada, which refers specifically to this plant and its fruit. In the Southwest United States (particularly New Mexico), chile also denotes a thick, spicy, un-vinegared sauce made from this fruit, available in red and green varieties, and served over the local food, while chili denotes the meat dish. The plural is chile or chiles.

Chilli was the original Romanization of the Náhuatl language word for the fruit (chīlli) and is the preferred British spelling according to the Oxford English Dictionary, although it also lists chile and chili as variants. Chilli (and its plural chillies) is the most common spelling in Australia, India, Malaysia, New Zealand, Pakistan, Singapore and South Africa.

 

The name of the plant is almost certainly unrelated to that of Chile, the country, which has an uncertain etymology perhaps relating to local place names. Chile, Colombia, Ecuador, Panama, Peru, Dominican Republic and Puerto Rico are some of the Spanish-speaking countries where chilies are known as ají, a word of Taíno origin. Though pepper originally referred to the genus Piper, not Capsicum, the latter usage is included in English dictionaries, including the Oxford English Dictionary (sense 2b of pepper) and Merriam-Webster. The word pepper is also commonly used in the botanical and culinary fields in the names of different types of chili plants and their fruits.

 

WIKIPEDIA

Hands stretched out these boys make their way through the corridors. I'm sure they feel my presence, they feel the shift in the air column and they hear the shuffling of my feet. Through experience and from the signs I’ve dropped they can probably guesstimate someone twice their height is crouched on the floor on his knees and is leaning forward in a rather awkward angle and they have no reason of telling why. I’m yet another obstacle in their path but than again experience has taught them to overcome such obstacles with a smile and they do

 

Imagine living a day without seeing, imagine someone has fastened an oval bandages over your eyes the kind that ophthalmists favor so much. You go about your day exploring how loosing one of your senses affects your life in unpredictable ways. I would imagine your day to be a kind of sensory travel which would test the limits of the visible. Once you’re on your morning train to work – mostly a circumstance of the kindness of some stranger. I’m sure you’ll inhabit a world very different than one you are used to the underlying irony being nothing is quiet changed except for the temporary loss of one of your senses. May be your commute will sound quieter than usual may or even sound empty, or even quiet. May be you’ll hear the distant whisper of Gujurati men swapping stock tips or the tinny echoes of distant voices of your local radio station or the occasional ringing of a mobile phone. I’m sure in fact the compartment is packed but the morning office crowd isn’t in the mood for conversation. To the blind man, the mute crowd is undetectable. As a photographer so often there is so much more to be felt than there is to be seen and it then becomes your job to translate what is being felt into what is felt through your cameras. May be being blind is when your whole world is to be felt and not to be seen,

 

[Read More]

This is an adult Meadow Pipit in the middle of its post-breeding moult. At this time of the year any Meadow Pipit in extensive moult will be an adult. Unlike the Starling the juveniles only have a partial post-juvenile moult which only involves the body feathers and the wing feathers are retained until after breeding the following year. This adult has dropped a lot of the coverts and if you look carefully some flight feathers which are being replaced sequentially. This is a stressful time of the year for the adults - they have just worked their butts off rearing their offspring and now replace all their feathers. Because of this many species keep a low profile out of the way of potential predators (efficient flight may be compromised) and this is one of the reasons why small birds are relatively undetectable at this time of the year. Territory battles are over and done with so the males have fallen silent also which reduces detection (and identification). Some of our migrant species, however, will put moult on hold until they are in their winter quarters, for example the Swallow.

This coat has a lovely dense, soft shiny fur.. and I have had a subtle modification carried out on its satin lining.

 

I have had a little loop and clasp sewn into the lining adjacent to the right hand arm-pit/sleeve joint. The clasp allows undetectable stowage and easy reach of both crop and ball gag. How thoroughly useful and very pleasing.

1️⃣no heat 2️⃣no glue 3️⃣no sewing 4️⃣no damage to the natural hair 5️⃣comfortable to wear & undetectable 6️⃣you can wear you hair up in diferent styles 7️⃣super comfortable 8️⃣application lasts up to 3 months 9️⃣the hair is reusable 🔟ethically sourced product 👉👉You can find a salon close to you and you can book a free consultation. Ask Us How 📲 #easilocks #hair #hairstylist #longhair #hairextensions #hairextension #easilocksusa #easilocksextensions #haircolor

The Saluki inside the bike-specific vestibule. A tight fit - especially if you're running wide handlebars and platform pedals. One of the pedals had to push into the tent screen and I bumped it a few times getting in the tent. Overall, it's nice to have the bike protected and virtually undetectable.

Fed up with floppies? Turned off by throbbers? Weary of wagglers?

 

Help is at hand!

 

Fresh from Grotley Industries R&D labs, the all new Koq-Bloq ™ Filter Mask!

 

Simply slip on this lightweight, unobtrusive device before opening Flickr and in the twinkling of an eye all those unsolicited offerings will be replaced by your own selection of reassuring images. Kittens, mountains, Nick Clegg... the choice is yours!

 

The Koq-Bloq ™ reacts to unwanted pictures in less than a thousandth of a second. Undetectable in everyday use - even your closest friends won't know you're wearing it!

 

Koq-Bloq ™. A girl's best friend.

Here is a scene that is a bit if a chuckle and I didn't really have to wait at the previous spot at all to capture this scene of transportation modes. The bike riders may not even be aware of the late 17th century wagon road on the hillside above them. They best pay attention to not spilling into the drink over on the other side. It spans from wagon roads to paved roads to Boulder biking. Riding the hill is a perfect way to burn the carbs and then pack them back on at the Jamestown Mercantile. The "Merc" is the perfect place to pause, regenerate and meet a wide array of new friends before heading up the grade to see if you can find Gresham. It is wise to drive slowly enough to be able to react to bike riders because you WILL meet some on the hill's windy roads.

 

I have been mentioning the old road so I thought I better get as good a shot as I could for you. I was on the way down from from my washout trek to Gold Hill, Colorado, a remnant of the old mining days and caught sight of this just visible view of the abandoned wagon road, above left, in the canyon just below the Lefthand/James canyons confluence. The built up rock on the side is visible. Though this is not an enormously strong view, it looks like it is heading uphill from this viewpoint but it is really more nearly level and winding than the modern paved road. There was an access road from Lyons that connected below here, at Jamestown and finally Gresham. It may have an undetectable connection to this route. The best info comes from the 1903 Boulder topo even though this route does not show on the map any longer. It must have slip the cartographer's eye even then. I have no idea if either of the narrow gauge railways had intended on using this exact route. I'm not sure it could realistically have been accomplished. The Boulder-originated grade can just barely be seen rounding the hill and up the canyon south of the river on Google maps. I thought that I better stop on my way back down for a shot under this flat skylight.

  

+++ DISCLAIMER +++

Nothing you see here is real, even though the conversion or the presented background story might be based historical facts. BEWARE!

 

Some background:

NAe São Paulo is a Clemenceau-class aircraft carrier currently in service with the Brazilian Navy. São Paulo was first commissioned in 1963 by the French Navy as Foch and was transferred in 2000 to Brazil, where she became the new flagship of the Brazilian Navy. In December 2014 it was announced that São Paulo will be expected to continue active service until 2039, at which time the vessel will be nearly 80 years old.

 

From this carrier, the Marinha do Brasil operates its only fixed-wing aircraft, and these were initially A-4 Skyhawks. In 1997 Brazil negotiated a $70 million contract for purchase of 20 A-4KU and three TA-4KU Skyhawks from Kuwait. The Kuwaiti Skyhawks, modified A-4Ms and TA-4Js delivered in 1977, were among the last of those models built by Douglas. The Kuwaiti Skyhawks were selected by Brazil because of low flight time, excellent physical condition, and a favorable price tag. The Brazilian Navy Re-designated AF-1 and AF-1A Falcões (Hawks), the ex-Kuwaiti Skyhawks arrived in Arraial do Cabo on 5 September 1998.

 

Anyway, the Skyhawks' life span was limited and in 2005 the Brazilian Navy started looking for a potential replacement, while the AF-1s were to kept operational due to limited military budgets. On 14 April 2009, Brazlian aircraft manufacturer EMBRAER signed a contract to modernize 12 Skyhawks, nine AF-1s (single-seat) and three AF-1As (two-seat). This upgrade will restore the operating capacity of the Navy 1st Intercept and Attack Plane Squadron (VF-1). The program includes restoring the aircraft and their current systems, as well as implementing new avionics, radar, power production, and autonomous oxygen generating systems. The first of the 12 modified Skyhawks was delivered on 27 May 2015. EMBRAER stated that the modifications would allow the aircraft to remain operational until 2025, by which time a successor was to be fully operational.

 

Several replacement candidates were evaluated under Brazil's F-X2 fighter program together with the Air Force which was looking to replace its Northrop F‐5EM and Dassault Mirage 2000C aircraft. In October 2008, Brazil selected three finalists: the Dassault Rafale, the Boeing F/A-18 Super Hornet, and the SAAB JAS 39 Gripen. The Brazilian Air Force initially planned to procure at least 36 and possibly up to 120 aircraft later, while the Brazilian Navy was looking for 24 aircraft (20 single seater and 4 two-seaters with dual controls) until 2025.

 

In February 2009, SAAB submitted a tender, and on 5 January 2010, reports claimed that the final evaluation report placed the Gripen ahead of other contenders; the decisive factor was reportedly lower unit and operational costs, the most compact size and the Swedish manufacturer's willingness to accept EMBRAER as a technological partner for the aircraft's further development, especially for the navalized version.

 

Amid delays due to financial constraints, President Dilma Rousseff announced in December 2011 the Gripen NG's selection and the start of a joint Swedish-Brazilian joint venture called SABRA. Argentina and Ecuador were interested in procuring Gripens from or through Brazil, and Mexico and Argenitina were potential export targets for SABRA's navalized Gripen derivative that was tailored to the Marinha do Brasil's needs.

 

The respective SABRA aircraft was appropriately christened "Grifo" and the development of thei 4th generation fighter started immediately after closing the cooperation deal in 2011. While based on the SAAB 39, the Grifo became a very different aircraft, due to several factors. The major influence was the carrier operation capability, which called for major structural modifications and enforcements as well as special equipment like foldable wings, a strengthened landing gear, an arrester hook and a new engine that would better cope with the naval environment than the Swedish RM 12 engine, a derivative of the General Electric F404-400.

 

Additionally, the mission focus of air superiority with additional attack capabilities was reversed, and the need for excellent low speed handling for carrier approaches was requested.

 

This led to a complelety different aircraft layout, with the SAAB 39's instable canard design being changed into a conservative aircraft with conventional tailplanes. The nose section was shortened in order to provide the pilot with a better field of view, while the more powerful F414-EPE afterburning turbofan was moved slightly forward due to CG reasons, resulting in a slightly shortened rear fuselage.

 

A mock-up of the new aircraft for the Brazlian Navy was presented and approved in early 2012, and the government placed an official order for two prototypes. Even though the Grifo appeared like a completely different aircraft, it shared a lot of elements with the SAAB 39, so that development time and costs could be reduced to a minimum - and the first prototype, internally designated EMB 391-001, made its maiden flight in early 2013. The second aircraft followed 3 months later.

 

The Grifo's equipment includes an AN/APG-79 active electronically scanned array (AESA), capable of executing simultaneous air-to-air and air-to-ground attacks, and providing higher quality high-resolution ground mapping at long standoff ranges. The AESA radar can also detect smaller targets, such as inbound missiles, and can track air targets beyond the range of the aircraft's air-to-air missiles, which include the AIM-9 Sidewinder for close range and the AIM-120 AMRAAM for medium range.

 

The Grifo features, like the Gripen fighter, an advanced and integrated electronic warfare suite, capable of operating in an undetectable passive mode or to actively jam hostile radar; a missile approach warning system passively detects and tracks incoming missiles.

 

The Grifo can be tailored to specific missions through external sensor pods, e .g. for reconnaissance and target designation. These include Rafael's LITENING targeting pod, Saab's Modular Reconnaissance Pod System or Thales' Digital Joint Reconnaissance Pod. On the Brazilian Navy's request the Grifo is also designed that it can be equipped with an aerial refueling system (ARS) or "buddy store" for the refueling of other aircraft, filling the tactical airborne tanker role.

 

The two prototypes completed a thorough test program until summer 2015 and subsequently went on a sales tour in South America and Asia. In the meantime, serial production started at EMBRAER's Gavião Peixoto in November 2015. The first serial machines, now officially designated AF-2A, arrived at the Brazilian Navy's São Pedro da Aldeia air base where a new Intercept and Attack Plane Squadron, VF-2 'Arquieros' (Archers) was founded. The squadron became operational in April 2016 and Grifos embarked on NAe São Paulo for the first time in September 2016, serving alongside the venerable AF-1.

  

General characteristics:

Crew: 1

Payload: 5,300 kg (11,700 lb)

Length: 13,54 m (44 ft 4 in)

Wingspan (incl. wing tip launch rails): 8.32 m (27 ft 2 in)

Height: 4.25 m (13 ft 11 in)

Wing area: 30.0 m² (323 ft²)

Empty weight: 6,800 kg[330] (14,990 lb)

Loaded weight: 8,500 kg (18,700 lb)

Max. takeoff weight: 14,000 kg (31,000 lb)

Wheel track: 2.4 m (7 ft 10 in)

Powerplant:

1 × General Electric F414-EPE afterburning turbofan with

a dry thrust of 54 kN (12,100 lbf) and 85 kN (19,100 lbf) with afterburner

 

Performance:

Maximum speed: Mach 2 (2,204 km/h (1,190 kn; 1,370 mph) at high altitude

Combat radius: 800 km (497 mi, 432 nmi)

Ferry range: 3,200 km (1,983 mi) with drop tanks

Service ceiling: 15,240 m (50,000 ft)

Wing loading: 283 kg/m² (58 lb/ft²)

Thrust/weight: 0.97

Maximum g-load: +9 g

 

Armament:

1× 27 mm Mauser BK-27 Revolver cannon with 120 rounds

Eight hardpoints (three on each wing and two under fuselage)

for a wide range of guide and unguided ordnance of up to 14,330 lb (6.5 t)

  

The kit and its assembly:

The fictional Grifo is the result of a generic idea of converting a canard layout aircraft like the Saab Viggen into a conventional design. The Viggen was actually a serious candidate, but then I found an Italeri Gripen in the stash without a real purpose (it had been cheap, though), and with Brazil's real world procurement as background, the more conservative Grifo was born.

 

I wanted to use as many OOB Gripen parts as possible, and there are actually only a few external donations involved – with the outlook of converting further Gripens this way. You never know… ;)

 

Work started with the wings, which were cut off of the fuselage shell. Having the landing gear retract into the fuselage (much like the X-29) is a convenient detail of the Gripen, making the wing transplantation easier than on a Viggen where the wells have to be moved, too.

 

The original canard attachment points were faired over/hidden. The pointed Gripen nose with its pitot was cut off and replaced by a shorter, more stocky nose tip - from an F-4 Phantom II IIRC. Once the fuselage was completed, the wings were mounted, closer to the air intakes. This went smoothly, only some gaps on the undersides had to be filled.

 

Once the wings were in place I had to make a decision concerning the stabilizers. Despite the plan to use as many OOB parts as possible I found the OOB canards to be too sharply swept and considered several donation options.

I eventually settled for the most unique option: the stabilizers are actually main wings from a (rather malformed) Italeri/Dragon 1:200 F-117 that comes as a set with the B-2 bomber. A part of the F-117’s fuselage flank was cut off and taken over to the Grifo, too, so that these create ‘muscular’ bulges.

 

The stabilizers were mounted on scratched consoles/trailing wing root extensions that were somewhat inspired by the F-16’s tail design – putting the stabilizers directly onto the fuselage would have looked awkward, and with this solution I was able to extend the Gripen’s BWB-design all along the fuselage. As a side effect these consoles also offered a plausible place for rearward chaff dispensers.

 

The rear fuselage was shortened by 3mm, too – through the shorter nose and the wings further forward, the rest of the aircraft looked rather tail-heavy. While 3mm does not sound much, it helped with overall proportions.

 

The cannon fairing and the OOB pylons were taken over, as well as the cockpit interior. For carrier operations, several details were added, though: folding wing mechanism seams were engraved on the wings and an arrester hook with a fairing added under the tail section, flanked by new stabilizer fins.

 

The landing gear was basically taken OOB, too, but lengthened with styrene inserts for a higher stance: the main struts are now 2mm longer, while the front strut is 3mm taller. The latter was reversed, so that a catapult hook could be added to the front side, and slightly bigger wheels were mounted, too, so that the Grifo now has a rather stalky stance with a nose-up attitude. Simple, but effective!

 

The Sidewinders were taken OOB while the pair of AGM-84 Harpoon comes from Italeri’s 1:72 NATO weapons set.

 

Painting and markings:

I used the contemporary AF-1 paint scheme in three shades of grey as benchmark. These are FS 36187 (RAF Ocean Grey), FS 36307 (Flint Grey) and FS 36515 (Canadian Voodoo Grey) - sourced from a painting guide from Brazilian decal manufacturer FCM and backed by other knowledgeable sources from the region, too. And while the Ocean Grey appears a bit dark, I think that overall the colors are authentic. All paints are Modelmaster enamels.

 

After basic painting a light black ink wash was applied and panels highlighted through dry-brushing with lighter tones.

 

The cockpit interior was painted in Neutral Grey (FS 36173), while the landing gear became all-white.

The Brazilian Navy markings had to be improvised - there are 1:72 AF-1 decals available, but either not obtainable or prohibitively expensive - or both. Therefore I rather improvised, with basic Brazilian Navy markings from a vintage FCM Decal sheet for various Brazilian aircraft.

 

The respective roundels and codes actually belong to helicopters, and I had to wing it somehow. Unfortunately, the old FCM decals turned out to be ...old. Brittle and very delicate, application was already messy and they did not adhere well to the model. To make matters worse the acrylic varnish turned cloudy, so that a lot of paintwork repair had to be done - not helping much with a satisfactory kit finish. :(

  

Another interesting conversion – I am amazed how purposeful the Grifo looks. It reminds me with its high stance of a modern A-4 Skyhawk (what it somehow is), and there’s also some Super Étendard in it, esp. in the profile? At some point before painting it also had a somewhat Chinese look - maybe because the top view and the wing planform reminds of the classic MiG-21…? The wings might have been placed 3-4mm further backwards, since it is always difficult to judge proportions while work is still, but the Grifo looks convincingly like a real aircraft (model).

 

Aeronaves bonita! :D

+++ DISCLAIMER +++

Nothing you see here is real, even though the conversion or the presented background story might be based historical facts. BEWARE!

 

Some background:

NAe São Paulo is a Clemenceau-class aircraft carrier currently in service with the Brazilian Navy. São Paulo was first commissioned in 1963 by the French Navy as Foch and was transferred in 2000 to Brazil, where she became the new flagship of the Brazilian Navy. In December 2014 it was announced that São Paulo will be expected to continue active service until 2039, at which time the vessel will be nearly 80 years old.

 

From this carrier, the Marinha do Brasil operates its only fixed-wing aircraft, and these were initially A-4 Skyhawks. In 1997 Brazil negotiated a $70 million contract for purchase of 20 A-4KU and three TA-4KU Skyhawks from Kuwait. The Kuwaiti Skyhawks, modified A-4Ms and TA-4Js delivered in 1977, were among the last of those models built by Douglas. The Kuwaiti Skyhawks were selected by Brazil because of low flight time, excellent physical condition, and a favorable price tag. The Brazilian Navy Re-designated AF-1 and AF-1A Falcões (Hawks), the ex-Kuwaiti Skyhawks arrived in Arraial do Cabo on 5 September 1998.

 

Anyway, the Skyhawks' life span was limited and in 2005 the Brazilian Navy started looking for a potential replacement, while the AF-1s were to kept operational due to limited military budgets. On 14 April 2009, Brazlian aircraft manufacturer EMBRAER signed a contract to modernize 12 Skyhawks, nine AF-1s (single-seat) and three AF-1As (two-seat). This upgrade will restore the operating capacity of the Navy 1st Intercept and Attack Plane Squadron (VF-1). The program includes restoring the aircraft and their current systems, as well as implementing new avionics, radar, power production, and autonomous oxygen generating systems. The first of the 12 modified Skyhawks was delivered on 27 May 2015. EMBRAER stated that the modifications would allow the aircraft to remain operational until 2025, by which time a successor was to be fully operational.

 

Several replacement candidates were evaluated under Brazil's F-X2 fighter program together with the Air Force which was looking to replace its Northrop F‐5EM and Dassault Mirage 2000C aircraft. In October 2008, Brazil selected three finalists: the Dassault Rafale, the Boeing F/A-18 Super Hornet, and the SAAB JAS 39 Gripen. The Brazilian Air Force initially planned to procure at least 36 and possibly up to 120 aircraft later, while the Brazilian Navy was looking for 24 aircraft (20 single seater and 4 two-seaters with dual controls) until 2025.

 

In February 2009, SAAB submitted a tender, and on 5 January 2010, reports claimed that the final evaluation report placed the Gripen ahead of other contenders; the decisive factor was reportedly lower unit and operational costs, the most compact size and the Swedish manufacturer's willingness to accept EMBRAER as a technological partner for the aircraft's further development, especially for the navalized version.

 

Amid delays due to financial constraints, President Dilma Rousseff announced in December 2011 the Gripen NG's selection and the start of a joint Swedish-Brazilian joint venture called SABRA. Argentina and Ecuador were interested in procuring Gripens from or through Brazil, and Mexico and Argenitina were potential export targets for SABRA's navalized Gripen derivative that was tailored to the Marinha do Brasil's needs.

 

The respective SABRA aircraft was appropriately christened "Grifo" and the development of thei 4th generation fighter started immediately after closing the cooperation deal in 2011. While based on the SAAB 39, the Grifo became a very different aircraft, due to several factors. The major influence was the carrier operation capability, which called for major structural modifications and enforcements as well as special equipment like foldable wings, a strengthened landing gear, an arrester hook and a new engine that would better cope with the naval environment than the Swedish RM 12 engine, a derivative of the General Electric F404-400.

 

Additionally, the mission focus of air superiority with additional attack capabilities was reversed, and the need for excellent low speed handling for carrier approaches was requested.

 

This led to a complelety different aircraft layout, with the SAAB 39's instable canard design being changed into a conservative aircraft with conventional tailplanes. The nose section was shortened in order to provide the pilot with a better field of view, while the more powerful F414-EPE afterburning turbofan was moved slightly forward due to CG reasons, resulting in a slightly shortened rear fuselage.

 

A mock-up of the new aircraft for the Brazlian Navy was presented and approved in early 2012, and the government placed an official order for two prototypes. Even though the Grifo appeared like a completely different aircraft, it shared a lot of elements with the SAAB 39, so that development time and costs could be reduced to a minimum - and the first prototype, internally designated EMB 391-001, made its maiden flight in early 2013. The second aircraft followed 3 months later.

 

The Grifo's equipment includes an AN/APG-79 active electronically scanned array (AESA), capable of executing simultaneous air-to-air and air-to-ground attacks, and providing higher quality high-resolution ground mapping at long standoff ranges. The AESA radar can also detect smaller targets, such as inbound missiles, and can track air targets beyond the range of the aircraft's air-to-air missiles, which include the AIM-9 Sidewinder for close range and the AIM-120 AMRAAM for medium range.

 

The Grifo features, like the Gripen fighter, an advanced and integrated electronic warfare suite, capable of operating in an undetectable passive mode or to actively jam hostile radar; a missile approach warning system passively detects and tracks incoming missiles.

 

The Grifo can be tailored to specific missions through external sensor pods, e .g. for reconnaissance and target designation. These include Rafael's LITENING targeting pod, Saab's Modular Reconnaissance Pod System or Thales' Digital Joint Reconnaissance Pod. On the Brazilian Navy's request the Grifo is also designed that it can be equipped with an aerial refueling system (ARS) or "buddy store" for the refueling of other aircraft, filling the tactical airborne tanker role.

 

The two prototypes completed a thorough test program until summer 2015 and subsequently went on a sales tour in South America and Asia. In the meantime, serial production started at EMBRAER's Gavião Peixoto in November 2015. The first serial machines, now officially designated AF-2A, arrived at the Brazilian Navy's São Pedro da Aldeia air base where a new Intercept and Attack Plane Squadron, VF-2 'Arquieros' (Archers) was founded. The squadron became operational in April 2016 and Grifos embarked on NAe São Paulo for the first time in September 2016, serving alongside the venerable AF-1.

  

General characteristics:

Crew: 1

Payload: 5,300 kg (11,700 lb)

Length: 13,54 m (44 ft 4 in)

Wingspan (incl. wing tip launch rails): 8.32 m (27 ft 2 in)

Height: 4.25 m (13 ft 11 in)

Wing area: 30.0 m² (323 ft²)

Empty weight: 6,800 kg[330] (14,990 lb)

Loaded weight: 8,500 kg (18,700 lb)

Max. takeoff weight: 14,000 kg (31,000 lb)

Wheel track: 2.4 m (7 ft 10 in)

Powerplant:

1 × General Electric F414-EPE afterburning turbofan with

a dry thrust of 54 kN (12,100 lbf) and 85 kN (19,100 lbf) with afterburner

 

Performance:

Maximum speed: Mach 2 (2,204 km/h (1,190 kn; 1,370 mph) at high altitude

Combat radius: 800 km (497 mi, 432 nmi)

Ferry range: 3,200 km (1,983 mi) with drop tanks

Service ceiling: 15,240 m (50,000 ft)

Wing loading: 283 kg/m² (58 lb/ft²)

Thrust/weight: 0.97

Maximum g-load: +9 g

 

Armament:

1× 27 mm Mauser BK-27 Revolver cannon with 120 rounds

Eight hardpoints (three on each wing and two under fuselage)

for a wide range of guide and unguided ordnance of up to 14,330 lb (6.5 t)

  

The kit and its assembly:

The fictional Grifo is the result of a generic idea of converting a canard layout aircraft like the Saab Viggen into a conventional design. The Viggen was actually a serious candidate, but then I found an Italeri Gripen in the stash without a real purpose (it had been cheap, though), and with Brazil's real world procurement as background, the more conservative Grifo was born.

 

I wanted to use as many OOB Gripen parts as possible, and there are actually only a few external donations involved – with the outlook of converting further Gripens this way. You never know… ;)

 

Work started with the wings, which were cut off of the fuselage shell. Having the landing gear retract into the fuselage (much like the X-29) is a convenient detail of the Gripen, making the wing transplantation easier than on a Viggen where the wells have to be moved, too.

 

The original canard attachment points were faired over/hidden. The pointed Gripen nose with its pitot was cut off and replaced by a shorter, more stocky nose tip - from an F-4 Phantom II IIRC. Once the fuselage was completed, the wings were mounted, closer to the air intakes. This went smoothly, only some gaps on the undersides had to be filled.

 

Once the wings were in place I had to make a decision concerning the stabilizers. Despite the plan to use as many OOB parts as possible I found the OOB canards to be too sharply swept and considered several donation options.

I eventually settled for the most unique option: the stabilizers are actually main wings from a (rather malformed) Italeri/Dragon 1:200 F-117 that comes as a set with the B-2 bomber. A part of the F-117’s fuselage flank was cut off and taken over to the Grifo, too, so that these create ‘muscular’ bulges.

 

The stabilizers were mounted on scratched consoles/trailing wing root extensions that were somewhat inspired by the F-16’s tail design – putting the stabilizers directly onto the fuselage would have looked awkward, and with this solution I was able to extend the Gripen’s BWB-design all along the fuselage. As a side effect these consoles also offered a plausible place for rearward chaff dispensers.

 

The rear fuselage was shortened by 3mm, too – through the shorter nose and the wings further forward, the rest of the aircraft looked rather tail-heavy. While 3mm does not sound much, it helped with overall proportions.

 

The cannon fairing and the OOB pylons were taken over, as well as the cockpit interior. For carrier operations, several details were added, though: folding wing mechanism seams were engraved on the wings and an arrester hook with a fairing added under the tail section, flanked by new stabilizer fins.

 

The landing gear was basically taken OOB, too, but lengthened with styrene inserts for a higher stance: the main struts are now 2mm longer, while the front strut is 3mm taller. The latter was reversed, so that a catapult hook could be added to the front side, and slightly bigger wheels were mounted, too, so that the Grifo now has a rather stalky stance with a nose-up attitude. Simple, but effective!

 

The Sidewinders were taken OOB while the pair of AGM-84 Harpoon comes from Italeri’s 1:72 NATO weapons set.

 

Painting and markings:

I used the contemporary AF-1 paint scheme in three shades of grey as benchmark. These are FS 36187 (RAF Ocean Grey), FS 36307 (Flint Grey) and FS 36515 (Canadian Voodoo Grey) - sourced from a painting guide from Brazilian decal manufacturer FCM and backed by other knowledgeable sources from the region, too. And while the Ocean Grey appears a bit dark, I think that overall the colors are authentic. All paints are Modelmaster enamels.

 

After basic painting a light black ink wash was applied and panels highlighted through dry-brushing with lighter tones.

 

The cockpit interior was painted in Neutral Grey (FS 36173), while the landing gear became all-white.

The Brazilian Navy markings had to be improvised - there are 1:72 AF-1 decals available, but either not obtainable or prohibitively expensive - or both. Therefore I rather improvised, with basic Brazilian Navy markings from a vintage FCM Decal sheet for various Brazilian aircraft.

 

The respective roundels and codes actually belong to helicopters, and I had to wing it somehow. Unfortunately, the old FCM decals turned out to be ...old. Brittle and very delicate, application was already messy and they did not adhere well to the model. To make matters worse the acrylic varnish turned cloudy, so that a lot of paintwork repair had to be done - not helping much with a satisfactory kit finish. :(

  

Another interesting conversion – I am amazed how purposeful the Grifo looks. It reminds me with its high stance of a modern A-4 Skyhawk (what it somehow is), and there’s also some Super Étendard in it, esp. in the profile? At some point before painting it also had a somewhat Chinese look - maybe because the top view and the wing planform reminds of the classic MiG-21…? The wings might have been placed 3-4mm further backwards, since it is always difficult to judge proportions while work is still, but the Grifo looks convincingly like a real aircraft (model).

 

Aeronaves bonita! :D

Blueberry juice feels rather decadent when you consider how many of the tiny fruits are required to produce just a glass or two of juice. Luckily, blueberry pulp is very easy to use. It becomes almost invisible when combined with chocolate or cocoa powder in baked goods, where it lends moisture and can even replace some of the oil or butter in your recipe.

 

www.foodthinkers.com/2010/05/blueberry-papaya-cucumber-ju...

  

BLUEBERRY PAPAYA CUCUMBER JUICE

 

Juice Ingredients

 

1¼ cup blueberries

1 medium papaya, peeled, and trimmed, seeds removed

1 large cucumber, peeled and seededjuice of 1 to 2 sweet limes or 1 Valencia orange

 

Juice Instructions

 

1. Process blueberries and cucumber in your juicer and reserve the pulp in one bag.

2. Juice papaya and reserve its pulp separately.

3. Add the sweet lime or orange juice to the mixture, stir, and enjoy.

Serves 3.

 

BLUEBERRY CHOCOLATE CAKE WITH DARK CHOCOLATE GANACHE AND TOASTED COCONUT

 

The above juice left me with about 4 ounces (½ cup) of cucumber-blueberry pulp and ¾ cup of papaya pulp. Using slightly more or less pulp in your recipe probably will not affect your finished product all that much.

 

Here I adapted my standard vegan chocolate cake recipe, with the pulp serving as a substitute for a large portion of the oil. As I mentioned above, the pulp in the batter is virtually undetectable and the cake came out incredibly moist and tender.

 

Cake Ingredients

 

1½ cups whole wheat pastry flour

1½ cups all purpose flour

⅔ cup unsweetened cocoa powder, plus extra for dusting

(I add a tablespoon or two of black onyx cocoa powder to my regular cocoa when I make chocolate cake — it gives a slightly richer product. Onyx cocoa powder can be ordered from the Savory Spice Shop.)

1½ cups sugar

1 teaspoon baking soda

1 teaspoon salt

½ cup blueberry-cucumber pulp

½ cup vegetable oil

2 cups brewed black tea*, chilled

1 tablespoon vanilla

4 tablespoons apple cider vinegar

*Either coffee or tea works very well in this recipe — for best results be sure to use a strong brew.

 

Cake Instructions

 

1. Grease two 9-inch round cake pans and dust with cocoa powder. Line bottoms of the pans with parchment paper and grease the parchment as well.

2. Preheat oven to 375°F (190°C) with a rack in the middle.

3. Sift flours, sugar, cocoa, baking soda, and salt together in a large bowl.

4. In a separate bowl, combine the blueberry-cucumber pulp, vegetable oil, chilled tea, and vanilla.

5. Pour the wet ingredients into the dry and combine with a rubber spatula. Add the vinegar and mix in with as few strokes as possible (it’s okay if there are streaks in the batter).

6. Pour batter into the prepared pans and bake for 30 to 35 minutes, testing doneness with a wooden toothpick.

7. Let cakes cool in their pans for 5 to 10 minutes before running a knife around the edge of each pan and unmolding to cool completely.

  

While cakes are cooling, put the papaya pulp and a tablespoon or two or orange juice into a small saucepan and bring to a simmer. Add a tablespoon of sugar and stir as the mixture simmers gently for about 5 minutes. Cook until you have a thick, spreadable paste. Cool.

 

Filling Instructions

 

When the cake has cooled you may want to even out the surface of your first layer by slicing off the dome to create a flat, even round. Spread the papaya filling over the bottom cake layer and top with second cake.

 

Ganache Ingredients

 

8 ounces chopped dark chocolate, or chocolate chips (about 60% cocoa)

⅔ cup soy milk

4 tablespoons maple syrup

topping: ½ cup toasted* unsweetened shredded coconut

(*spread coconut onto a sheet pan and toast at 325°F (163°C) in a toaster oven for about 10 minutes)

 

Ganache Instructions

 

1. Heat the soy milk in a small saucepan until it begins to boil. Remove from heat and immediately add the chocolate.

2. Stir until all the chocolate has melted, then stir in maple syrup until the mixture is completely smooth.

3. Let cool slightly before pouring over the cake. Top your cake with the toasted coconut, and chill in fridge to set the ganache.

 

This cake keeps beautifully for 3 to 4 days at room temperature when wrapped in plastic or stored inside a cake dome.

The stealthy Night Raider prowls the Brikverse to hunt down and disable lost convoys and vulnerable orbital stations. Its shrouded engines and angular design make it nearly undetectable to conventional sensor systems, allowing it to unleash a deadly surprise attack with its multiple cannons and armor-piercing missiles. The Rubrum Crucesignatis has a standing bounty on all Night Raiders, but its uncanny aptitude at hit-and-fade tactics have made it difficult to catch.

 

The Empire of Luchardsko is a cool-looking, if lore-light, faction created by Falk for Brikwars. One of my favorites.

+++ DISCLAIMER +++

Nothing you see here is real, even though the conversion or the presented background story might be based historical facts. BEWARE!

 

Some background:

NAe São Paulo is a Clemenceau-class aircraft carrier currently in service with the Brazilian Navy. São Paulo was first commissioned in 1963 by the French Navy as Foch and was transferred in 2000 to Brazil, where she became the new flagship of the Brazilian Navy. In December 2014 it was announced that São Paulo will be expected to continue active service until 2039, at which time the vessel will be nearly 80 years old.

 

From this carrier, the Marinha do Brasil operates its only fixed-wing aircraft, and these were initially A-4 Skyhawks. In 1997 Brazil negotiated a $70 million contract for purchase of 20 A-4KU and three TA-4KU Skyhawks from Kuwait. The Kuwaiti Skyhawks, modified A-4Ms and TA-4Js delivered in 1977, were among the last of those models built by Douglas. The Kuwaiti Skyhawks were selected by Brazil because of low flight time, excellent physical condition, and a favorable price tag. The Brazilian Navy Re-designated AF-1 and AF-1A Falcões (Hawks), the ex-Kuwaiti Skyhawks arrived in Arraial do Cabo on 5 September 1998.

 

Anyway, the Skyhawks' life span was limited and in 2005 the Brazilian Navy started looking for a potential replacement, while the AF-1s were to kept operational due to limited military budgets. On 14 April 2009, Brazlian aircraft manufacturer EMBRAER signed a contract to modernize 12 Skyhawks, nine AF-1s (single-seat) and three AF-1As (two-seat). This upgrade will restore the operating capacity of the Navy 1st Intercept and Attack Plane Squadron (VF-1). The program includes restoring the aircraft and their current systems, as well as implementing new avionics, radar, power production, and autonomous oxygen generating systems. The first of the 12 modified Skyhawks was delivered on 27 May 2015. EMBRAER stated that the modifications would allow the aircraft to remain operational until 2025, by which time a successor was to be fully operational.

 

Several replacement candidates were evaluated under Brazil's F-X2 fighter program together with the Air Force which was looking to replace its Northrop F‐5EM and Dassault Mirage 2000C aircraft. In October 2008, Brazil selected three finalists: the Dassault Rafale, the Boeing F/A-18 Super Hornet, and the SAAB JAS 39 Gripen. The Brazilian Air Force initially planned to procure at least 36 and possibly up to 120 aircraft later, while the Brazilian Navy was looking for 24 aircraft (20 single seater and 4 two-seaters with dual controls) until 2025.

 

In February 2009, SAAB submitted a tender, and on 5 January 2010, reports claimed that the final evaluation report placed the Gripen ahead of other contenders; the decisive factor was reportedly lower unit and operational costs, the most compact size and the Swedish manufacturer's willingness to accept EMBRAER as a technological partner for the aircraft's further development, especially for the navalized version.

 

Amid delays due to financial constraints, President Dilma Rousseff announced in December 2011 the Gripen NG's selection and the start of a joint Swedish-Brazilian joint venture called SABRA. Argentina and Ecuador were interested in procuring Gripens from or through Brazil, and Mexico and Argenitina were potential export targets for SABRA's navalized Gripen derivative that was tailored to the Marinha do Brasil's needs.

 

The respective SABRA aircraft was appropriately christened "Grifo" and the development of thei 4th generation fighter started immediately after closing the cooperation deal in 2011. While based on the SAAB 39, the Grifo became a very different aircraft, due to several factors. The major influence was the carrier operation capability, which called for major structural modifications and enforcements as well as special equipment like foldable wings, a strengthened landing gear, an arrester hook and a new engine that would better cope with the naval environment than the Swedish RM 12 engine, a derivative of the General Electric F404-400.

 

Additionally, the mission focus of air superiority with additional attack capabilities was reversed, and the need for excellent low speed handling for carrier approaches was requested.

 

This led to a complelety different aircraft layout, with the SAAB 39's instable canard design being changed into a conservative aircraft with conventional tailplanes. The nose section was shortened in order to provide the pilot with a better field of view, while the more powerful F414-EPE afterburning turbofan was moved slightly forward due to CG reasons, resulting in a slightly shortened rear fuselage.

 

A mock-up of the new aircraft for the Brazlian Navy was presented and approved in early 2012, and the government placed an official order for two prototypes. Even though the Grifo appeared like a completely different aircraft, it shared a lot of elements with the SAAB 39, so that development time and costs could be reduced to a minimum - and the first prototype, internally designated EMB 391-001, made its maiden flight in early 2013. The second aircraft followed 3 months later.

 

The Grifo's equipment includes an AN/APG-79 active electronically scanned array (AESA), capable of executing simultaneous air-to-air and air-to-ground attacks, and providing higher quality high-resolution ground mapping at long standoff ranges. The AESA radar can also detect smaller targets, such as inbound missiles, and can track air targets beyond the range of the aircraft's air-to-air missiles, which include the AIM-9 Sidewinder for close range and the AIM-120 AMRAAM for medium range.

 

The Grifo features, like the Gripen fighter, an advanced and integrated electronic warfare suite, capable of operating in an undetectable passive mode or to actively jam hostile radar; a missile approach warning system passively detects and tracks incoming missiles.

 

The Grifo can be tailored to specific missions through external sensor pods, e .g. for reconnaissance and target designation. These include Rafael's LITENING targeting pod, Saab's Modular Reconnaissance Pod System or Thales' Digital Joint Reconnaissance Pod. On the Brazilian Navy's request the Grifo is also designed that it can be equipped with an aerial refueling system (ARS) or "buddy store" for the refueling of other aircraft, filling the tactical airborne tanker role.

 

The two prototypes completed a thorough test program until summer 2015 and subsequently went on a sales tour in South America and Asia. In the meantime, serial production started at EMBRAER's Gavião Peixoto in November 2015. The first serial machines, now officially designated AF-2A, arrived at the Brazilian Navy's São Pedro da Aldeia air base where a new Intercept and Attack Plane Squadron, VF-2 'Arquieros' (Archers) was founded. The squadron became operational in April 2016 and Grifos embarked on NAe São Paulo for the first time in September 2016, serving alongside the venerable AF-1.

  

General characteristics:

Crew: 1

Payload: 5,300 kg (11,700 lb)

Length: 13,54 m (44 ft 4 in)

Wingspan (incl. wing tip launch rails): 8.32 m (27 ft 2 in)

Height: 4.25 m (13 ft 11 in)

Wing area: 30.0 m² (323 ft²)

Empty weight: 6,800 kg[330] (14,990 lb)

Loaded weight: 8,500 kg (18,700 lb)

Max. takeoff weight: 14,000 kg (31,000 lb)

Wheel track: 2.4 m (7 ft 10 in)

Powerplant:

1 × General Electric F414-EPE afterburning turbofan with

a dry thrust of 54 kN (12,100 lbf) and 85 kN (19,100 lbf) with afterburner

 

Performance:

Maximum speed: Mach 2 (2,204 km/h (1,190 kn; 1,370 mph) at high altitude

Combat radius: 800 km (497 mi, 432 nmi)

Ferry range: 3,200 km (1,983 mi) with drop tanks

Service ceiling: 15,240 m (50,000 ft)

Wing loading: 283 kg/m² (58 lb/ft²)

Thrust/weight: 0.97

Maximum g-load: +9 g

 

Armament:

1× 27 mm Mauser BK-27 Revolver cannon with 120 rounds

Eight hardpoints (three on each wing and two under fuselage)

for a wide range of guide and unguided ordnance of up to 14,330 lb (6.5 t)

  

The kit and its assembly:

The fictional Grifo is the result of a generic idea of converting a canard layout aircraft like the Saab Viggen into a conventional design. The Viggen was actually a serious candidate, but then I found an Italeri Gripen in the stash without a real purpose (it had been cheap, though), and with Brazil's real world procurement as background, the more conservative Grifo was born.

 

I wanted to use as many OOB Gripen parts as possible, and there are actually only a few external donations involved – with the outlook of converting further Gripens this way. You never know… ;)

 

Work started with the wings, which were cut off of the fuselage shell. Having the landing gear retract into the fuselage (much like the X-29) is a convenient detail of the Gripen, making the wing transplantation easier than on a Viggen where the wells have to be moved, too.

 

The original canard attachment points were faired over/hidden. The pointed Gripen nose with its pitot was cut off and replaced by a shorter, more stocky nose tip - from an F-4 Phantom II IIRC. Once the fuselage was completed, the wings were mounted, closer to the air intakes. This went smoothly, only some gaps on the undersides had to be filled.

 

Once the wings were in place I had to make a decision concerning the stabilizers. Despite the plan to use as many OOB parts as possible I found the OOB canards to be too sharply swept and considered several donation options.

I eventually settled for the most unique option: the stabilizers are actually main wings from a (rather malformed) Italeri/Dragon 1:200 F-117 that comes as a set with the B-2 bomber. A part of the F-117’s fuselage flank was cut off and taken over to the Grifo, too, so that these create ‘muscular’ bulges.

 

The stabilizers were mounted on scratched consoles/trailing wing root extensions that were somewhat inspired by the F-16’s tail design – putting the stabilizers directly onto the fuselage would have looked awkward, and with this solution I was able to extend the Gripen’s BWB-design all along the fuselage. As a side effect these consoles also offered a plausible place for rearward chaff dispensers.

 

The rear fuselage was shortened by 3mm, too – through the shorter nose and the wings further forward, the rest of the aircraft looked rather tail-heavy. While 3mm does not sound much, it helped with overall proportions.

 

The cannon fairing and the OOB pylons were taken over, as well as the cockpit interior. For carrier operations, several details were added, though: folding wing mechanism seams were engraved on the wings and an arrester hook with a fairing added under the tail section, flanked by new stabilizer fins.

 

The landing gear was basically taken OOB, too, but lengthened with styrene inserts for a higher stance: the main struts are now 2mm longer, while the front strut is 3mm taller. The latter was reversed, so that a catapult hook could be added to the front side, and slightly bigger wheels were mounted, too, so that the Grifo now has a rather stalky stance with a nose-up attitude. Simple, but effective!

 

The Sidewinders were taken OOB while the pair of AGM-84 Harpoon comes from Italeri’s 1:72 NATO weapons set.

 

Painting and markings:

I used the contemporary AF-1 paint scheme in three shades of grey as benchmark. These are FS 36187 (RAF Ocean Grey), FS 36307 (Flint Grey) and FS 36515 (Canadian Voodoo Grey) - sourced from a painting guide from Brazilian decal manufacturer FCM and backed by other knowledgeable sources from the region, too. And while the Ocean Grey appears a bit dark, I think that overall the colors are authentic. All paints are Modelmaster enamels.

 

After basic painting a light black ink wash was applied and panels highlighted through dry-brushing with lighter tones.

 

The cockpit interior was painted in Neutral Grey (FS 36173), while the landing gear became all-white.

The Brazilian Navy markings had to be improvised - there are 1:72 AF-1 decals available, but either not obtainable or prohibitively expensive - or both. Therefore I rather improvised, with basic Brazilian Navy markings from a vintage FCM Decal sheet for various Brazilian aircraft.

 

The respective roundels and codes actually belong to helicopters, and I had to wing it somehow. Unfortunately, the old FCM decals turned out to be ...old. Brittle and very delicate, application was already messy and they did not adhere well to the model. To make matters worse the acrylic varnish turned cloudy, so that a lot of paintwork repair had to be done - not helping much with a satisfactory kit finish. :(

  

Another interesting conversion – I am amazed how purposeful the Grifo looks. It reminds me with its high stance of a modern A-4 Skyhawk (what it somehow is), and there’s also some Super Étendard in it, esp. in the profile? At some point before painting it also had a somewhat Chinese look - maybe because the top view and the wing planform reminds of the classic MiG-21…? The wings might have been placed 3-4mm further backwards, since it is always difficult to judge proportions while work is still, but the Grifo looks convincingly like a real aircraft (model).

 

Aeronaves bonita! :D